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Tuberculous pericarditis is an extra pulmonary form of tuberculosis (TB) which leads to a life-
threatening form of pericardial fibrosis in up to 25% of patients despite anti tuberculous 
therapy.  The mechanisms leading to the fibrotic phenotype following infection are poorly 
understood.  A proof of concept study revealed decreased levels of the antifibrotic N-acetyl-
seryl-aspartyl-lysyl-proline or Ac-SDKP in tuberculous pericardial fluid as compared to control 
(non infectious) pericardial fluid.  Ac-SDKP is a physiological peptide that is synthesised from 
its precursor protein thymosin β4 by the sequential action of meprin-α and prolyl 
oligopeptidase (POP) and is cleaved by angiotensin-1 converting enzyme (ACE).  Importantly, a 
role of ACE and Ac-SDKP in the regulation of inflammation and fibrosis in multiple tissues and 
organs has been increasingly described in the literature.  This has prompted interest in both 
the mechanisms of and potential for protective benefits of ACE inhibitors and Ac-SDKP 
analogue administration in fibrotic disease.  The aim of this project was to investigate a) the 
molecular mechanisms of the antifibrotic effects of Ac-SDKP in the development of fibrosis, 
particularly in TB pericarditis, and b) the potential of ACEi and Ac-SDKP analogues in vitro in 
fibrosis prevention. 
Pericardial fluid and blood samples from patients with TB pericarditis or undergoing coronary 
artery bypass surgery (non-infectious controls) was used to investigate the metabolism of Ac-
SDKP in the tuberculous pericardium.  Ac-SDKP levels as measured by ELISA, were significantly 
decreased (2.3 fold) in TB pericardial fluid as compared to controls.  This reduction in Ac-SDKP 
levels was accompanied by a local 28% increase in the enzymatic activity of ACE, but no change 
in POP enzyme activity levels, both of which were measured using fluorogenic assays.  This 
suggests that an increase in ACE activity in the pericardium following infection by the 
mycobacterium leads to a reduction of the levels of the antifibrotic peptide which is likely to 
contribute to the pathophysiology of fibrosing pericarditis.  
 A mass spectrometric (MS) approach was employed in order to identify proteins whose 
expression is modulated by the effect of Ac-SDKP in the proteome and secretome of a human 
lung fibroblast cell line (WI-38).  Label free quantitative MS was employed to identify 114 and 
44 differentially expressed proteins in Ac-SDKP fibroblast proteome and secretome 
respectively.   Various extracellular matrix components and their related factors such as 
collagens, cytoskeletal proteins and inflammatory proteins, were identified among the 
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differentially regulated proteins.  Reactome pathway analysis confirmed the significant 
enrichment of Ac-SDKP-related extracellular matrix proteoglycans and extracellular matrix in 
the differentially expressed proteins of the secretome.   
Using the same cell line, the antifibrotic effects of Ac-SDKP analogues and ACE inhibitors were 
investigated through quantitative western blotting for transforming growth factor β (TGF-β) 
and Smad 3 levels, and using a hydroxyproline assay.  Ac-SDKP prevented TGF-β  and collagen 
expression through inhibition of Smad 3 phosphorylation.  The Ac-SDψKP analogue (whereby 
the peptide bond between the aspartate and lysine is reduced) alone prevented TGF-β 
mediated collagen secretion.  The combination of Ac-SDKP and the N domain-selective 
inhibitor RXP407, but not the non-selective lisinopril had an additive effect on the inhibition of 
collagen in fibroblasts.  However, the antifibrotic effect of Ac-SDψKP was comparable to the 
combination of Ac-SDKP and RXP407 and was not improved with added ACE inhibition.  Finally, 
the ACE signalling response to Ac-SDKP and the ACE inhibitors RXP407 and lisinopril was 
investigated using mass spectrometry and quantitative western blotting for phospho JNK and 
JNK.  The ACE inhibitors as well as Ac-SDKP triggered the ACE signalling cascade to induce JNK 
phosphorylation.  This highlights a potential new mechanism for the anti-inflammatory and 
antifibrotic effects of Ac-SDKP and the inhibitors. 
This thesis has demonstrated an altered metabolism of Ac-SDKP is associated with increased 
ACE activity in the tuberculous pericardium.  It has also provided a deeper understanding of 
the antifibrotic action of the tetrapeptide, and in vitro evidence for the use of the analogue Ac-
SDψKP and inhibtion of N domain catalytic activity for decreasing fibrosis.  These findings form 
a solid basis for future in vivo pharmacological studies on the effects of Ac-SDKP analogues and 
ACE inhibitors in the prevention and management of fibrotic conditions.  Importantly, these 
therapeutic options present an exciting avenue to follow in the prevention of fibrosing 
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ACE: Angiotensin converting enzyme.  
ACEi: ACE inhibitor.  
AChE: acetyl-cholinesterase.  
ACN: Acetonitrile.  
Ac-SDKP: N-acetyl-seryl-aspartyl-lysyl-proline.  
ADA: adenosine deaminase.  
AMC: amino methyl coumarin.  
Ang 1-7: Angiotensin 1-7.  
AngI: angiotensin I.  
AngII: angiotensin II.  
AP-1: apoprotein-1.  
ARBs: angiotensin receptor blockers.  
AT1: angiotensin receptor type I. ,  
Bcl2: B-cell lymphoma 2.  
bFGF: basic fibroblast growth factor.  
BiNGO: Biological Networks Gene Ontology tool.  
BK: bradykinin.  
BMP-2: bone morphogenetic protein 2.  
BSA: Bovine serum albumin.  
CHO: Chinese Hamster Ovary.  
CK-2: casein kinase-2.  
CMR: cardiac magnetic resonance. ,  
Co-Smads: common-partner Smads.  
COX-2: cyclooxygenase-2.  
CRD: carbohydrate recognition domain.  
CTGF: connective tissue growth factor.  
DMSO: dimethyl sulfoxide.  
ECG: electrocardiogram.  
ECM: extracellular matrix accumulation.  
ECP: Effusive Constrictive Pericarditis.  
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ELISA: Enzyme Linked Immunosorbent Assay.  
EMT: epithelial-mesenchymal transition.  
EndMT: endothelial-to-mesenchymal transition. ,  
ESI: electrospray ionisation.  
ET-1: endothelin-1.  
FA: formic acid.  
FASP: Filter aided sample preparation.  
FCS: foetal calf serum.  
FDR: false discovery rate.  
FGF: fibroblast growth factor.  
FT-MS: Fourier transform ion cyclotron.  
Gal-3: galectin-3.  
GnRH: Gonadotropin Releasing Hormone.  
GO: Gene Ontology.  
HIV: Human Immunodeficiency Virus.  
HL: Histidyl-Leucine.  
IFN-γ: interferon-gamma.  
IL: Interleukin.  
ILK: integrin-linked kinase.  
IMPI: Investigation of the Management of Pericarditis.  
I-Smads: inhibitory Smads.  
iTRAQ: Isobaric Tags for Relative and Absolute Quantitation.  
JNK: c-Jun N-terminal kinases.  
KKS: Kallikrein-Kinin System.  
KLB: β-klotho protein.  
LAP: Latency Associated Protein.  
LC-MS/MS: liquid chromatography tandem MS.  
LFQ: label free quantification.  
LTBP: Latent TGF-β Binding Proteins.  
M.Tb: Mycobacterium tuberculosis.  
m/z: mass-to-charge ratio.  
MALDI: matrix assisted laser desorption ionisation.  
MAP4K4: mitogen-activated protein kinase kinase kinase kinase 4.  
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MAPKs: mitogen-activated protein kinases.  
MI: myocardial infarction.  
mins: minutes.  
MKK7: Map kinase kinase 7.  
MMP: matrix metalloprotease. ,  
MMPs: matrix metalloproteases.  
MS: mass spectrometry.  
MWCO: molecular weight cut off.  
NADPH: nicotinamide adenine dinucleotide phosphate.  
PAGE: polyacrylamide gel electrophoresis.  
PDGF: platelet derived growth factor.  
PEP: posterior error probability.  
PICs: Pericardial interstitial cells.  
QE: Q-Exactive.  
RAAS: Renin-Angiotensin-Aldosterone System.  
R-Smads: receptor-regulated Smads.  
SDS: sodium dodecyl sulphate.  
SEM: standard of the mean.  
SHP-2: Src homology 2-containing protein tyrosine phosphatase-2.  
SILAC: Stable Isotope Labelling by/with Amino acids in Cell culture.  
Smad: small mother against decapentaplegic.  
Smurfs: Smad ubiquitination regulatory factors.  
SPARC: secreted protein acidic and rich in cysteine. ,  
STRING: search tool for the retrieval of interacting genes/proteins.  
TB: Tuberculosis.  
TB-: TB negative.  
TB+: TB positive.  
TGF-β: transforming growth factor-β.  
Th-1: T helper-1.  
TIC: total ion counts.  
TNF-α: tumour necrosis factor-α.  
TOF: time-of-flight.  
Tβ4: thymosin β4.  
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uIFNγ: unstimulated IFN-γ.  
VEGF: vascular endothelial growth factor.  
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Constrictive pericarditis is a common, and potentially life-threatening, complication of 
tuberculous pericarditis (Mayosi et al., 2005).  Tuberculosis (TB), caused by the pathogen 
Mycobacterium tuberculosis (M.tb) is still widely prevalent in the developing world, where 
socio-economic conditions are poor and access to healthcare is scarce.  Compounded by the 
Human Immunodeficiency Virus (HIV) pandemic, the incidence of TB and its manifestation in 
the heart such as TB pericarditis is high and contributes to the burden of cardiovascular disease 
in South Africa (Ntsekhe and Mayosi, 2012).  The pathophysiological mechanisms leading to 
constriction following infection by the bacterium are poorly understood.  A proof of concept 
study by Ntsekhe et al. revealed the presence of the antifibrotic N-acetyl-seryl-aspartyl-lysyl-
proline (Ac-SDKP), a physiological peptide cleaved by angiotensin-1 converting enzyme (ACE), 
in normal and tuberculous pericardial fluid. The levels of Ac-SDKP were significantly lower in 
TB pericardial fluid  suggesting a potential disruption of the ACE/Ac-SDKP balance in TB 
pericarditis which could potentially contribute to the onset and/or progression of fibrosis 
(Ntsekhe et al., 2012). 
ACE is predominantly known for its role in the Renin-Angiotensin-Aldosterone System (RAAS) 
and the Kallikrein-Kinin System (KKS), where it is involved in blood pressure and fluid 
homeostasis.  The centrality of ACE in the RAAS has led to the development of ACE inhibitors 
(ACEi), which are widely used in the treatment of hypertension and cardiovascular disease.  
However, it has become increasingly apparent that the physiological functions of ACE extend 
well beyond blood pressure regulation, reflecting the diversity of substrates of the enzyme.  
Among many peptides, ACE cleaves  the amyloid-β protein, (the deposition and accumulation 
of which in the brain, is associated with Alzheimer’s disease), Gonadotropin Releasing 
Hormone (GnRH) and the aforementioned Ac-SDKP (Skidgel and Erdös, 1985)(Hemming and 
Selkoe, 2005).  The role of ACE and Ac-SDKP in the prevention and reversal of tissue and organ 
fibrosis, both in vitro and in vivo, has prompted interest in the protective benefits of ACEi in 
fibrotic disease (Brilla et al., 2000) (Gross et al., 2004) (Kumar and Yin, 2018). 
This chapter provides insights into the molecular mediators of the fibrotic progression to 
constrictive pericarditis from various studies.  It also details the ACE/Ac-SDKP axis of fibrosis 
and the signalling mechanisms involved in the antifibrotic action of Ac-SDKP as well as the 
rationale for and the research questions of the current study. 
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 The normal pericardium 
The pericardium is a double layered flask-like sac which encloses the heart through its 
attachments to the great vessels, namely the vena cava, aorta, and pulmonary artery and vein.  
Whilst the pericardium is not essential for normal cardiac function, it has multiple functions.  
These include, but are not restricted to, lubricating the heart surface for reduced friction upon 
motion, anchoring the heart in its correct anatomic position, shielding the heart from 
surrounding structures to prevent adhesion formation and the spread of inflammation or 
neoplasia, and restricting any excessive dilatation of the cardiac chamber.  The pericardium 
has an independent blood supply from the internal mammary arteries and is innervated by the 
phrenic nerve (Holt, 1970)(Spodick, 1992)(Shabetai et al., 1979). 
 




The pericardium is lined by an outer fibrous layer of connective tissue rich in elastic fibres and 
collagenous fibres (Figure 1-1).  This fibrosa is supplied by a network of blood and lymphatic 
vessels and it contains macrophages and fibroblasts.  The inner serous pericardium is 
composed of a single layer of flat, irregular, ciliated mesothelial cells resting on a thin basement 
membrane and separated from the fibrous layer by a thin sub-mesothelial space.  The serosa 
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comprises a visceral layer and a parietal layer coating the heart and the fibrous pericardium 
respectively (Ishihara et al., 1980)(Mutsaers, 2002).  These two layers of the pericardium are  
1 to 2 mm thick and give rise to a cavity which contains on average 10 to 35 ml of pericardial 
fluid, under normal physiological conditions (Little and Freeman, 2006).  Pericardial fluid is 
formed from ultrafiltration of plasma and comprises largely globular proteins, phospholipids 
and surfactant-like prostaglandins (Spodick, 1992). 
 Pericarditis 
The pathophysiological response of the pericardium to injury results in the clinical syndrome 
of pericarditis.  Pericarditis refers to the inflammation of the pericardium and it is a common 
disorder (Imazio et al., 2015).  Clinically, pericarditis often presents with prolonged pleuritic 
chest pain, which radiates to the neck, back and left arm.  A pericardial friction rub is a 
pathognomonic sign of acute pericarditis and is detected in 60% to 85% of cases.  Abnormal 
electrocardiogram (ECG) findings are common with a classical initial profile of ST-segment 
elevations, sometimes accompanied by PQ or PR segment depression.  The progression of ECG 
changes has been described to happen in  stages; from ST elevations in stage 1 and their return 
to the isoelectric position in stage 2, negative T waves in stage 3 and a restoration to the 
baseline ECG in stage 4 (Sagristà Sauleda et al., 2005)(Spodick, 2003).   
The accumulation of pericardial fluid rich in inflammatory cells and fibrin in the pericardium 
following pericarditis can compromise cardiac function by compressing the underlying 
myocardium and causing cardiac tamponade.  Chronic inflammation of the pericardium can 
result in thickening, adhesion, fibrosis calcification of the pericardium, obliteration of the 
pericardial space and constrictive pericarditis (Singhal et al., 2016).  Both cardiac tamponade 
with and without hemodynamic instability in the short term, and constrictive pericarditis with 
and without effusion in the long term are major complications of pericarditis (Little and 
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 Aetiology of pericarditis 
Pericarditis may arise from a range of aetiologies, both infectious and non-infectious 
(summarised in Table 1-1)(Maisch et al., 2004).  Pericarditis can present clinically  as acute  dry 
pericarditis (non-effusive), effusive pericarditis, effusive constrictive pericarditis (ECP) and non-
effusive constrictive pericarditis (Imazio et al., 2015).  A pericardial effusion is said to be present 
when the amount of fluid exceeds the normal 10 to 35ml in the pericardial space (Spodick, 
2003). 
Table 1-1: A summary of the common aetiologies of pericarditis 
Infectious  
 
- Viral: Enteroviruses (Coxsackie viruses, echoviruses); herpes viruses 
(Epstein-Barr virus, cytomegalovirus, human herpes virus 6) and 
adenoviruses 
- Bacterial: M.tb, Coxiella burnetii and Borrelia burgdorferi 
- Fungal: Histoplasma, Aspergillus, Blastomyces, and Candida species 
- Parasitic: Echinococcus and Toxoplasma species 
Autoimmune and 
auto-inflammatory 
- Systemic autoimmune diseases: systemic lupus erythematosus, 
rheumatoid arthritis and systemic sclerosis  
- Type 2 auto-immune processes following infection/surgery: rheumatic 
fever, post-cardiotomy syndrome, post-myocardial infarction syndrome, 
epistenocardica and auto-reactive (chronic) pericarditis  
Malignant  - Secondary metastatic tumours: lung and breast cancer, leukaemia, 
lymphoma, melanoma and cancers of contiguous anatomical structures 
such as the oesophagus 
Metabolic - Renal insufficiency: uraemia 




- Direct injury: penetrating thoracic injury and oesophageal perforation 
- Indirect injury: radiation injury 
- Drug-related: procainamide, hydralazine, isoniazid, phenytoin, 
penicillins, and doxorubicin  
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 Constrictive pericarditis 
Constrictive pericarditis is a clinical syndrome, characterised by a thickened, stiff and non-
compliant pericardium, which restricts cardiac filling (Goldstein, 2004).  Constrictive 
pericarditis arises as a result of severe acute inflammation or recurrent inflammatory events 
over a highly variable time course from the period of injury (Syed et al., 2014)(D’Elia et al., 
2019).  However, the risk factors for the progression to constriction are poorly understood.  
Table 1-2 summarises some of the potential pathophysiological mechanisms of constriction in 
pericardial diseases which commonly progress to constriction. 
The incidence of constrictive pericarditis following the inflammatory process depends on the 
aetiology of the pericarditis.  Whilst idiopathic and viral pericarditis have a low incidence of 
constrictive complications, tuberculous and purulent pericarditis result in a large proportion of 
pericardial constriction (Imazio et al., 2015). 
The most apparent pathological features of constrictive pericarditis are the thickening and 
fibrosis of the thin and elastic parietal and visceral pericardial linings.  The pericardium 
commonly bears areas of inflammation of the serosa, scarring, and fibro-calcification 
(Goldstein, 2004).  This leads to a classical haemodynamic profile arising from altered 
pericardial compliance and impaired ventricular diastolic function and ventricular 
interdependence.  Atrial filling pressures increase whilst cardiac output decreases, eventually 
leading to diastolic heart failure (Myers and Spodick, 1999)(Shabetai et al., 1970).  This 
haemodynamic pattern is reflected in elevated waveforms in the jugular venous pulse and right 
atrial pressures, accompanied by prominent A waves.  A distinctive RV waveform shape, 
referred to as a “dip and plateau” or “square root” pattern, indicates the resistance to 
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Table 1-2: Pathophysiological manifestations in common causes of constrictive pericarditis. 
(Excluding TB pericarditis, discussed separately) 
Manifestations and potential underlying causes of constrictive pericarditis References 
Uraemic 
pericarditis 
Serous/haemorrhagic effusions typically evolve into a fibrinous 
state with irregular, scattered adhesions in a “bread and butter” 
pattern but can also progress to densely adherent pericarditis and 
gross pericardial thickening.  Pericarditis is more frequent in cases 
of severe uraemia, but there is no correlation between blood urea 
and creatinine levels and the degree of constriction. 
(Kumar and Lesch, 
1980) (Reyman, 1969) 
(de Gouveia et al., 
2016) (Lindsay et al., 




Radiation toxicity can cause micro-vascular damage and episodic 
pericardial ischemia, leading to permeable neovascularization and 
fibrous deposition.  There is also evidence of vascular and 
lymphatic fibrosis.  The degree of inflammation and thickening 
corresponds to the x-ray exposure, suggesting a cellular injury and 
necrosis induced inflammatory response. 
(Botti et al., 1968) 
(Morton et al., 1973) 
(Taunk et al., 2015) 
Systemic 
sclerosis 
Pericardial manifestations include effusions, fibrous pericarditis, 
pericardial adhesions or constrictive pericarditis. However, the 
pathogenesis is believed to differ from the traditional 
inflammatory pathways as evidenced by a ‘non-inflammatory’ 
profile of the pericardial fluid but may instead be due to the 
release of fibroblast growth factor (FGF) and histamine by mast 
cells. 
(Lambova, 2014) 
(Byers et al., 1997) 
Episteno-
cardica 
Vascular injury and myocardial necrosis have been associated with 
increased incidence of pericarditis, suggesting an inflammatory 
response to injury.  Fibrous deposits and adhesions often develop 
in the visceral and parietal pericardium covering the area of 
infarction but may also involve wider and more diffuse pericardial 
surfaces (Roberts, 2005. 
(Roberts, 2005) 
(Dorfman and Aqel, 







Adhesions and fibrous patches in the pericardium post-surgery can 
lead to constrictive pericarditis.  The presence of blood in the 
pericardial cavity may play a role, with failure to drain bloody 
effusions being a risk factor for the development of fibrosis.  Blood 
in the pericardium may result in irritation of the serosal layer and 
inflammation, but fibrosis can occur in its absence. 
(Cohen and 
Greenberg, 1979)  
(Matsuyama et al., 





Effusions are common in neoplastic pericarditis and can be bloody.  
Malignant invasion of the heart and the deposition of fibrous 
tissue often lead to constriction.  Sub-acute inflammation with 
lymphocytic accumulation and mesothelial hyperplasia has been 
described in primary pericardial mesothelioma. 
(Thurber et al., 1962) 
(Smets et al., 2013) 
(Wilkes et al., 1995) 
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 Tuberculosis in South Africa 
Tuberculosis contributes an enormous global burden of disease concentrated in Asia, Africa 
and Latin America.  An estimated 10.0 million cases of TB have been recorded in 2018 alone 
(“WHO | Global tuberculosis report 2019,” n.d.).  HIV infection not only represents a potent 
risk factor for TB but also results in the aggressive latent reactivation of TB and rapid 
progression of newly acquired or reinfection with M.tb (Daley et al., 1992)(Corbett et al., 2003).  
It is hence not surprising that in South Africa, where the incidence and prevalence of HIV is high 
(Figure 1-2), there is an accompanying high TB incidence (227 999 new and relapse notified 
cases in 2018 alone), with a disproportionately higher rate of mortality when both co-
morbidities are present (“WHO | Global tuberculosis report 2019,” n.d.). 
 Tuberculous pericarditis 
TB pericarditis is a form of extra-pulmonary tuberculosis which affects the pericardium.  
Tuberculosis is a major cause of pericardial diseases in both HIV-uninfected and HIV-infected 
populations in Sub Saharan Africa (Noubiap et al., 2019)(Syed and Mayosi, 2007).  This is in 
contrast to the developed world where TB pericarditis accounts for only a small proportion of 
cases of acute pericarditis and constrictive pericarditis (Fowler NO, 1991).  Whilst TB pericardial 
disease accounted for 4% of admission in a Spanish case series, pericardial effusions in South 
Africa are predominantly caused by TB infection, ranging from 64.9 to 70% (Isiguzo et al., 2020).  
This is in part due to the HIV pandemic with HIV co-infection not only increasing the number 
of TB pericarditis cases but has also changing its clinical manifestations and therapeutic 
considerations (Ntsekhe and Mayosi, 2012). 
Patients with TB pericarditis present predominantly with effusive pericarditis, with a smaller 
percentage having ECP and myopericarditis (Noubiap et al., 2019).  TB pericarditis has a poor 
outcome bearing a mortality rate of up to 40% in those patients coinfected with HIV as 
compared to 17% in patients without HIV at 6 months (Mayosi et al., 2008).  Given that many 
patients are not on ARV therapy, it is likely that the difference is attributable to the impaired 
response to the presence of the mycobacterium, with fewer granulomas observed in the 
tuberculous pericardium.  Mortality results primarily from heart failure arising from 
constrictive disease and cardiac tamponade (Mayosi et al., 2005)(Noubiap et al., 2019).   




Figure 1-2: Worldwide TB incidence and fatalities adapted from the WHO Global Tuberculosis Report 2018.   
As depicted in the map, South Africa has one of the highest incidence rates and case fatality ratios for 
Tuberculosis worldwide. 
Available at: https://www.who.int/tb/publications/global_report/en/ 
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 Pathophysiology of TB pericarditis 
The spread of M.tb to the pericardium occurs either through retrograde lymphatic spread or 
through haematogenous spread from primary sites of infection (Mayosi et al., 2005) (Myers 
and Spodick, 1999).  Among both HIV-infected and HIV-uninfected patients, high M.tb bacillary 
loads have been identified suggesting that the condition is not paucibacillary, as previously 
believed (Isiguzo et al., 2020).  
Infection of the pericardium with the bacilli elicits an immune response, stimulating 
lymphocytes to release cytokines which activate macrophages and influence granuloma 
formation.  Marked elevations of Interleukin-10 (IL-10) and interferon-gamma (IFN-γ) 
accompanied by low levels of bioactive transforming growth factor-β (TGF-β) levels in 
tuberculous pericardial fluid suggest a T helper-1 (Th-1) mediated delayed type hypersensitivity 
response to the pathogen (Ntsekhe et al., 2013).  Similarly, Reuter et al, measured significantly 
increased IFN-γ levels in the pericardial fluid and observed large numbers of mesothelial cells 
in tuberculous pericardial aspirates (Reuter et al., 2006).  A role for complement fixing 
antimyolemmal antibodies has also been suggested in the development of exudative 
tuberculous pericarditis through cardiocyte cytolysis (Maisch et al., 1982).  The inflammatory 
process in TB pericarditis follows a sequence of pathological events.  An early fibrinous exudate 
is formed with leucocytosis, accompanied by early granuloma formation, followed by a sero-
sanguineous effusion with a predominantly lymphocytic exudate.  The effusion gradually 
recedes whilst the granulomatous architecture is organised to restrict mycobacterial spread.  
Fibrin, collagen and extracellular matrix deposition lead to pericardial thickening and fibrosis 
(Mayosi et al., 2005). 
 Diagnosis and treatment of TB pericarditis 
A definitive diagnosis of tuberculous pericarditis is made by isolating the acid-fast tubercle 
bacilli from pericardial fluid or by demonstrating its presence through pericardial histology or 
culture. However, isolating the organism is often challenging. A diagnosis can also be made 
with evidence of other forms of TB in a patient, accompanied by otherwise unexplained 
lymphocytic predominant  exudative pericarditis and where other infectious agents have been 
excluded (Reuter et al., 2006) (Mayosi et al., 2005).  Elevated pericardial adenosine deaminase 
(ADA) activity, lysozyme levels and un-stimulated IFN-γ (uIFN-γ) have also been associated with 
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TB pericarditis, and considered of significant value in the diagnosis of TB pericarditis (Reuter et 
al., 2006) (Pandie et al., 2014) (Kim et al., 2018)(Seo et al., 2020).   
The poor definition of end points makes TB pericarditis a therapeutic challenge (Sharma and 
Mohan, 2019). The immediate goal of treatment involves symptomatic relief for the patient 
whereas the long term management plan centres on the prevention of constrictive pericarditis 
(Mayosi et al., 2005).  The standard of care for TB pericarditis is similar to the management of 
TB and involves a minimum of six months of therapy with two months of intensive drug phase 
using four anti-tuberculous drugs namely rifampicin, isoniazid, ethambutol, and pyrazinamide 
followed by at least four months of dual drug therapy (Isiguzo et al., 2020). 
 Tuberculous constrictive pericarditis 
Constrictive pericarditis represents the end stage of TB pericarditis pathology. It is 
characterised by thickening, fibrotic scarring and/or calcification of the visceral and parietal 
pericardial pleura, which restricts diastolic cardiac filling, hence leading to cardiac failure 
(Mayosi et al., 2005).  Up to 26% of patients with TB pericarditis develop constrictive 
pericarditis if untreated; effective antituberculous medication including rifampicin-based 
therapy merely reduces this progression rate to around 17% (Trautner and Darouiche, 
2001)(Mayosi et al., 2008)(Noubiap et al., 2019)(D’Elia et al., 2019).  The evolution of TB 
pericarditis to constriction with or without an effusion is the fastest of all the different forms 
of pericarditis, which explains the poor short term prognosis of the disease (Mayosi et al., 
2008).  This may be due to the poor penetration and rapid clearance of rifampicin into the 
pericardial space.  A decreased penetration of the drug has been measured in the pericardium 
over time, supporting previous observations of the rapid progression to thickening and fibrosis 
of the pericardium in TB pericarditis (Shenje et al., 2015).   
Recently, the debate surrounding the use of corticosteroids in the management of the 
condition was addressed by the Investigation of the Management of Pericarditis (IMPI) trial 
which revealed a significantly reduced rate of constrictive pericarditis in both HIV negative and 
positive  patients on prednisone (Mayosi et al., 2014).  Corticosteroids also reduce the need 
for repeat pericardiocentesis and deaths from pericarditis in HIV negative patients.  However 
in the same trial, corticosteroids increased the risk of opportunistic malignancies and a 
subsequent Cochrane review  found that their efficacy  in the HIV positive population not 
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conclusive (Wiysonge et al., 2017). The value of routine surgical drainage in the effusive stage 
of pericarditis  as a preventative measure remain unclear (Schwefer et al., 2009) 
The treatment of choice for those with established constrictive pericarditis is a pericardiectomy 
with complete decortication of the pericardium (Depboylu et al., 2017).  To date, there are no 
effective predictors for constrictive pericarditis, and a lack of prophylactic therapy.  Cardiac 
tamponade in the early clinical stage of TB pericarditis is the best predictive factor of 
subsequent constrictive pericarditis (Schwefer et al., 2009).  High ADA levels are also prognostic 
for the development of constrictive pericarditis (Burgess et al., 2002).  Importantly, the degree 
of fibrosis of the pericardium at the onset of treatment may constitute the most important 
determinant of whether or not constriction develops (Suwan and Potjalongsilp, 1995).  Further, 
the rates of constrictive pericarditis are considerably lower in patients with effective 
pericardiocentesis, suggesting that the removal of pro-inflammatory and profibrotic cytokines 
from the pericardium may thereby reduce the fibrotic process (Naicker and Ntsekhe, 2020). 
 
Fibrosis refers to the hyper-proliferation, hardening and tissue scarring which arises as a result 
of collagen and extracellular matrix accumulation (ECM).  Fibrosis and fibrotic disorders arise 
in a number of organ systems as a result of interstitial fibroblast proliferation from marrow 
stromal cell progenitors or epithelial-mesenchymal transition (EMT) (Iwano et al., 2002).  In 
contrast to the controlled fibroblast to myofibroblast transformation which promotes wound 
contraction and healing in acute inflammation, fibrosis is usually a consequence of chronic 
inflammation.  An increased turnover of the net collagen and ECM levels arises in chronic 
inflammation leads to the gradual formation of fibrotic scar tissue and subsequent loss of organ 
function, typical of organ fibrosis (Wynn, 2007) (Wynn, 2008). 
 Aetiology of fibrosis 
Fibrosis represents the pathological end stage of various inflammatory diseases; Table 1-3 
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Table 1-3: Major organ systems affected by fibrogenesis. 
Liver Viral hepatitis, alcohol-abuse, related pathologies, schistosomiasis, 
hepatocellular cancer 
Lung Idiopathic lung disease, pulmonary hypertension, right sided heart failure, 
sarcoidosis, silicosis, infections, rheumatoid arthritis, systemic sclerosis 
Kidney Diabetes, hypertension, anaemia  
Heart/ vascular Myocardial infarction, hypertension, atherosclerosis, restenosis, 
infections, arrhythmias 
Eye Macular degeneration, retinal and vitreal retinopathy, strabismus 
Skin Systemic sclerosis, scleroderma, burns, keloids and hypertrophic scars 
Pancreas Diabetes, malabsorption, cancer 
Adapted from (Wynn, 2008) and (Rockey et al., 2015). 
 Molecular mechanisms of fibrosis 
Molecular mechanisms of fibrogenesis involve unique contributing factors for different 
pathologies; however, certain key processes and pathways are common to most fibrotic 
events.  The fibrotic cascade of events is triggered upon insult to epithelial or endothelial cells 
which release inflammatory mediators resulting in the activation of the coagulation cascade.  
The formation of blood clots gives rise to a provisional ECM to which platelets are exposed 
(Diegelmann, 2004).  They respond by aggregating and propagating the blood clot before 
releasing a plethora of effector proteins through degranulation and lysis which induce 
vasodilation and enhance blood vessel permeability.  Simultaneously, the epithelial or 
endothelial cells, aided by stimulated myofibroblasts, produce matrix metalloproteases 
(MMPs) which degrade the basement membrane.  The combination of these processes results 
in the recruitment of inflammatory cells to the site of injury (Kalluri and Neilson, 2003).  The 
initial inflammatory response is characterised by the release of various pro-inflammatory 
cytokines, including tumour necrosis factor-α (TNF-α)(Wynn, 2007)(Wynn, 2008).  TNF-α is a 
pleiotropic cytokine with a central role in the activation and recruitment of immune cells and 
the regulation of pro-inflammatory cytokine production (Parameswaran and Patial, 2010).  
Activated leukocytes then proceed to release pro-fibrotic cytokines such as IL-13 and TGF-β 
which drive EMT and ECM component production.  These include hyaluronic acid, fibronectin, 
proteoglycans, and interstitial collagens which accumulate to form the fibrotic scar (Frantz et 
al., 2010). 
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 TGF-β: a master regulator of fibrosis 
TGF-β belongs to the TGF-β super-family of secreted polypeptide factors comprising BMPs, 
activins, inhibins, and other growth and differentiation related factors.  The TGF-β family 
regulates a range of cellular responses in various cell types, including growth, differentiation, 
migration and apoptosis (Miyazono, 2000).   
TGF-β responses are not only diverse, but highly complex.  The cytokine mediates different 
effects in different physiological contexts; it also has antithetic effects in cells of different 
developmental lineages (Lai et al., 2005)(Moustakas et al., 2002).  For example, TGF-β 
stimulates ECM deposition, cardiomyocyte hypertrophy and fibroblast proliferation in the 
heart, leading to overall cardiac hypertrophy and dysfunction (Rosenkranz, 2004).  In the blood 
vessel however, TGF-β inhibits leukocyte recruitment and activation, migration of vascular 
smooth muscle cells and prevents formation of unstable lesions; these processes exert a 
protective role in atherosclerosis (Grainger, 2004).  The physiological role of TGF-β and its 
centrality in various signalling pathways is highlighted in various TGF-β knock-out mice models 
where mice present with life-threatening systemic inflammation, rapid wasting and premature 
death (Kulkarni et al., 1993)(Shull et al., 1992).  Whilst some TGF-β antagonists effectively 
reduced rates of metastasis in mice without significant side effects, the mouse immune 
response to a simultaneous infection or environmental stressor remains to be investigated 
(Yang et al., 2002)(Akhurst, 2002). 
 Synthesis of the TGF- β complex 
TGF-β occurs as three isoforms (β1, β2, and β3) transcribed from three separate genes and 
encoded as large precursor proteins, linked to a unique Latency Associated Protein (LAP), of 
390–412 amino acids in size (Massague et al., 1994).  The precursor proteins are processed in 
various stages in the Golgi apparatus and the endoplasmic reticulum prior to being secreted 
(Figure 1-3).  Briefly, two TGF-β precursor proteins dimerise via disulphide bridge formation.  
Furin then cleaves the TGF-β dimer between amino acids 278 and 279 to yield the N-terminal 
LAP protein, and the 25KDa C-terminal mature TGF-β dimer.  These two portions however 
remain connected by non-covalent bonds, termed the small latent TGF-β complex (Tran, 2012) 
(Hayashi and Sakai, 2012). The LAP is necessary for proper TGF-β homo-dimer folding and its 
secretion from cells.  Various Latent TGF-β Binding Proteins (LTBP) such as LTBP-1, LTBP−3 and 
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LTBP−4, can thereafter bind to LAP to yield a large latent TGF-β complex which further 
facilitates the secretion of TGF-β and its incorporation into the ECM (Massagué et al., 2000). 
 
Figure 1-3: TGF-β synthesis in the cell. 
Following dimerisation of the precursor, furin cleaves the Latency Associated Protein- LAP from the TGF-β 
homo-dimer. LAP and mature TGF-β remain associated in a non-covalent fashion in the small latent complex 
which can bind Latent TGF- β binding protein- LTBP to form the large latent complex. 
Adapted from (Hayashi and Sakai, 2012) 
 
 TGF- β signalling 
TGF-β is a key mediator of the fibrotic response and it acts via canonical (small mother against 
decapentaplegic (Smad)-dependent) and non-canonical (non-Smad-based) signalling pathways 
to coordinate an ECM accumulation through increased synthesis as well as a reduced 
degradation of ECM components (Branton and Kopp, 1999)(Moustakas et al., 2001)(Zhang, 
2009).   
In the canonical TGF-β/Smad pathway, TGF-β family members activate type I and type II 
serine/threonine kinase receptors on the cell surface membrane (Figure 1-4)(Dijke and Hill, 
2004).  Ligand binding to the type II receptor results in type I receptor kinase activation through 
the phosphorylation of a glycine-serine rich region of the juxta-membrane domain of the type 
I receptor.  The type I receptor propagates an intracellular signalling cascade by 
phosphorylating (Smad) proteins (Miyazono et al., 2000).  Smad proteins are grouped into 
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three subclasses namely the receptor-regulated Smads (R-Smads), common-partner Smads 
(Co-Smads) and inhibitory Smads (I-Smads).  R-Smads (Smad 1, Smad 2, Smad 3, Smad 5 and 
Smad 8) anchored to the cell surface membrane are activated via phosphorylation by the type 
I receptor and recruit Smad 4 (the Co-Smad) to form heteromeric complexes.  These complexes 
translocate to the nucleus where they recruit histone acetyl-transferases to induce 
transcription of their target genes.  The I-Smads, Smad 6 and Smad 7, are antagonists of the R-
Smads and inhibit their signalling by various mechanisms.  They inhibit R-Smad binding to the 
type I receptor by acting as competitive inhibitors and recruit Smad ubiquitination regulatory 
factors (Smurfs) to activate type I receptors, promoting their ubiquitination and degradation 
(Miyazono, 2000)(Dijke and Hill, 2004)(Lai et al., 2005).  
 
Figure 1-4: Illustration of TGF-β/Smad signalling in fibrosis.   
TGF- β binding to its receptor induces dimerisation of the Type I and Type II receptors which get activated to 
induce on the cytosolic side, R-Smad (Smad2/3) phosphorylation and activation.  The R-Smads associate with 
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 Molecular mechanisms of constrictive pericarditis 
Molecular mechanisms of pericardial constriction remain to be fully elucidated but are likely 
to follow a classical pattern of pericardial inflammation mediated by various cytokines (Table 
1-4), including TNF-α, followed by abnormal healing with an exaggerated TGF-β mediated pro-
fibrotic response leading to pericardial fibrosis.  Both experimental mice models of acute 
pericarditis and pericardial fluid from patients with tuberculous ECP (associated with a high 
incidence of pericarditis), demonstrate a mixed picture of both pro-inflammatory IFN-γ, and 
anti-inflammatory cytokines IL-8, and IL-10 (Fairweather et al., 2004), but their exact roles are 
as yet unclear.  
Patterns of inflammation and fibrosis in the pericardium suggest that both myocardial and 
pericardial cells play a role in the pathogenesis of pericarditis and constriction.  A change in 
mesothelial cell morphology has been consistently described in various forms of pericarditis.  
Further, a loss of the mesothelial cell architecture, as well as mesothelial desquamation often 
accompanies constrictive pericarditis.  The transition from a ‘flat’ to a ‘cuboidal’ shape has 
been associated with an ‘activation’ of mesothelial cells and a distinct enzymatic profile of the 
cells with functions being geared towards oxidative stress and inflammatory responses 
(Vogiatzidis et al., 2015)(Whitaker et al., 1982).  Activated mesothelial cells secrete chemokines 
and adhesion molecules to aid in the recruitment and migration of leukocytes across the 
mesothelium.  They are also known to mediate the inflammatory process and produce ECM 
components (Mutsaers et al., 2015).  Further, mesothelial cells can undergo phenotypic 
changes similar to EMT transition to adopt fibroblast-like morphology and function in the 
healing serosa (Yáñez-Mó et al., 2003)(Mutsaers, 2002).  The active regulation of both pro- and 
anti-inflammatory mediators by mesothelial cells suggests a key role for the cells in maintaining 
pericardial homeostasis and in the pathogenesis of pericardial fibrosis.  Pericardial interstitial 
cells (PICs) have also been implicated in the production of ECM and calcification in the 
pericardium (Liu et al., 2012).  PICs have a comparable immune phenotype to mesenchymal 
stem cells.  PICs cultured from fibro-calcific human samples could be differentiated into 
myofibroblasts and osteoblasts which are central to the development of fibrosis and the 
production of extra-osseous calcification.  TGF-β and bone morphogenetic protein 2 (BMP-2) 
are associated with the trans-differentiation process.   
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Table 1-4: Summary of inflammatory and fibrotic cytokines and growth factors (detected in pericardial 









ECM deposition and remodelling 
(Yarnold and Vozenin Brotons, 
2010) (Ristić et al., 2013) (Ntsekhe 




ECM deposition and remodelling 
(Yarnold and Vozenin Brotons, 
2010)  
TNF-α 
Inducer and regulator of inflammation 
Macrophage and Natural Killer cell 
recruitment 
(Ristić et al., 2013) (Pankuweit et 
al., 2000) 
IL-6 
Late role in inflammatory cascade 
Adaptive Immune system activation 
(Ristić et al., 2013) (Pankuweit et 
al., 2000) 
IL-8 
Later role in inflammatory cascade 
Neutrophil cell recruitment 
(Ristić et al., 2013) (Pankuweit et 
al., 2000) 
IL-10 Inflammatory mediator (Ntsekhe et al., 2013) 
IFN-γ 
Immune response modulation 
Macrophage and NK cell activation 
Antifibrotic 
(Ristić et al., 2013) (Pankuweit et 
al., 2000) (Karatolios et al., 2012) 
(Ntsekhe et al., 2013) (Kulkarni et 
al., 1995) 
VEGF 
Angiogenesis and fibrosis promotion 
Fibrosis resolution 
(Karatolios et al., 2012) 
bFGF ECM deposition 
(Karatolios et al., 2012) (Byers et 
al., 1997) 




(Ntsekhe et al., 2012) 
 
Increased pericardial fluid and serum levels of TGF-β have been described in various forms of 
pericarditis and have been associated with increased collagen synthesis.  Thus, TGF-β might 
play a key role in the development of fibrosis in the pericardium.  Interestingly, Ristic et al. did 
not detect any increase in TGF-β levels in viral pericardial fluid and this could account for the 
low proportion of constrictive pericarditis arising in this group (Ristić et al., 2013).   
An increase in connective tissue growth factor (CTGF) was associated with ECM deposition and 
pericardial remodelling (Yarnold and Vozenin Brotons, 2010).  This is not surprising as CTGF 
expression is known to be induced by TGF-β in cardiac fibroblasts and cardiac myocytes, 
whereby it contributes to the expression of fibronectin, collagen type I and plasminogen 
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activator inhibitor-1 (Chen et al., 2000).  Interestingly, a decrease in vascular endothelial 
growth factor (VEGF) was observed in viral pericarditis which rarely results in a constrictive 
pericarditis.  Whilst VEGF mediated angiogenesis is known to be important for the promotion 
of fibrosis, it also plays a role in fibrosis resolution (Yang et al., 2014).  Indeed, an angio-fibrotic 
switch of VEGF and CTGF has been described in proliferative diabetic retinopathy, whereby the 
VEGF to CTGF ratio closely dictates the progression to fibrosis (Geest et al., 2012) (Kuiper et al., 
2008).  CTGF has also been shown to bind to VEGF and to inhibit its angiogenic functions (Inoki 
et al., 2002).  It is possible that such CTGF-VEGF interplay is also involved in the progression to 
fibrosis in the pericardium.  This would further explain the high VEGF levels coinciding with low 
levels of basic fibroblast growth factor (bFGF) in viral pericardial fluid. 
Galectin-3 (Gal-3) levels were found to be mildly but non-significantly up-regulated in TB 
pericardial fluid (Ntsekhe et al., 2012). Gal-3, also referred to as MAC-2 antigen belongs to a 
large family of β-galactoside-binding adhesion and growth-regulation lectins. Gal-3 expressed 
by inflammatory cells is a major player in cardiac inflammation and fibrosis.  Elevated Gal-3 
levels induce the release of various fibrotic mediators, including, IL-1 and IL-2 to promote 
cardiac fibroblast proliferation, collagen deposition (De Boer et al., 2010) (Henderson et al., 
2006). 
Finally, Ac-SDKP, which is known to decrease TGF-β signalling (Castoldi et al., 2009) (Kanasaki 
et al., 2003) (Pokharel et al., 2004) (Lin et al., 2008), may play a role in the progression of 
pericardial fibrosis.  As previously mentioned, patients with TB pericarditis, have been found 
to have diminished Ac-SDKP levels compared to participants without pericarditis (Ntsekhe et 
al., 2012).  Lowered Ac-SDKP levels could arise from an increase in ACE activity, which is known 
to degrade Ac-SDKP (Azizi et al., 2001) (Inoue et al., 2011).   
On a gene expression level, a range of changes in various forms non-coding RNAs, including 
microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) are likely 
to influence signalling pathways involved in the fibrotic process.   A recent study on differential 
gene expression in patients with constrictive pericarditis has identified a plethora of 
differentially expressed mRNAs likely to contribute to the pathological processes involved in 
constriction (Chen et al., 2020).   These RNA functions were mapped predominantly to 
inflammation processes, including apoptotic process, regulation of immune system process, 
cell activation and adhesion, chemokine signalling and leukocyte activation.  Importantly, 
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deregulation of the known inflammatory STAT1 and RUNX3 transcriptional factors were also 
observed (Chen et al., 2020).  
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 ACE in the RAAS and KKS 
ACE is a key enzyme of the RAAS which has two components: a circulating RAAS is involved in 
the homeostasis of systemic perfusion and a tissue RAAS operates at the local tissue level.  
Whilst the functions of the circulating and tissue RAAS and their effects differ, the pathways 
are common for both (Xiao et al., 2004).  ACE hydrolyses the metabolically inactive decapeptide 
angiotensin I (AngI) generating the octapeptide angiotensin II (AngII) and a histidyl-leucine (HL) 
dipeptide (Skeggs Jr et al., 1954)(Skeggs Jr et al., 1956).  AngII is a potent vasopressor which 
mediates its effects via the angiotensin receptor type I (AT1).  These effects include sodium 
reabsorption, growth and differentiation, and aldosterone secretion (Kaschina and Unger, 
2003).  AngII binding to the AT1 receptor also influences cell growth, inflammation and fibrosis 
besides mediating circulatory integrity (Suzuki et al., 2003).   
 
 
Figure 1-5: Schematic representation of the RAAS and KKS.  
ACE cleaves Ang I, resulting in the formation of angiotensin II, which predominantly mediates 
vasoconstriction, aldosterone secretion, renal sodium reabsorption and cell growth and migration by 
binding the commonly expressed AT1 receptor.  ACE also degrades BK preventing the vasodilation and 
nitric oxide release which occurs upon its binding to the B2 receptor. 
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Ang II can also bind the angiotensin receptor type II (AT2) to mediate a plethora of counter-
regulatory effects including immune modulation, the prevention of inflammation and fibrosis, 
neuroprotection and neuroregeneration, as well as antihypertensive and antiapoptotic actions 
(Namsolleck et al., 2014) (Steckelings et al., 2017).   
ACE also hydrolyses the vasodilator bradykinin (BK) in the KKS, thus preventing its binding to 
the bradykinin B2 receptor (Yang et al., 1971).  Operating as a central node in the RAAS and KKS 
(Figure 1-5), ACE is thus critical for the physiological regulation of blood pressure, by mediating 
both a downstream increase in vasoconstriction (AT1) and decrease in vasodilation (B2). 
 Properties of ACE 
ACE (EC 3.4.15.1) is a zinc dipeptidyl carboxypeptidase of the M2 gluzincin family, involved in 
the hydrolysis of dipeptides from the carboxyl terminus of a range of oligopeptides (Sturrock 
et al., 2004) (Hooper, 1994). 
There are two distinct isoforms of ACE in human tissue: a somatic form (sACE) and a smaller 
germinal form found in the testes (tACE) (Soubrier et al., 1988) (Ehlers et al., 1989).  Both sACE 
and tACE are transcribed through two alternate promoters from a single 21kb gene on 
chromosome 17, which comprises 26 exons, to give rise to the 170kDa and 110kDa protein 
respectively (Hubert et al., 1991) (Ehlers et al., 1989).   
Approximately 90% of the sACE exists as a membrane bound form on the plasma membranes 
of vascular endothelial cells, microvillar brush border epithelial cells, and neuro-epithelial cells 
(Caldwell et al., 1976) (Ryan et al., 1976).  The ACE protein is composed of a larger ectodomain 
which is found in the extracellular space and a shorter C-terminal intracellular cytoplasmic 
region (Figure 1-6).  A small trans-membrane region anchors the enzyme on the cell surface 
(Soubrier et al., 1988). Both sACE and tACE are solubilised from their membrane form, through 
the proteolytic cleavage of a protease (‘sheddase’) at identical sites in the juxtamembrane or 
stalk region (Ehlers et al., 1996).   
 
 
Figure 1-6: Schematic representation of sACE 
TM: transmembrane region, CT: cytoplasmic tail region 
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 ACE protein domains 
Somatic ACE comprises two individual domains termed the N and C domains which share an 
overall  60% sequence identity and 90% identity in their catalytic active sites (Soubrier et al., 
1988).  The two domains are joined via a small linker region and likely occured as a result of a 
gene duplication event in their evolutionary history (Hubert et al., 1991).  Each domain contains 
within its active site, a His-Glu-X-X-His motif which tetrahedrally coordinates a zinc atom (Wei 
et al., 1991).  Both the N and C domains exhibit independent catalytic activity, but they are not 
catalytically equal (Wei et al., 1991).  The enzymatic activity of the C domain is heavily reliant 
on chloride ion concentration as compared to the N domain (Wei et al., 1991).  Importantly, 
the rates of substrate hydrolysis and the sensitivity to inhibitors differ across the two domains 
(Wei et al., 1992) (Jaspard et al., 1993).  
 ACE substrates 
ACE cleaves a myriad of peptides or varying sizes besides Ang I and BK.  As mentioned, the two 
domains of ACE display substrate selectivity making them preferential sites of hydrolysis for 
certain substrates.  For instance, the cleavage of AngI is carried out predominantly by the C 
domain (Fuchs et al., 2008) (Wei et al., 1991) whereas the N domain is predominantly 
responsible for the metabolism of other biologically active peptides including amyloid beta-
peptide (Aβ), Ac-SDKP and GnRH (Zou et al., 2007)(Rieger et al., 1993)(Skidgel and Erdös, 1985).  
Given the wide range of physiological peptides cleaved by ACE, it is no surprise that the known 
roles of ACE have vastly expanded beyond those of blood pressure regulation and fluid 
homeostasis in the RAAS to important functionalities in inflammation, haematopoiesis and 
immune modulation in more recent years (Bernstein et al., 2018).   
 Ac-SDKP 
Ac-SDKP, previously known as goralatide or seraspenide, was first extracted from fetal calf bone 
marrow as an inhibitor of haematopoietic cell proliferation, specifically of the spleen colony 
forming unit (Frindel and Guigon, 1977).  It was subsequently purified and its tetrapeptide 
amino acid sequence identified in 1989 (Lenfant et al., 1989).  Ac-SDKP is ubiquitously found in 
mammalian tissues, with a higher level of expression in the spleen (Pradelles et al., 
1990)(Pradelles et al., 1991). 
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 Biological synthesis of Ac-SDKP 
Ac-SDKP is formed from the enzymatic cleavage of its precursor thymosin β4 (Tβ4): an 
exogenous addition of Tβ4 to kidney homogenates in vitro results in an increase in the 
production of Ac-SDKP (Lenfant et al., 1991) (Cavasin et al., 2004).  Tβ4 is a small intracellular 
peptide of the thymosin family, composed of 43 amino acid residues.  It was first isolated from 
bovine thymus tissue as one of the biologically active peptides in thymosin fractions, which are 
involved in the regulation and differentiation of lymphocytes of thymic origin (Low et al., 1981) 
(Low and Goldstein, 1982).  Various functions have been attributed to Tβ4 including the 
sequestering of intracellular actin through binding and stabilising of monomeric G-actin, 
cardioprotection, wound healing and angiogenesis (Mannherz and Hannappel, 2009).   
 
 
Figure 1-7: Biological synthesis of Ac-SDKP 
Ac-SDKP is formed from the sequential cleavage of thymosin β4 by the enzymes meprin-α (at 
putative cleavage sites indicated by the yellow arrows) and POP.  The tetrapeptide mediates 
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Ac-SDKP represents the N terminal sequence of Tβ4 and is generated by a two-step hydrolysis 
process (Figure 1-7).  The first step, mediated by meprin-α, produces an NH2-terminal 
intermediate peptide and the second step involves the cleavage of a Pro-Asp bond by the 
enzyme prolyl oligopeptidase (POP)(Kumar et al., 2016) (Crockford et al., 2010) (Cavasin et al., 
2004) (Grillon et al., 1990).  Long term POP inhibitor administration has been shown to 
significantly reduce circulating plasma levels of Ac-SDKP in vivo without affecting blood 
pressure levels (Cavasin et al., 2004)(Cavasin et al., 2007).   
The precise mechanism of Ac-SDKP binding and interaction with the FGFR1 receptor has not 
been elucidated. However, colocalisation of Ac-SDKP with the receptor to induces its 
phosphorylation has been observed (Li et al., 2017).  FGFR1 is a known inhibitor of fibrosis by 
inhibiting the TGF-β/Smad pathway.  These observations have led to speculation that the FGFR-
1 receptor might be the endogenous receptor or one of the endogenous receptors for Ac-SDKP 
(Li et al., 2017).  Phosphorylation of FGFR1 on the cytoplasmic side upon binding/ interaction 
in the extracellular environment results in the mitogen-activated protein kinase kinase kinase 
kinase 4 (MAP4K4) being recruited and phosphorylated both in vitro and in vivo. 
Phosphorylated MAP4K4 suppresses integrin-β1, which is a potent activator of TGF-β.   
An alternate mechanism of activation has been proposed by Gao et al., which involves the β-
klotho protein (KLB) of the newly defined klotho protein group (R. Gao et al., 2019).  There are 
type I single‐pass trans-membrane proteins, which have a high degree of homology to family 1 
β‐glycosidases, involved in fibrosis regulation (Doi et al., 2011)(Satoh et al., 2012). Ac-SDKP was 
shown to increase KLB expression through interaction with FGFR1.  KLB expression inhibits 
EndMT through inhibition of MEK1/2 and ERK1/2 phosphorylation (R. Gao et al., 2019).  
 Cleavage of Ac-SDKP by ACE 
ACE is the predominant enzyme responsible for Ac-SDKP hydrolysis in vivo; an acute inhibition 
of ACE by the slightly N domain-selective inhibitor captopril resulted in almost total abolition 
of [3H]-Ac-SDKP (radiolabelled tetrapeptide) hydrolysis.  Importantly, single dose 
administration of captopril caused an approximately 5.5-fold increase in plasma levels of Ac-
SDKP in healthy human subjects (Azizi et al., 1996) (Inoue et al., 2011).  Similarly, chronic ACE 
inhibition by ACEi, regardless of their chemical characteristics, resulted in approximately a five-
fold increase in Ac-SDKP levels in both hypertensive and normotensive subjects (Azizi et al., 
1997).  A massive accumulation of Ac-SDKP during chronic ACEi therapy has not been observed, 
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however.  This is due to an intermittent reactivation of ACE in between doses of ACEi as well 
as an increase in the glomerular filtration of Ac-SDKP by the kidney.  A 2- to 5-fold increase in 
urinary Ac-SDKP concentration is observed in chronic ACE inhibition (Azizi et al., 1999) (Comte 
et al., 1997). 
Ac-SDKP displays similar affinities for the N and C domains of ACE.  However, in studies 
whereby one of the ACE domains was catalytically inactivated by a mutation of the zinc 
coordinating residue, the N domain was found to be 40 times more effective at cleaving Ac-
SDKP as compared to the C domain.  Further, a monoclonal antibody to the N domain resulted 
in a similar level of inhibition in both the wild type recombinant somatic ACE as compared to 
the ACE N active mutant of ACE (C domain inactive), suggesting that the N domain is the 
primary site of Ac-SDKP hydrolysis (Rousseau-Plasse et al., 1996).  Abz-SDK(Dnp)P-OH, a 
fluorescent analogue of Ac-SDKP-OH, in which Abz and Dnp (2,4-dinitrophenyl) are the 
fluorescent donor-acceptor pair was hydrolysed with high specificity by the N domain of ACE 
at the D-K(Dnp) bond with hardly any cleavage by the C domain (Araujo et al., 2000).  Hence, 
ACE cleaves Ac-SDKP by a dipeptidase activity, generating the C-terminal dipeptide Lys-Pro 
from Ac-SDKP.  Hydrolysis by ACE is believed to be the first limiting step of Ac-SDKP degradation 
in human plasma (Rieger et al., 1993).  
 Ac-SDKP as an inhibitor of cell proliferation 
Ac-SDKP was discovered with regards to its ability to inhibit haematopoietic stem cell 
proliferation.  The protective effect of Ac-SDKP is conferred by its ability to reversibly inhibit 
the high proliferative activity of most primitive haematopoietic cells as well as their progenitors 
at nanomolar concentrations (Cashman et al., 1994) (Bonnet et al., 1993). Ac-SDKP 
demonstrated the ability to prevent G0/G1 progression into S phase in continuous cell lines in 
vivo as well as in vitro (Volkov et al., 1996).  Ac-SDKP at physiological levels was shown to  inhibit 
the entry of cardiac and renal cells into the S phase of the cell cycle (Iwamoto et al., 2000)(Peng 
et al., 2001).  Importantly, Ac-SDKP improved the recovery of haematopoietic progenitor cells 
in vivo against 5-fluoroacil with a significant increase in the number of colony forming units 
after exposure to the chemotherapeutic agent (Aidoudi et al., 1996).  Administration of Ac-
SDKP also allows for protection from Ara-C, as shown by higher levels  of circulating blood cells 
in recovery periods (Bogden et al., 1998).  
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Initial interest into the therapeutic potential of exogenous Ac-SDKP administration was centred 
on haematopoietic cell protection during cancer chemotherapy (Carde et al., 1992).  However, 
further studies have not been reported. 
 Ac-SDKP as an inhibitor of fibrosis 
A physiological role for Ac-SDKP in preventing fibrosis has been shown by Cavasin et al. By 
inhibiting POP which releases Ac-SDKP from Tβ4, there was increased collagen deposition in 
various organ tissues leading to cardiac and renal perivascular fibrosis and nephro-sclerosis, 
thereby implicating Ac-SDKP in the prevention of organ fibrosis (Cavasin et al., 2007).  
 Ac-SDKP in cardiac fibrosis  
Cardiac remodelling in hypertensive and ischaemic pathologies is a major cause of chronic 
heart failure and is characterised by cardiac hypertrophy and fibrosis.  Both in cardiac failure 
and post MI, inflammatory responses play a key role in the pathogenesis of interstitial and 
perivascular cardiac fibrosis.  ACEi have been shown to exert protective effects in ischaemic 
pathology with a regression of myocardial fibrosis and an improvement in left ventricular 
function on lisinopril therapy (Brilla et al., 2000).   
Various studies, outlined below, suggest a role for Ac-SDKP in the protective effects of ACE 
inhibition in cardiovascular pathology.  An increase in the endogenous expression of cardiac 
ACE was correlated with a decrease in Ac-SDKP levels in the heart giving rise to cardiac fibrosis 
(Pokharel et al., 2004).  Ac-SDKP has been shown to inhibit cardiac fibroblast proliferation as 
measured by serum-stimulated 3H-thymidine incorporation (Rhaleb et al., 2001b).   
In a 2-kidney, 1-clip (2K-1C) rat model of hypertension, small levels of Ac-SDKP were able to 
reduce cell proliferation, macrophage infiltration as well as collagen synthesis in the left 
ventricular (LV) interstitial spaces and to prevent right ventricular fibrosis (Rhaleb et al., 2001a).  
Ac-SDKP specifically decreased the cardiac infiltration of pro-inflammatory M1 macrophages 
but not M2 macrophages and neutrophils in a mice model of heart failure (Nakagawa et al., 
2018). However, the peptide failed to reduce the dry weight of the ventricles, implicating a 
different mechanism for the prevention of LV hypertrophy during ACE inhibition (Peng et al., 
2001). Yang et al., observed that treatment with Ac-SDKP not only prevented cardiac fibrosis 
but also reversed the fibrotic process in non-infarcted regions of the myocardium.  The 
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tetrapeptide has been shown to inhibit the inflammatory process associated with infarction 
(Yang et al., 2004) (Song et al., 2014).  
Ac-SDKP was also found to be an inhibitor of aortic fibrosis (Lin et al., 2008). Moreover, Ac-
SDKP protects against diabetic cardiomyopathy with marked reduction in interstitial and 
perivascular collagen deposition in diabetic rats even under conditions whereby their blood 
glucose levels and blood pressure were high.  Ac-SDKP administration partially abolished the 
diastolic dysfunction associated with diabetes (Castoldi et al., 2010).   
 Ac-SDKP in renal fibrosis 
Ac-SDKP has demonstrated beneficial effects on renal inflammation and fibrosis in various 
models of renal pathology (Chan et al., 2015) (Rhaleb et al., 2001b).  Mesangial cell 
proliferation and mesangial cell hypertrophy occurs in a range of glomerular pathologies.  Ac-
SDKP was observed to inhibit mesangial cell DNA synthesis and hence proliferation without 
affecting their viability (Kanasaki et al., 2006).  
In aldosterone-salt hypertension rats which develop renal fibrosis, Ac-SDKP markedly reduced 
interstitial collagen deposition and fibroblast proliferation (Peng et al., 2001).  Furthermore, 
Ac-SDKP reduced urinary albuminuria and reduced macrophage infiltration in salt-sensitive 
hypertension model of kidney disease (M. Wang et al., 2010).  
Ac-SDKP administration in diabetic rats was also effective at decreasing glomerular, and 
perivascular fibrosis, conferring better protection than the ACE inhibitor ramipril.  Co-
treatment with both Ac-SDKP and ramipril further reduced fibrosis, demonstrating an additive 
effect of Ac-SDKP with respect to ACE inhibition only (Castoldi et al., 2013).  In unilateral ureter 
obstruction models, a reduction in renal interstitial inflammation and fibrosis caused by the 
ACEi captopril was found to be mediated by the increase in Ac-SDKP levels (Chan et al., 2018). 
 Ac-SDKP in other forms of fibrosis 
Ac-SDKP also exerted protective effects in bile duct ligation-induced liver fibrosis and 
ameliorated carbon tetrachloride-induced liver fibrosis (Zhang et al., 2012).  In cases of lung 
silicosis, Ac-SDKP reduced the extent of collagen deposition and myofibroblast differentiation 
(Xu et al., 2012)(Deng et al., 2016)(Y. Sun et al., 2010)(Xiaojun et al., 2016)(X. Gao et al., 2019). 
Ac-SDKP treatment reversed AngII mediated collagen deposition through a restoration of the 
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protective arm of the RAAS axis, namely the ACE2/Angiotensin 1-7 (Ang 1-7)/Mas in silicotic 
rats and in fibroblasts (X. Gao et al., 2019).  
 
 
Antifibrotic effects of Ac-SDKP appear to be mediated by numerous cell signalling pathways, 
likely to involve an Ac-SDKP receptor.  Using the radioactive analogue 125I-Hpp-Aca-SDKP, Zhuo 
et al., demonstrated the presence of a single class of high-affinity and highly specific receptor 
binding sites for Ac-SDKP in cardiac fibroblasts (Zhuo et al., 2007). 
A wide range of cytokines which promote cell growth and proliferation as well as ECM 
accumulation contribute to the development of organ fibrosis.  Some of the major drivers of 
fibrosis include TGF-β, PDGF, CTGF, endothelin-1 (ET-1) and AngII (Leask, 2010).  Hence, various 
studies have investigated the role of Ac-SDKP in modulating the signalling pathways initiated 
by these cytokines.  
 
 
 Ac-SDKP modulation of the TGF-β pathway 
Ac-SDKP decreases levels of TGF-β in a dose-dependent manner by decreasing TGF-β 
transcription (Castoldi et al., 2010).  Administration of the tetrapeptide in rat cardiac fibroblasts 
significantly reduced the luciferase signal in a Smad-sensitive luciferase construct in cardiac 
fibroblasts.  The phosphorylation of Smad2 and Smad3 and their translocation to the nucleus 
is inhibited by Ac-SDKP in the cells in vitro and in vivo (Pokharel et al., 2002) (Kanasaki et al., 
2003) (Pokharel et al., 2004)(Lin et al., 2008)(Castoldi et al., 2010).  Furthermore, Ac-SDKP 
increases the cytoplasmic distribution of I-Smad (Smad 7).   
Interestingly, AngII is known to modulate TGF-β expression through the AT1 receptor in cardiac 
myocytes and fibroblasts.  This results in activation of nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase which stimulates TGF-β production (Bataller et al., 2003) 
(Rosenkranz, 2004).  Ac-SDKP also prevents AngII-mediated TGF-β expression and significantly 
inhibited the 5-fold increase in Smad-2 phosphorylation induced by AngII (Lin et al., 2008).  
Further, an increase in the levels of CTGF was attenuated by Ac-SDKP in the heart, probably 
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due to inhibition of TGF-β/Smad signalling (Peng et al., 2003).  While the relationship between 
Ac-SDKP and TGF- β has been demonstrated in both in vivo and in vitro rat and cell culture 
models, whether the same pathways and mechanisms are involved within the pericardium is 
not known. 
 Ac-SDKP and Map kinase signalling 
The cytosolic serine/threonine kinases, MAPKs are involved in cellular growth and proliferation 
pathways and they respond to various growth stimuli (Blenis, 1993). MAPKs play a vital role in 
fibroblast cell proliferation and have been implicated in AngII-mediated DNA synthesis and 
cardiac fibroblast proliferation via the AT1 receptor (Pagès et al., 1993)(Schorb et al., 1995).  
ET-1 is a potent vaso-constrictive peptide found at high circulating levels in various pathologies 
(Masaki, 2004).  It has been found to increase the synthesis of collagen and the proliferation of 
cardiac fibroblasts (Guarda et al., 1993) (Gray et al., 1998).  Ac-SDKP inhibits ET-1–induced 
collagen synthesis and reduces ET-1 dependent extracellular signal-regulated kinase (ERK1/2) 
phosphorylation by up-to 50% (Zhuo et al., 2007).  Ac-SDKP also attenuates the ET-1-mediated 
increase in intracellular calcium from basal levels (Zhuo et al., 2007).  Calcium signalling 
pathways play an important role in cell growth and proliferation by inducing the transcription 
of genes that allow cells in the resting (G0) stage to enter the mitotic cell cycle (Berridge, 
1995)(Berridge et al., 2000).   
In rat mesangial cells, ET-1 was shown to rapidly induce MAPK activation via the activation of 
protein kinase C and protein tyrosine kinases (Wang et al., 1992).  Ac-SDKP has indeed been 
shown to inhibit MAPK p44/42 activation in a biphasic and concentration-dependent fashion 
(Rhaleb et al., 2001a).  Peng et al., found that Ac-SDKP failed to inhibit ET-1 induced p44/42 
MAPK phosphorylation in cells where the Src homology 2-containing protein tyrosine 
phosphatase-2 (SHP-2) was knocked down.  SHP-2 is an unusual protein tyrosine phosphatase 
(PTP) which mediates Ras-MAPK activation by receptors for various cytokines as opposed to 
the negative regulatory functions of other PTPs (Matozaki et al., 2009).  It is thus highly likely 
that Ac-SDKP prevents p44/42 MAPK activation via SHP-2 activation (Peng et al., 2012). 
PDGF is a potent stimulant of cellular growth and proliferation of connective tissue including 
smooth muscle cells and fibroblasts (Bornfeldt et al., 1995).  Stimulation of cardiac fibroblasts 
with PDGF was shown to increase cellular proliferation.  An observed upregulation in ERK1/2 
and c-Jun N-terminal kinases  (JNK) phosphorylation is a likely downstream effect of PDGF 
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receptor binding as simultaneous treatment of PDGF with ERK1/2 and JNK inhibitors 
significantly reduced fibroblast proliferation.    
Ac-SDKP inhibited PDGF-induced ERK1/2 and JNK phosphorylation with a concomitant 
reduction of fibroblast proliferation and collagen expression suggesting that Ac-SDKP may 
inhibit fibrosis by inhibiting ERK1/2 and JNK pathway activation (Zhang et al., 2011).  JNK is an 
effector of the MAPK signalling pathway.  The JNK pathway is triggered in response to a wide 
variety of stimuli including cytokines and environmental stressors.  Downstream effects of the 
JNK pathway include a range of cellular responses such as differentiation, proliferation, 
inflammation and apoptosis (Robinson and Cobb, 1997). 
The inhibition of PDGF induced JNK signalling by Ac-SDKP is achieved by upregulating the cell 
cycle modulators p53 and p27kip1 protein and Ac-SDKP was also shown to inhibit PDGF induced 
expression of cyclin D1 (Kanasaki et al., 2006). 
Finally, endothelial-to-mesenchymal transition (EndMT) is known to significantly contribute to 
fibrotic pathologies in various organs. TGF-β/Smad signalling is a major driver of EndMT and 
Ac-SDKP has been shown to inhibit TGF-β mediated EndMT through interaction with FGFR1 to 
phosphorylate MAP4K4.  To date the role of Ac-SDKP in Map kinase signalling has not been 
investigated in pericardial fluid so whether the findings above are relevant in patients with TB 
pericarditis is not known and would need to be verified. 
 Ac-SDKP and ACE signalling 
Observations of ACEi potentiation of bradykinin responses lead to the discovery of an ACE 
signal transduction pathway, illustrated in Figure 1-8 (Kohlstedt et al., 2004).  Briefly ACEi 
binding to ACE on the cell surface membrane triggers ACE dimerisation, the initial step in the 
cascade (Kohlstedt et al., 2006).  Upon dimerisation, a serine residue on the cytoplasmic tail at 
position 1270 of the ACE sequence (ser1270) undergoes casein kinase-2 (CK-2) mediated 
phosphorylation.  This leads to the activation of the c-Jun NH2-terminal kinase (JNK) with the 
likely involvement of Map kinase kinase 7 (MKK7) which is co-immunoprecipitated with the 
ACE-CK2 complex (Tournier et al., 1997)(Kohlstedt et al., 2004).  Increased JNK activity causes 
c-jun to phosphorylate and translocate to the nucleus whereby it dimerises into the 
apoprotein-1 (AP-1) transcription factor.  AP-1 induces the expression of ACE (ACE99 gene) and 
of cyclooxygenase-2 (COX-2) (Kohlstedt et al., 2004)(Kohlstedt et al., 2005).  COX-2 is a pro-
inflammatory agent which has been implicated in pathological processes via its ability to induce 
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the local production of prostaglandins and is targeted by COX-2 inhibitors in the treatment of 
inflammatory processes (Crofford, 1997).   
In porcine aortic endothelial cells, the presence of a functional C-terminal active site, as seen 
in the C domain knock out mutant (two zinc coordinating histidines converted to lysines thus 
inactivating only the C domain) was crucial for sACE dimerisation (Kohlstedt et al., 2006).  
However, a C domain knock out murine sACE construct was able to activate JNK in a Chinese 
Hamster Ovary cell line (CHO) (X. Sun et al., 2010) (Kohlstedt et al., 2004).  In studies in murine 
sACE whereby either the N or C domains or both were inactivated, Ac-SDKP was shown to 
induce JNK phosphorylation in the N or C domain mutant only, which was abolished by a CK-2 
inhibitor (Y. Sun et al., 2010).  Thus Ac-SDKP requires binding to either the N or C domain to 
induce ACE signalling via Ser1270 phosphorylation.  However, the pathway appears to be 
species specific with no signalling response registered to AngI in porcine cells expressing 
human sACE but a definite increase in JNK levels on AngI binding to murine sACE in CHO cells 
(Kohlstedt et al., 2005).  Whether such an ACE signal transduction pathway is active in normal 
pericardial fluid and in the pericardial fluid of participants with TB pericarditis is not known and 
may have implications for the potential to prevent pericardial fibrosis.  
 
 
Figure 1-8: Schematic of the ACE signalling cascade 
32 | Chapter 1: Introduction 
 
ACEi or substrate binding on the N terminus of the protein induces 
phosphorylation of the C-terminal cytoplasmic tail serine residue and subsequent 







 ACE inhibitors in fibrosis 
 ACE inhibitors in clinical practice  
An understanding of the RAAS physiology allows for the prediction of the beneficial effects of 
ACE antagonism: an inhibition of AngII formation, a decrease in the systolic and diastolic 
pressure with no effect on the cardiac output and a decrease in bradykinin breakdown.  This 
lead to the search for and development of the first ACEi captopril, for the treatment of 
hypertension (raised mean arterial blood pressure: systolic pressure >140mmHg and diastolic 
pressure >90mmHg, WHO guidelines) (Whitworth, 2003) (Cushman and Ondetti, 1991).  
Various ACEi have since been developed (enalapril, lisinopril, benazepril, fosinopril, quinapril, 
moexipril, perindopril and ramipril among others) and are widely used in the management 
hypertension, a range of conditions primarily involving the cardiac system including chronic 
heart failure, acute myocardial infarction (MI), arrhythmia, atherosclerotic vascular diseases, 
stroke, and coronary artery disease, and finally in renal failure.  Interestingly, the beneficial 
effects of ACEi in cardio- and nephro-protection cannot be simply explained by their blood 
pressure-lowering effects (Wong et al., 2004).  Nevertheless, despite these beneficial effects, 
ACEi are associated with side effects which have been attributed to BK accumulation.  The two 
principal adverse effects include life-threatening angioedema and a persistent dry cough 
arising in 10-44% of patients which reduces adherence to the long term administration 
required for the preventative management of cardiovascular events (Kulkarni et al., 2006) (Fox 
et al., 1996) (Agostoni et al., 1999).  An alternative way of inhibiting the RAAS, through the 
means of AT1 receptor blockers (ARBs) such as candesartan and losartan, is often utilised in 
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patients who cannot tolerate ACEi.  However, each class of drugs offers unique protective 
effects and combination therapy of ACEi and ARBs is often the most effective in therapy 
(McMurray et al., 2003) (Laverman et al., 2002).  The development of next generation, domain-
selective ACEi, targeting the cleavage of specific ACE substrates has hence been proposed as a 
means to avoid the adverse effects (Acharya et al., 2003).   
 ACE inhibitors in fibrotic conditions 
The role of the RAAS in cardiac inflammation and fibrosis is well established; its activation 
results in up-regulated AngII levels, and the subsequent expression of pro-inflammatory and 
pro-fibrotic cytokines (Brilla et al., 1993).  It is hence no surprise that antifibrotic effects of ACEi 
are increasingly being reported.  However, prospective trials of ACEi with clinical end points 
comparing markers of fibrosis in chronic inflammatory conditions are scarce.  A clinical trial 
assessing the 6-month outcome of ACEi therapy in hypertensive patients revealed a significant 
regression in myocardial fibrosis evidenced by a reduction of left ventricular collagen volume 
fraction and myocardial hydroxyproline levels (Brilla et al., 2000).   
Protective effects of ACEi have however been reported in mouse and rat models of diverse 
diseases ranging from radiation-induced pulmonary injury, tubule-interstitial fibrosis and 
progressive renal fibrosis, bleomycin-induced lung fibrosis, liver fibrosis, peritoneal fibrosis to 
Duchenne muscular dystrophy (Morrissey et al., 1996)(Gross et al., 2004)(A. Molteni, 2000) 
(Yoshiji et al., 2006)(Wang et al., 2000)(Yoshiji et al., 2005)(Morales et al., 2013)(Sawada et al., 
2002)(Takeda et al., 2010). The antifibrotic mechanisms of action of the ACEi were similar in 
most studies involving: a reduction in fibroblast activation or cellular transition to adopt 
fibroblast-like function; a decrease in TGF-β expression both at the protein and mRNA levels; 
down-regulation of MMP activity, and an overall reduction in collagen levels (Jonsson et al., 
2001)(Kuno et al., 2003).  In some of these studies the effects of ACEi was compared to ARBs, 
but there was no overall consensus: whilst similar efficacy was observed in certain disease 
models, ACEi showed different mechanisms of action or improved/reduced protection against 
fibrosis in other studies (Yu et al., 2001) (A. Molteni, 2000).  For instance, ramipril as compared 
to candesartan showed enhanced reduction in glomerular and tubulo-interstitial fibrosis and 
an overall decrease in the number of fibroblasts through a greater down-regulation of TGF-β, 
CTGF and MMP levels (Gross et al., 2004).  Further, in a ventricular fibrosis model, ACEi and 
ARBs differentially regulated collagen gene expression and MMP activity but the overall 
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suppression of fibrosis was similar (Yamamoto et al., 2005).  These observations further 
support a role for ACEi extending beyond the mere inhibition of the formation of the pro-
fibrotic AngII.  Indeed, the accumulation of Ac-SDKP as well as the anti-inflammatory RAAS 
peptide Ang 1-7 has been increasingly recognised as a mechanism of  action of ACEi (Carretero, 
2005). These findings and observations may have important implications for the potential role 




Gal-3 belongs to the galectin protein family characterised by evolutionarily conserved 
amino acid sequences in their carbohydrate-binding site and an affinity for β-galactoside 
(Leffler et al., 2002).  Fifteen galectins have been identified, belonging to three main 
groups; a prototype group bearing a single carbohydrate recognition domain 
(CRD)(galectins 1, 2, 5, 7, 10, 11, 13, and 14), a tandem repeat group containing two CRDs 
(galectins 4, 6, 8, 9, and 12) and a chimera group (galectin-3) containing a proline- and 
glycine- rich domain (Liu et al., 2002). 
Gal-3, previously referred to as Mac-2 antigen, IgE-binding protein, L-29 and CBP30, is a 
circulating 35kDa lectin with a C-terminal CRD connected to a long N-terminal domain, 
coded for by the singular LGALS3 gene located on chromosome 14 (locus q21-22)(Dumic et 
al., 2006).  Gal-3 is expressed in inflammatory cells as well as different types of activated 
microglial cells.  Gal-3 can be found in most subcellular compartments, but the localisation 
of Gal-3 is dependent on the cell type and proliferation stage of the cell.  It is ubiquitously 
distributed in tissues including haematopoietic tissue, lymph nodes, respiratory, digestive 
and urinary tracts and skin (H. Kim et al., 2007)(Li et al., 2020). 
  Galectin-3 structure 
Gal-3 bears one C-terminal CRD and a flexible N-terminal domain (Dumic et al., 2006) 
(Birdsall et al., 2001). The N domain comprises 7–14 repeats of specific nine amino acid 
long sequence of Pro-Gly-Ala-Tyr-Pro-Gly-X-X-X. It is important for the oligomerisation of 
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Gal-3 as well as its secretion and nuclear translocation (Massa et al., 1993)(Gong et al., 
1999).  
The CRD of Gal-3 is around 130 amino acids long and forms a globular structure with five- 
and six-stranded β-sheets arranged in a β-sandwich (Seetharaman et al., 1998).  The CRD 
bears a NWGR (Asp-Trp-Gly-Arg) motif which allows binding to β-galactosides.  This motif 
also present in members of the B-cell lymphoma 2 (Bcl2) apoptotic protein family also 
contributes to the anti-apoptotic action of Gal-3 (Akahani et al., 1997). 
Gal-3 occurs primarily as a monomer in solution (Morris et al., 2004).  However, it can form 
homodimers through the CRD and polymerise in the presence of carbohydrate binding 
counterparts through its N domain (Massa et al., 1993)(Yang et al., 1998)(Ahmad et al., 
2004).  Extracellular gal-3 commonly multimerises and cross-links with cell surface ligands 
to form complexes which initiate cell surface molecule-associated cellular signalling 
(Ochieng et al., 2002). 
 Physiological roles of Galectin-3 
The physiological functions of Gal-3 are wide ranging: it has been implicated in processes 
ranging from cellular proliferation, cell adhesion, inflammation to immune regulation 
(Newlaczyl and Yu, 2011). Gal-3 localises predominantly to the cytoplasm but it can also 
shuttle into the nucleus (Yang et al., 1996).  Further, it is secreted into the extracellular 
environment and biological fluids. The varying locations of the molecule contribute to its 
plethora of biological functions.  In the cellular environment, cytoplasmic Galectin-3 plays 
a vital role to cell survival through its interactions with anti-apoptotic Bcl-2 proteins and 
activated guanosine-5′-triphosphate-bound K-Ras (Akahani et al., 1997)(Yang et al., 
1996)(Shalom-Feuerstein et al., 2005). Nuclear galectin-3 induced pre-mRNA splicing and 
functions to regulate gene transcription (Dumic et al., 2006) (Elad-Sfadia et al., 2004).  
Finally, extracellular galectin-3 is involved in cell-cell interaction modulation, including 
extracellular matrix regulation (Ochieng et al., 2002). 
 Galectin-3 in fibrosis 
In fibroblasts and macrophages, gal-3 secretion can be triggered as a result of various stress 
stimuli including heat shock and irradiation (Sato and Hughes, 1994).  Secreted gal-3 plays a role 
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in EMT, scar tissue formation as well as pathological remodelling of tissue architecture (Li et 
al., 2014). Gal-3 has been implicated in fibrotic pathway modulation in various tissues including 
the liver, heart, vascular tissue, kidney, and lungs (Calvier et al., 2013)(Li et al., 2014). 
 Galectin-3 in cardiac fibrosis 
Gal-3 plays a role in the modulation of pro-inflammatory and pro-fibrotic pathways in cardiac 
regulation (Sharma et al., 2004)(Yu et al., 2013).  Gal-3 is known to regulate the integrity of the 
cardiac matrix and myocardial Gal-3 levels in rodents correlate with the degree of hypertrophy 
in hearts which are prole to failure (Schroen Blanche et al., 2004).  Further, exogeneous 
administration of gal-3 into rodent heart promotes cardiac hypertrophy, pathological fibrotic 
remodelling and eventually leads to heart failure (Sharma et al., 2004).  This is supported by 
observations of suppressed inflammation, and collagen type I deposition in response to 
aldosterone in gal-3 knock out mice (Calvier et al., 2013).  Further both pharmacological and 
genetic inhibiton of gal-3 lead to a reduction in collagen I and III formation, processing, 
cleavage, cross-linking, and deposition leading to an inhibition in left ventricular dysfunction 
and fibrosis (Yu et al., 2013).  Moreover, Gal-3 has emerged as a prognostic marker in cardiac 
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Tuberculous pericarditis is prevalent in South Africa, where 10 million cases of TB were 
recorded in 2018 alone.  TB pericarditis is associated with the development of constrictive 
pericarditis, a complication which arises in up to 26% of patients.  The treatment of choice for 
severe constrictive pericarditis involves the surgical resection of the pericardium.  This 
procedure has a poor post-operative prognosis and is not available in most of sub Saharan 
Africa.  Thus, the identification of preventative strategies for the development of fibrosis in TB 
pericarditis is strongly warranted.  Importantly, the mechanisms underlying the molecular 
processes leading to the pathophysiological manifestations of fibrotic disease have not been 
well established.  Therefore, a better understanding of the key molecular pathways and 
mediators of fibrosis in TB pericarditis will pave the way to the identification of potential 
targets to prevent the onset of fibrosis in these patients. 
A significant down regulation of Ac-SDKP levels as well as a mild increase in Gal-3 levels has 
been demonstrated in TB pericardial fluid in a small study.  Ac-SDKP is a physiological 
tetrapeptide degraded by ACE, Gal-3 is a lectin which plays an important role in cardiac 
inflammatory and fibrotic pathways.  However, the role played by these molecules in the 
development of constrictive pericarditis is poorly understood.  An implication of altered Ac-
SDKP regulation in TB pericarditis could pave the way for the implementation of already 
available ACEi in the management of the condition. 
ACEi and Ac-SDKP analogues are promising approaches not only for the treatment of 
constrictive pericarditis but various other fibrotic conditions.  Despite the vast array of 
manifestations of fibrosis which translates into a major cause of morbidity and mortality in 
many chronic inflammatory diseases, there are currently very few treatment strategies which 
specifically target the pathophysiological processes occurring in fibrosis.  Thus, further studies 
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 Aims and Objectives 
The aim of this project is to increase our current understanding of the molecular mechanisms 
and mediators involved in the development of fibrosis, particularly in TB pericarditis by: a] 
investigating the role played by Ac-SDKP, ACE, POP and Gal-3 in the pathophysiology of 
constrictive TB pericarditis; b] investigating the in vitro potential of ACEi and Ac-SDKP 
analogues as therapeutic targets in the progression to fibrosis; and c] investigating the 
molecular mechanisms of action of Ac-SDKP. 
 
The objectives are as follows: 
1) To investigate the deregulated Ac-SDKP metabolism in TB pericardial fluid.    
2) To determine the molecular specificity of the antifibrotic action of Ac-SDKP. 
3) To investigate the in vitro antifibrotic potential of Ac-SDKP analogues and ACE 
inhibitors. 
4) To characterise the signalling mechanism of the Ac-SDKP mediated effect on fibrosis.  
 





Tuberculous pericarditis remains an important challenge in sub-Saharan Africa owing to the 
endemicity of TB and the HIV/AIDs pandemic.  Most of the scientific studies conducted in sub-
Saharan Africa in the field of tuberculous heart diseases have occurred over the past couple of 
decades (Zumla et al., 2015).  While progress has been made in the understanding of the immune 
responses within the pericardium, diagnostic approaches and overall survival, important gaps 
remain. 
A major complication of TB pericarditis is constrictive pericarditis which is characterised by fusion 
of the visceral and parietal pericardium with progressive fibrosis (Mutyaba and Ntsekhe, 2017).  
This manifests as a loss of compliance of the pericardium, eventually leading to heart failure.  
Constrictive pericarditis arises in up to 26% of patients and has a poor prognosis (Noubiap et al., 
2019).  This highlights the need for better predictors of constrictive pericarditis and development 
of targeted fibrosis prevention strategies in those treated for TB pericarditis. 
Infection of the pericardium by M.tb is likely to elicit an initial inflammatory reaction which when 
poorly resolved progresses on to the fibrotic phenotype of TB constrictive pericarditis (Mayosi et 
al., 2008).  Various studies have established a distinct profile of TB pericardial fluid as compared 
to normal pericardial fluid (Matthews et al., 2015)(Ntsekhe et al., 2013).   
Importantly, when paired TB pericardial fluid and blood samples were tested for a panel of 
inflammatory and fibrotic mediators,  a strong profibrotic gene expression response was 
observed, with an accompanying pro-inflammatory response in the pericardial fluid  at the protein 
level (Matthews et al., 2015).    
In 2012, it was shown for the first time that Ac-SDKP and Gal-3 could be detected in pericardial 
fluid (Ntsekhe et al., 2012).  Ac-SDKP is a physiological antifibrotic tetrapeptide generated from 
the protein Tβ4 by the enzymatic action of POP and primarily hydrolysed by ACE (Azizi et al., 
1997).  ACE, as previously described is known to play a role in inflammation and fibrosis by 
cleaving AngI into the pro-inflammatory AngII, a potent inducer of cardiac fibrosis (Schnee and 
40 | Chapter 2: Dysregulation of Ac-SDKP metabolism in TB pericardial fluid 
 
 
Hsueh, 2000)(Lijnen et al., 2004).  Gal-3, on the other hand, has been associated with various 
fibrotic conditions; its expression leading to fibroblast activation and collagen synthesis both in 
vitro and in vivo (De Boer et al., 2010)(Henderson et al., 2006).  An upregulation in Gal-3 has been 
implicated in the pathophysiology of cardiac failure and its potential as a biomarker and as 
pharmacological target in the treatment of cardiac failure has been assessed (D. J. Lok et al., 
2010).  Ntsekhe et al., compared the levels of Gal-3 and Ac-SDKP in pericardial fluid from control 
patients and TB pericarditis patients in a small study.  Whilst no significant difference was 
observed in Gal-3 levels, Ac-SDKP levels in TB pericardial effusions were significantly reduced.  
These findings suggest a possible physiological role for these molecules in maintaining pericardial 
homeostasis and possibly in the pathogenesis of pericardial fibrosis.  
An understanding of mechanisms of pericardial fibrosis is key to the identification of novel 
strategies to curb the progression to constriction in TB pericarditis.  Further study is hence 
warranted to determine the mechanism for the reduction in Ac-SDKP levels.  This will provide 
useful information regarding the pathophysiology of pericardial fibrosis and potential 
pharmacological targets for TB constrictive pericarditis.  An increase in ACE serum levels has been 
reported in granulomatous conditions including M.tb infection and sarcoidosis.  Levels of sACE 
correlate well with the disease progression and are believed to arise from an overflow of ACE 
produced by the macrophages and phagocytes in the granulomatous lesions into the circulation 
(Weinstock, 1986)(Brice et al., 1995)(Ainslie and Benatar, 1985).  However, increased activity of 
POP in experimentally produced granulomatous skin and liver inflammation has also been 














The objective of this chapter was to investigate the metabolism of Ac-SDKP in TB pericardial fluid 
by: 
• identifying any dysregulation of Ac-SDKP levels, of its synthesising enzyme POP and its 
degrading enzyme ACE 
• identifying any dysregulation in Gal-3 levels 
• analyzing whether Ac-SDKP metabolism was affected locally in the pericardium, or 
systemically by contrasting with serum levels   




 Patient recruitment 
This was a sub study of the Investigation in the Management of PericarditIs (IMPI registry) 
(UCTHREC 102/2003 sub studies 492/2007 and HREC 289/2007).  Patients with effusive 
pericarditis suspected to be of tuberculous origin referred to Groote Schuur Hospital in Cape Town 
between July 2014 and December 2018 at Groote Schuur Hospital, Observatory, Cape Town were 
recruited to participate in the registry. Consenting adults (age >18) who were undergoing 
diagnostic and therapeutic pericardiocentesis, gave permission to have their pericardial fluid 
analysed and investigated for the molecular mechanisms and mediators of fibrosis.   Participants 
were in the analysis if they had definite and probable TB pericarditis as defined in the Introduction 
(see section 1.2.4). 
Participants in the control group were screened and recruited from adult patients (age >18) 
undergoing elective coronary artery bypass surgery at Groote Schuur Hospital during the same 
period (patients on ACEi were excluded from the study).  All participants provided written, 
informed and voluntary consent and permission to conduct the sub-study was provided by the 
University of Cape Town Health Research Ethics Committee. 
 Biological sample processing 
Pericardial fluid and blood samples were collected from patients at the time of enrolment and a 
blood sample was collected upon follow up.  Pericardial fluid was collected in sodium heparin 
tubes (BD Vacutainer, UK) and blood was collected in SSTTM II Advance Plus blood collection 
tubes (BD Vacutainer, UK).  Baseline pericardial fluid and blood samples, as well as follow up blood 
samples were processed in a biosafety level 3 facility.  Briefly, Heparin tubes containing pericardial 
fluid and serum tubes containing whole blood were centrifuged at 3000 g for 15 minutes (mins) 
to collect the supernatant Pericardial Cell Free Fluid (PCFF) and serum respectively.  These were 
filtered (0.2 m syringe filters, LASEC, South Africa) and cryopreserved at -80oC until ELISAs and 
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 Ac-SDKP and Gal-3 enzyme linked immunosorbent assay 
 Ac-SDKP ELISA 
A competitive ELISA (SPI Bio, France) was used for the quantitative measurement of Ac-SDKP 
levels in PCFF, according to manufacturer’s protocol (adapted from (Engvall and Perlmann, 1971).  
The principle of the assay is based on the competition for specific rabbit anti-Ac-SDKP antiserum 
sites between unlabelled Ac-SDKP (from standard or sample) and Ac-SDKP linked to acetyl-
cholinesterase (AChE) (tracer).  The AChE activity of the tracer was measured from the intensity 
of the yellow product formed from its reaction with Ellman’s reagent (Ellman et al., 1961).  The 
absorbance was measured using a spectrophotometer (iMARKTM, Biorad) at 412 nm and was 
proportional to the amount of tracer and hence inversely proportional to the amount of Ac-SDKP 
from the standard or sample solution.  A sigmoidal standard curve was used to quantify the 
amounts of Ac-SDKP in the biological samples (see Appendix). 
2.3.3.2 Gal-3 ELISA 
Gal-3 levels in pericardial CFF were measured using a specific Sandwich ELISA kit, according to 
manufacturer’s protocol (eBioscience, USA).  Briefly, an anti-human Gal-3 antibody adsorbed onto 
the wells of the plate captures Gal-3 from the samples/standard solutions.  The wells were 
incubated with a biotin-conjugated anti-human Gal-3 antibody which binds the captured Gal-3.  A 
streptavidin-horseradish peroxidase was then added which recognises the biotin-conjugated anti-
human Gal-3 antibody prior to a chromogenic substrate solution (TMB) (Mesulam, 1978).  
Absorbance was measured with a spectrophotometer (iMARKTM, Biorad) at 450 nm and   the 
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2.3.4 Enzyme assays 
2.3.4.1 Prolyl oligopeptidase assay 
POP hydrolyses peptide bonds on the carboxyl side of L-proline.  POP activity was measured by a 
fluorometric assay using the substrate Z-Gly-Pro-Amino-Methyl Coumarin (Bachem, Switzerland) 
(adapted from (Browne and O’Cuinn, 1983)).  The assay is based on the generation of the 
fluorescent product amino methyl coumarin (AMC) from cleavage of the substrate by POP.  The 
substrate was dissolved in dimethyl sulfoxide (DMSO, 2% of final volume) and made up to a final 
concentration of 0.1 mM in 0.1 M of potassium phosphate buffer (pH 7.4) and 30 mM of DL-
dithiothreitol (Sigma, USA).  The assay was performed in a 96 well plate by incubating 10 μl of 
sample with 40 μl Z-Gly-Pro-AMC at 37 °C for 60 min.  The reaction was stopped by adding 100 μl 
of 1.5 M acetic acid (pH 4.2) and fluorescence was read at γexcitation and γemission of 370 and 440 nm, 
respectively (Varian Cary Eclipse, Agilent).  Background fluorescence was measured in controls 
where the sample was not added.  Relative fluorescence was thereupon converted to AMC 
concentration using an AMC (Bachem, Switzerland) standard curve (see appendix).  Activities are 
expressed as pmol of AMC released per millilitre of sample. 
2.3.4.2 ACE assay 
ACE catalyses the hydrolysis of dipeptides from the carboxy-terminus of oligopeptides.  A 
fluorometric assay for measuring ACE activity was performed using the substrate Z-Phenylalanine-
L-histidyl-L-leucine (ZFHL) (Bachem, Switzerland) which yields the HL peptide upon cleavage by 
ACE.  The fluorescent adduct of the HL, upon o-phthaldialdehyde (Sigma, USA) derivitization, was 
quantified fluorimetrically.  HL formation from the substrate was quantified by using an adapted 
protocol from Schwager et al. (Schwager et al., 2006).  Briefly 6µl of diluted sample was incubated 
in 30 µl of 1 mM Z-FHL and incubated at 37oC for 20 mins.  The reaction was stopped with 125 µl 
of 0.4 M NaOH.  Endogenous fluorescence was measured by adding the sample to the mixture 
after the NaOH addition.  Derivitisation was carried out by adding 10 μL of 24 mg/ml o-
phthaldialdehyde, shaking at room temperature for 10 mins and the reaction stopped with 30 μL 
3M hydrochloric acid.  The plate was centrifuged at 2800 g for 15 mins at 18°C and the 
supernatants were transferred to a fresh 96 well plate.  Fluorescence was measured at γexcitation of 
360 nm and γemission of 485 nm (Varian Cary Elipse, Agilent).  A HL (Sigma, USA) standard curve was 
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generated to convert relative fluorescence into milliunits (mU) ACE activity: where 1 unit is 
defined as 1nmole of HL produced/minute/mL, by ACE, at 37oC (see Appendix). 
2.3.6 Statistical analysis 
Data analysis was performed using the statistical software GraphPad PRISM 6.0 (GraphPad software 
Inc, USA).  A Shapiro-Wilks test was used to determine whether distributions followed a Gaussian 
pattern.  Significant differences between the TB pericarditis and control groups were investigated 
accordingly: two tailed un-paired student t-tests or Mann-Whitney tests were used with a cut off for 
statistical significance of p<0.05.  Pearson’s correlation was used for correlation analysis. 
 
  




 Ac-SDKP and Gal-3 level comparison 
 Determination of Gal-3 levels in PCFF of TB+ and TB- patients 
For the determination of Gal-3 levels in PCFF, a specific ELISA kit was used.  Gal-3 levels in 35 TB 
PCFF (TB+) and 20 control (TB-) PCFF samples were determined.  Median Gal-3 concentrations in 
the TB+ group were 7.38 ng/ml (IQR 4.38- 9.77) and 8.37 ng/ml (IQR 5.34- 14.11) in the TB- group 
(Figure 2-1).  There was no significant difference in Gal-3 levels between the TB+ and the TB- 
group.  This finding is in concordance with previous measurements of Gal-3 in PCFF by Ntsekhe et 
al. (Ntsekhe et al., 2012).  
 
Figure 2-1: Scatterplot of Gal-3 levels grouped by TB pericarditis status.  
Gal-3 levels were measured in 35 TB+ and 20 TB- PCFF samples, 
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 Determination of Ac-SDKP levels in PCFF of TB+ and TB- patients 
A significant difference in Ac-SDKP levels was previously measured between TB pericarditis and 
controls in PCFF (Ntsekhe et al., 2012).  We used a specific ELISA kit to validate these findings in 
our study population.  Briefly, Ac-SDKP levels in 35 TB+ PCFF and 20 TB- PCFF samples were 
measured.  The median Ac-SDKP level in TB+ group was 0.191 ng/ml (IQR 0.085-0.344) and in TB- 
group was 0.443ng/ml (IQR 0.169-0.613)(Figure 2-2).  Ac-SDKP levels followed a Gaussian 
distribution for both the TB+ and TB- groups (Shapiro Wilk: 0.74 and 0.86 respectively); an 
unpaired t-test was used to compare between the two groups.  A significant difference (p=0.048) 




Figure 2-2: Scatterplot of Ac-SDKP levels grouped by TB pericarditis 
status.   
Ac-SDKP levels were significantly different between 35 TB+ and 20 TB- 
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 Gal-3/Ac-SDKP ratios in TB pericarditis vs controls 
The Gal-3/Ac-SDKP ratios were compared between the two groups (Figure 2-3). Whilst no 
significant difference was observed in the Gal-3/Ac-SDKP ratios, the TB+ group had some samples 
with markedly high Gal-3/Ac-SDKP ratios, driven predominantly by higher Gal-3 levels. 
 
Figure 2-3: Scatterplot of Gal-3/Ac-SDKP ratios grouped by 
TB pericarditis status.   
No significantly difference was observed. However, a mild 
increase in the ratios were found in the TB+ with 3 samples 
having a markedly increased Gal-3/Ac-SDKP proportion. 
 
 Enzymatic activity of ACE and POP in TB pericarditis vs controls 
In order to investigate the mechanism for the decreased Ac-SDKP levels measured in our TB+ 
group, the enzymatic activities of POP and ACE in the PCFF were investigated.  POP is the rate 
limiting enzyme for the synthesis of Ac-SDKP, whilst ACE is the only known physiological peptide 
to efficiently degrade Ac-SDKP (Grillon et al., 1990)(Azizi et al., 1996).  Enzymatic activities were 
investigated in both PCFF and serum in order to establish whether any observed enzyme activity 
dysregulation was a systemic effect or a localised one. 
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 POP activities in PCFF and serum 
To determine whether the rate of synthesis of Ac-SDKP from Tβ4 differed between the two 




Figure 2-4: POP activities grouped by TB pericarditis status.   
Scatterplot of POP activity levels measured in A. PCFF. POP activities in PCFF were comparable between the 
TB+ and TB- group B. Serum. Lower serum POP activities were measured than PCFF suggesting the local 
production of POP in the pericardium. 
 
POP activities in PCFF ranged from 1.02-2.25 nmol AMC ml-1 min-1 in the TB+ group and from 1.24-
2.53 nmol AMC ml-1 min-1 in the TB- group.  In serum, POP activities ranged from 1.35-3.27 and 
from 1.44-3.46 nmol AMC ml-1 min-1 in the two groups respectively. No difference in POP activities 
were seen in the PCFF and in serum.   
Serum POP levels observed were comparable to previous studies using the same substrate. 
However, POP activity in pericardial fluid has not been previously measured as far as can be seen 
in the literature. Higher pericardial POP levels were measured as compared to the serum 
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 ACE activities in PCFF and serum 
To investigate the rate of degradation of Ac-SDKP between the two groups, ACE activities were 
quantified using the substrate ZFHL which is cleaved by ACE to release HL.   
ACE activities in PCFF ranged from 1.02-2.25 nmol HL ml-1 min-1 in the TB+ group and from 1.24-
2.53 nmol HL ml-1 min-1 in the TB- group (Figure 2-5). This represents a significant difference in 
ACE activities in the PCFF between active and control groups (p= 0.038).    In serum, ACE activities 
ranged from 1.35-3.27 in the active and from 1.44-3.46 nmol HL ml-1 min-1 in the controls, 
suggesting no significant difference in the two groups. 
 
 
Figure 2-5: ACE activities grouped by TB pericarditis status.   
Scatterplot of ACE activity levels measured in A. PCFF. Significantly higher ACE activities were measured in 
TB+ PCFF as compared to the TB- group B. Serum. Serum ACE activities were comparable between the two 
groups. 
 
Further, ACE activities were lower in PCFF as compared to serum.  ACE activity in pericardial fluid 
has not been previously described.  This may be an indication that ACE from the pericardial fluid 
originates predominantly from the plasma ultrafiltrate.  Importantly, serum ACE levels measured 
were comparable between the two groups.  This indicates a localised dysregulation of ACE levels 





51 | Chapter 2: Dysregulation of Ac-SDKP metabolism in TB pericardial fluid 
 
 
 Correlation between Ac-SDKP levels and enzymatic activity 
To determine whether Ac-SDKP levels correlated with either POP levels or ACE levels, a Pearson’s 
correlation test was performed.  
 Ac-SDKP and POP correlation 
 
Figure 2-6: Correlation between Ac-SDKP and POP levels   
A significant (p=0.005) correlation between Ac-SDKP and POP levels were observed in 
the PCFF. 
 
A plot of POP activity (Figure 2-6) against corresponding Ac-SDKP levels measured revealed a R 
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 Ac-SDKP and ACE correlation 
 
Figure 2-7: Correlation between Ac-SDKP and ACE levels   
A significant (p=0.02) correlation between Ac-SDKP and ACE levels were observed in the 
PCFF. 
 
Ac-SDKP levels and corresponding ACE activities were plotted (Figure 2-7) and a Pearson’s 
correlation was performed.  Similar to the Ac-SDKP/POP correlation analysis, a significant (R: -
0.38, p=0.02) correlation was observed between Ac-SDKP and ACE levels. 
Thus, it would appear from our results that Ac-SDKP levels in PCFF are influenced by both its rate 











There were four main findings from this study.  The first two key findings were that Ac-SDKP was 
detectable in both TB and control pericardial fluid and the levels of Ac-SDKP were significantly 
decreased in TB pericardial fluid compared to normal fluid confirming similar observations made 
in a proof of concept study reported by Ntsekhe et al.  The third finding is that there was a 
significant increase in ACE activity in the pericardial fluid of those with TB. This novel finding which 
was noted only in pericardial fluid and not in serum and implicates local intra-pericardial TB 
bacillus induced inflammation as a key regulator of ACE activity. The finding is also important 
because It suggests that an increase in cleavage of Ac-SDKP by ACE is a potential mechanism for 
the observed decrease in Ac-SDKP levels.  The fourth and final key finding in this study which the 
first is to investigate the presence of POP and its enzymatic activity in pericardial fluid, was that 
there were no notable differences in POP enzymatic levels or activities measured between 
participants with and without disease. 
The measurement of Ac-SDKP as well as the rate-limiting enzyme responsible for its formation, 
POP suggests a possible local production of Ac-SDKP in the pericardium.  Whilst it is not known 
whether the POP is produced within the pericardial, this is entirely possible as POP has been 
shown to be expressed in most human cell types including fibroblasts, epithelial, endothelial and 
mesenchymal cells (Goossens et al., 1996) (Myöhänen et al., 2012).  The detection of ACE activity 
was expected as ACE has previously been detected in pericardial fluid (Gomes et al., 2008).  
Further, a mass spectrometric based technique was utilised to quantify the levels of RAAS 
metabolites in pericardial fluid in our group revealing the presence of AngI as well as AngII in the 
pericardial environment (data unpublished).  Ac-SDKP levels correlated mildly but significantly 
with both ACE (R: -0.38) and POP (R: 0.46) levels.  This is unsurprising as Ac-SDKP has a short half-
life of approximately 80 minutes, suggesting that it is constantly being synthesised and degraded 
in tissues (Rieger et al., 1993).  The local synthesis of Ac-SDKP would support a role for Ac-SDKP 
in pericardial homeostasis, thus strengthening our hypothesis that Ac-SDKP may be involved in 
the prevention of pathological fibrotic remodelling of the pericardium.  
Levels of Ac-SDKP measured in our study (0.19ng/ml) were ultimately comparable to those 
measured by Ntsekhe. et al, (1.56ng/ml) in the affected population (this is because our Ac-SDKP 
measurement protocol did not include an extraction step which results in a roughly 10-fold 
increase in Ac-SDKP levels but increases intra-sample variability).  Similarly, to Ntsekhe. et al, 
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significantly reduced Ac-SDKP concentrations were measured in TB pericardial fluid as compared 
to the controls.  This was accompanied by an increase in ACE activity levels as measured by the 
ZFHL assay.  However, POP activity levels were comparable between the TB+ and control groups.   
We thus conclude that the reduced Ac-SDKP levels are likely a result of increased cleavage by ACE 
in the pericardial environment.  Interestingly, the upregulated Ac-SDKP levels in the pericardium 
were not accompanied by an decrease in serum ACE levels.  A few studies have revealed an 
increase in ACE levels in instances of granulomatous lesions (Thillai et al., 2012)(Mehta et al., 
1990), but the precise mechanism for the ACE upregulation is unknown.  Importantly, 
accumulation of ACE is known to arise in cardiac inflammation through an influx of macrophages 
at the site of inflammation (Diet Frank et al., 1996).   
Levels of Galectin-3 measured in our current disease population (median 7.38 ng/ml in TB+ and 
8.37 in TB-) are also comparable to those observed by Ntsekhe (median 11ng/ml, IQR 7.55-15.60).  
Once again, we observed a similar trend with no significant increase in Gal-3 levels in the TB+ 
group.  This finding corroborates observations by Fernandes et al., of no difference in plasma Gal-
3 levels in patients with chronic constrictive pericarditis as compared to healthy individuals 
(Fernandes et al., 2020). 
The Ac-SDKP/Gal-3 ratios did not reveal any significant difference.  However, certain TB+ patients 
had disproportionately higher Ac-SDKP/Gal-3 which may constitute a predisposing factor for the 
development of fibrosis. 
 
 
Figure 2-8: Dynamic Ac-SDKP metabolism in the normal versus tuberculous pericardium. 
 An increase in ACE in the TB pericardial fluid results in increased cleavage of Ac-SDKP and hence its lowered 
concentration. This is likely to result in a decrease in Gal-3 and TGF-β inhibition or an increase in fibrosis and 
fibrosis gene expression. 
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Pathophysiological processes in TB pericardial remodelling are likely to involve in part mesothelial 
cells  of the pericardium which undergo EMT-like transition to demonstrate fibroblast-like 
morphology and function (Yáñez-Mó et al., 2003)(Mutsaers, 2002).   Central to EMT transition and 
fibrotic gene expression are TGF-β signalling and in the cardiac context, Gal-3 (Zeisberg et al., 
2007)(Ignotz and Massagué, 1986).  Ac-SDKP is known to inhibit both Gal-3 and TGF- β, to prevent 
collagen deposition thus conferring a crucial protective role in fibrosis (Rhaleb et al., 2001a) (Peng 
et al., 2010).   
The main complication of TB pericarditis is a reduction in visceral pericardial compliance which 
progresses to a constrictive pathophysiology.  Chronic inflammatory and fibrotic processes are 
likely to be involved in this progression.  A hypothesis driven study was performed by Ntsekhe et 
al., to investigate the levels of the antifibrotic Ac-SDKP in TB pericarditis, revealing decreased 
levels in Ac-SDKP in TB pericardial fluid (Ntsekhe et al., 2012).  We sought to confirm the finding 
of decreased Ac-SDKP levels in TB pericarditis and to further probe mechanisms of action for these 
diminished levels by investigating the enzymatic activities of POP and ACE which synthesise and 
degrade Ac-SDKP respectively.  In general, our findings are consistent with previous observations 
by Ntsekhe et al. and confers reproducibility to the original findings.  Further, we teased out a 
likely mechanism for the Ac-SDKP downregulation in TB pericardial fluid, implicating an overactive 
RAAS in the pericardial milieu (Figure 2-8).  These findings thus form the basis for future 
investigations into the deregulated RAAS in TB pericarditis.  This could provide exciting new 









Angiotensin Converting Enzyme inhibitors (ACEi) reverses cardiac fibrosis in patients in  various 
models of heart disease, an effect that was found to be independent of blood pressure regulation 
(Brilla et al., 2000)(Brilla et al., 1991)(Brown et al., 1999).  This suggests an alternative mechanism 
for fibrosis protection and reversal that is not mediated by a reduction in the pro-inflammatory 
AngII levels.  These findings, coupled with the  findings of increased plasma Ac-SDKP levels in the 
presence of an ACEi, led to the suggestion that  Ac-SDKP may be the alternative pathway through 
which fibrosis prevention occurs and spawned a number of studies to  investigate the antifibrotic 
action of Ac-SDKP (Azizi et al., 1996)(Rhaleb et al., 2001a)(Peng et al., 2001).  
This hypothesis-driven approach confirmed the antifibrotic effects of Ac-SDKP, and in 2007 
Cavasin et al. robustly demonstrated the physiological importance of Ac-SDKP in preventing 
disseminated multi-organ fibrosis.  Studies into the molecular mechanisms of action of Ac-SDKP 
have largely focused on well-established fibrotic pathways and mediators, particularly the TGF-
β/Smad and MAPK pathways (Pokharel et al., 2002)(Zhuo et al., 2007).   
While both our own group and other groups have established that Ac-SDKP inhibits TGF-β/Smad 
signalling to prevent collagen deposition, the precise physiological effects and mechanisms of 
actions of Ac-SDKP remain unclear and are likely to be more complex and to involve other 
signalling pathways (Kanasaki et al., 2003)(Pokharel et al., 2004)(Lin et al., 2008)(Castoldi et al., 
2010).  In particular, a better knowledge of the extracellular and intracellular proteins that are 
regulated by Ac-SDKP and elucidating the related complex regulatory networks would improve 
the current understanding of the Ac-SDKP mechanisms of action and identify potential targets for 
the physiological modulation of fibrosis.   
An analysis encompassing the whole cell machinery and extracellular environment would 
facilitate the ability to obtain a complete snapshot of the proteins and processes regulated by Ac-
SDKP.  One approach that would enable such a comprehensive analysis is mass spectrometry 
(MS)-based discovery proteomics (Aebersold and Mann, 2003).  The robustness of mass 
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spectrometry in the identification of proteins from small amounts of starting material has led to 
its widespread use in proteomic analysis (Aebersold and Mann, 2003).  
The two main approaches to MS-based proteomics are top-down and bottom-up proteomics 
(Zhang et al., 2013).  The former involves the study of proteins as intact entities, while bottom up 
proteomics refers to the identification of peptides generated by enzymatic digestion of intact 
proteins. Bottom-up proteomics is generally experimentally and computationally less complex 
than top-down and is therefore more commonly used. A schematic of a typical bottom-up 
proteomic approach is shown in Figure 3-1.  
A mass spectrometer comprises an ion source and a mass analyser to measure the mass-to-charge 
ratio (m/z) of ionised analytes, which is registered by a detector. Large biomolecules such as 
peptides are ionised primarily by electrospray ionisation (ESI) when they are in a mobile or liquid 
phase, or by matrix assisted laser desorption ionisation (MALDI), where a sample is spotted onto 
an energy-absorbing matrix prior to desorption and laser-induced ionisation of the matrix (Ho et 
al., 2003)(Caprioli et al., 1997). Following ionisation, peptide ions are detected by the mass 
analyser. The four main types of mass analysers include the ion trap, time-of-flight (TOF), 
quadrupole, and Fourier transform ion cyclotron (FT-MS) analysers.  These analysers each exploit 
diverse physical properties of ions to determine their m/z, and can either be used alone or in 
combination (Aebersold and Mann, 2003).   
For the analysis of complex samples, integrated liquid chromatography (LC) ESI-MS systems are 
favoured as high-performance LC allows separation of peptides over time for higher rates of 
identification.  In the current study, a Q-Exactive hybrid quadrupole-Orbitrap (Thermo) was used.  
Ion trap analysers in which ions are ‘trapped’ prior to MS analysis are known for their robustness 
and sensitivity, but have the inherent disadvantage of lower mass accuracy (Aebersold and Mann, 
2003). Orbitraps operate by trapping ions in an orbital motion around a central spindle electrode 
(Hu et al., 2005) and then Fourier transforming the resultant rotational signal into mass spectra. 
Orbitraps have an excellent mass accuracy and are extremely fast, and therefore are well suited 
to the analysis of complex samples. Quadrupoles are parallel charged rods that allow analytes 
with a specific m/z to pass through the field in their centre. The Q-Exactive features a combination 
of a quadrupole mass filter with an Orbitrap analyser to produce a high resolution instrument that 
is widely used in proteomic analysis (Michalski et al., 2011).  The benefits of this hybrid technology 
are excellent speed, resolution, and mass accuracy, all of which contribute to the popularity of 
this platform in modern proteomics workflows.  





Figure 3-1: Bottom-up discovery proteomics workflow.   
A. Sample preparation involves the extraction and digestion of proteins by a sequence-specific enzyme, 
trypsin being the most commonly used. Peptides are then separated by HPLC, ionized, and filtered by 
a quadrupole prior to detection in the Orbitrap mass analyser to obtain MS1 and MS2 scans. Raw MS 
data can be interpreted using software packages such as MaxQuant and the downstream Perseus 
environment.  
B. Peptide quantification generally uses the intensity of the MS1 peak of the precursor ion as a proxy 
for peptide quantity. MS2 scans of the fragmented precursors then allow identification of the parent 
ion. Advanced alignment and normalisation algorithms can be used to compare different peptides 













The objective of the present chapter is to investigate the molecular effects of Ac-SDKP by using 
MS-based discovery proteomics to survey the intracellular and extracellular proteins that are 
regulated by Ac-SDKP through the: 
1. identification, through label free quantification, of differentially expressed proteins upon 
Ac-SDKP treatment of TGF-β stimulated fibroblasts. 
2. characterisation of these differentially expressed proteins using gene ontology terms to 
clarify the mechanisms of Ac-SDKP protein modulation. 
 
  




 Cell culture 
WI-38 (American Type Culture Collection- ATCC® CCL-75™) lung fibroblasts (a kind gift from the 
Leaner group, UCT) were used to assess the effects of Ac-SDKP on intracellular and secreted 
protein levels. The cells were reconstituted into 75 cm2 flasks and grown in 10 ml of growth 
medium (100% HAMS-F12 (Sigma, USA), 20 mM HEPES buffer, pH 7.5, supplemented with 10% 
foetal calf serum (FCS) [heat-inactivated for 30 min at 56°C], and 1% Non-Essential Amino Acids 
(BioWhittaker®, USA).  Cells were grown to 70% confluency, lifted using Trypsin-EDTA (Gibco®, 
USA) and seeded into 10 cm dishes.  All flasks and plates were incubated at 37°C, 5% CO2 and 80% 
humidity.     
 Treatment with Ac-SDKP 
Cells were treated with 100 nM Ac-SDKP for 1 h prior to TGF-β stimulation to induce fibrosis.  TGF-
β (5 ng/ml) was added in the presence of ascorbic acid (50 μg/ml) for 6 to 48 h.  To assess the 
effects of Ac-SDKP, cells in a 75 cm2 flask were lysed in 300 μl of radioimmunoprecipitation assay 
buffer (RIPA) (100 mM Tris-HCl, pH 7.6, 1% SDS, 150 mM NaCl, 0.5% Sodium deoxycholate, with 1 
mM PMSF-supplemented protease inhibitor cocktail (Set III, Calbiochem, USA)).  The lysate was 
centrifuged at 10000 g at 4°C and the supernatant was removed for downstream analysis. 
 Sample preparation  
 Protein quantitation and concentration 
Protein quantitation from the cell lysates and cell culture supernatants was performed in parallel 
according to the Biorad Protein Assay Kit (Bio-Rad, USA).  Bovine serum albumin (BSA) was used 
as a standard and absorbance was read at 595 nm on a Biorad iMarkTM microplate reader using 
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 Cell supernatant concentration and purification 
The concentration of protein available in the culture supernatant is extremely low due to the high 
volume of the culture medium. In addition, the culture supernatant contains potential 
contaminants that may affect downstream MS analysis. Prior to tryptic digest, the cell 
supernatant samples were therefore first concentrated centrifugally on a 10 kDA molecular 
weight cut off filter (MWCO) (Merck, USA), and then purified by methanol chloroform 
precipitation at room temperature.  Aliquots of concentrated cell culture supernatant (400 μl) 
were mixed with 400 μl of methanol by vortexing.  Subsequently, 400 μl of chloroform was added, 
and the mixture was vortexed again. The sample was then centrifuged at 13 000 rpm for 5 min 
and the aqueous methanol layer was carefully removed from the top of the sample, preserving 
the protein interphase.  The proteins were then washed with 300 μl of methanol by vortexing and 
pelleted by centrifuging at 13 000 rpm for 15 minutes. The supernatant was gently decanted 
taking care not to dislodge the pellet.  The protein pellet was air dried before being resuspended 
in 100 μl deionised water and quantified using as per 3.3.3.1.  
 Filter aided sample preparation (FASP)  
Filter aided sample preparation (FASP) was used to obtain tryptic digests of all samples for the 
discovery proteomics experiments (Wiśniewski, 2017).  Briefly, 200 g of cell lysate or 
precipitated proteins from cell culture supernatants (see 3.3.2 and 3.3.3.2) were denatured by 
incubating with 0.1 M DTT in 50 mM NH4CO3 buffer for 30 mins.  The denatured proteins were 
loaded onto a 30 kDa molecular weight cut off filter (Millipore) and buffer exchange was 
performed with a urea buffer (8 M Urea, 0.1 M Tris; pH 8.5).  The proteins were then alkylated 
with 0.05 M iodoacetamide (prepared in 50 mM NH4CO3) for 20 minutes in the dark at room 
temperature.  The samples were washed with an 8 M urea solution twice prior to buffer exchange 
with 50 mM NH4CO3 three times. Tryptic digest was performed using a 1:100 trypsin to protein 
ratio. Trypsin (Promega, USA) was reconstituted in 50 mM NH4CO3 buffer containing 20 mM CaCl2, 
and samples were incubated in a wet chamber at 37°C for 16 hours.  Peptides were eluted by 
centrifuging the filter units at 15 000 rpm for 10 mins, followed by a second wash with 40 μl 
NH4CO3 which was centrifuged under the same conditions. The enzymatic reaction was stopped 
by the addition of formic acid (FA) to a final concentration of 0.1%.   
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 Sample desalting 
Prior to MS analysis, tryptic peptides were desalted on a C18 stage tip packed in-house with 2 x 5 
µg binding capacity C18 resin discs (Millipore, USA) to remove any potentially contaminating salts. 
C18 stage tips were activated with 80% MS grade acetonitrile (ACN) acidified with 0.1% FA (Sigma, 
USA).  Each stage tip was then equilibrated with 2% ACN with 0.1% FA prior to loading 10 μg of 
peptide from each sample. The samples were washed in 2% ACN acidified with 0.1% FA a total of 
three times. Peptides were then eluted into glass vials with 60% ACN acidified with 0.1 % FA. 
Desalted peptides were thereafter dried in a SavantTM SpeedyVac (ThermoFischer Scientific, USA) 
and resuspended in 2% ACN and 0.1% FA for MS analysis. 
 Mass spectrometry  
Desalted tryptic digests were analysed by liquid chromatography tandem MS (LC-MS/MS) on a Q-
Exactive (QE) quadrupole-orbitrap MS coupled to a Dionex Ultimate 3500 RSLC nano LC system 
(Thermo Scientific, USA). The sample was loaded on a 30 cm C18 analytical column packed in- 
house with Aeris peptide 3.6 μM beads (Phenomenex, USA).  Thereafter, elution was carried out 
using a curved gradient of 6-40% acetonitrile and 0.1% formic acid at a constant flow rate of 300 
nl/min over 120 minutes. MS scan parameters are outlined in Table 3-1 below.  Data acquisition 
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Table 3-1: Mass spectrometry parameter settings 
MS LEVEL PARAMETER  SETTINGS 
MS1 Run time  120 minutes 
Polarity  positive 
Default charge state  2 
Scan range  300-1750 m/z 
Resolution  70000 
Automatic gain control target 3e6 
Maximum injection time  250 ms 
MS2 Resolution  17500 
Automatic gain control target 5e4 
Maximum injection time  80 ms 
TopN  10 
Isolation window  2 m/z 
Scan range  200-2000 m/z 
Intensity threshold  6.3e3 
Dynamic exclusion  30 s 
 
 Data processing and analysis 
Raw data processing was performed using MaxQuant software (version) for peptide identification 
and label free quantification (LFQ) (Cox and Mann, 2008). Settings were set to default with the 
following modifications: a fixed modification of carbamidomethylation and variable modifications 
of oxidation and acetylation were selected.  The false discovery rate (FDR) was set at 1% against 
a reverse decoy of the database and 2 missed cleavages were allowed.  Unique peptides were 
used in the identification of protein groups. Andromeda, the inbuilt search engine in MaxQuant, 
was used for protein group identification against the 2018 UniProt Human proteome database.  
The LFQ algorithm was selected for quantification and only protein groups identified in all 
replicates from each treatment condition, and which satisfied a posterior error probability (PEP) 
score of lower than 0.01, were used for all downstream analysis.   
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Initial protein group analysis was performed with Perseus (version 1.6.1.3).  All peptides identified 
as contaminants, reverse/decoy, or identified only by site were excluded.  A Student’s t-test was 
performed to compare the different treatment groups and a p-value < 0.05 was used as a cut-off 
for significance. 
 Functional enrichment and interaction analysis  
For the analysis of protein-protein interaction, search tool for the retrieval of interacting 
genes/proteins (STRING) was used (https://string-db.org/)(Szklarczyk et al., 2017).  Active 
interaction sources were set to only include ‘experiments’ and databases and network edges were 
set to indicate confidence with thicker lines being indicative of the strength of data support.  The 
level of confidence was set at high confidence for the proteome but at medium confidence for 
the secretome, given the smaller data set. 
Functional classification analysis and gene annotation were performed using the Biological 
Networks Gene Ontology tool (BiNGO) on biological networks visualized in Cytoscape version 
3.7.2 (Maere et al., 2005) (Shannon et al., 2003).  Significantly overrepresented Gene Ontology 
(GO) terms were determined using a hypergeometric test with a significance threshold of 0.05. 
Resulting p-values were corrected by applying the Benjamini-Hochberg false discovery rate.  
Proteins were compared against the full human annotation GO database for the proteome and 
against the ExoCarta database for the secretome.  ExoCarta is a manually curated web-based 
compendium of exosomal proteins, RNAs and lipids (http://www.exocarta.org/ )(Simpson et al., 
2012).  To summarise long lists of GO terms generated from BiNGO, the clustering algorithm 
REVIGO was used (http://revigo.irb.hr/)(Supek et al., 2011). 
Pathway analysis was performed in Reactome to investigate biological pathways 
(https://reactome.org/)(Croft et al., 2011). 
  




 Proteome and secretome MS data 
 Proteome and secretome raw data processing 
Acquisition of MS1 and MS2 data from label-free peptides generated from lysates and cell culture 
supernatants of Ac-SDKP treated or untreated fibroblasts was performed on a QE MS instrument 
as described in 3.3.4.  Representative chromatograms of the total ion counts (TIC) and MS2 data 
are presented in Figure 3-2. 
 
Figure 3-2: Representative chromatogram of the proteome and secretome of WI-38 Ac-SDKP treated cells. 
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Raw data files were analysed using the MaxQuant software package. A total of 102103 spectra 
from fibroblast lysates were submitted for analysis, of which 44.8% were identified and mapped 
to human peptides from the Uniprot database. These corresponded to 2870 protein groups, of 
which 1210 (FDR < 0.01) were present across all triplicates. The percentage of contaminants 
across all samples was 0.59% of total protein groups, and the percentage of decoy hits was 0.87%. 
The number of missed cleavages is depicted in Figure 3-3A. 
 
 
Figure 3-3: Assessment of tryptic digest efficiency. 




A total of 149110 spectra from the cell culture medium were submitted for analysis but only 14.1% 
of spectra were identified and mapped to the Uniprot database. This was likely due to the 
presence of a low concentration of foetal calf proteins in the cell culture supernatant, which were 
excluded in the peptide mapping.  A challenge in the profiling of secreted proteins in a cell culture 
environment arises as a result of overlap between bovine and human peptide sequences. This is 
especially relevant for extracellular proteins including fibronectin, fibulin-1, and pigment 
epithelium derived factor, which share up to 90% sequence similarity to their human counterparts 
(Hathout, 2007). The quantification of proteins in the secretome was performed using only 
peptide sequences that are unique to human proteins. A total of 6470 peptides mapping to 315 
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human protein groups were detected in the cell culture supernatant, with 189 being detected 
across all replicates. The proportion of missed cleavages is presented in Figure 3-3B. 
 Proteome and secretome data quality and quantification 
Label-free quantitative proteomic methods, including the MaxQuant LFQ algorithm, are 
inherently less sensitive than label-based methods such as stable isotope labelling by/with amino 
acids in cell culture (SILAC) and isobaric tags for relative and absolute quantitation (iTRAQ).  It was 
thus important to establish that any observed differences in protein levels between the treated 
and control groups were not caused by technical variation. The correlation between biological 
replicates of both the proteome and secretome were assessed using Pearson’s co-efficient, which 
was greater than 0.95 across all comparisons (Figure 3-4). This indicated that the technical 
variation between replicates was minimal.  
 
 
Figure 3-4: Scatterplot of the biological triplicates.  
A. The proteome and B. secretome triplicates were compared using Pearson’s correlation co-efficient (R2) 
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 Effect of Ac-SDKP treatment on the secretome 
A total of 58 proteins were found to have significantly different expression levels (p<0.05). Of 
these 23 proteins had higher expression levels and 35 proteins had decreased expression levels 
in the Ac-SDKP group. The fold change in protein expression levels ranged from 1.67- to 5.19- fold 
with an average of 3.25- fold change. 
 STRING interactions of differentially expressed proteins 
 
Figure 3-5: String interactions of differentially expressed protein groups in the secretome following 
Ac-SDKP treatment. 
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In order to visualise the interactions between the significant protein groups, String analysis was 
performed (Figure 3-5). The STRING database contains all published interactions between 
proteins (Szklarczyk et al., 2017).  The protein interaction network contains 58 nodes with 99 
protein-protein interactions. The interactions with the strongest evidence (thicker lines) revealed 
two clusters involved in extracellular matrix remodelling: a first cluster of collagen and ECM 
proteins circled in blue, and a second cluster of inflammatory and EMC modulating proteins 
circled in red. 
 GO enrichment of differentially expressed secretome proteins 
To identify the relevant biological pathways that were significantly modulated by Ac-SDKP 
treatment, GO term enrichment was performed using BiNGO in Cytoscape.  The string network 
analysis from 3.4.2.1 was used as the input network in Cytoscape.   
A total of 40 biological pathway terms and 29 molecular function terms were significantly 
enriched (p <0.05) in the Ac-SDKP treated secretome.  
In the Molecular Function category, the two most significantly differentially expressed proteins 
mapped primarily to extracellular matrix organization (GO:0030198) and to extracellular structure 
organization (GO:0043062)(Table 3-2)(Figure 3-6).   
Enriched biological functions in the secretome included structural molecule activity 
(GO:0005198), extracellular matrix structural constituent (GO:0005201), phospholipase inhibitor 
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Table 3-2: Top 10 enriched molecular functions in the secretome 
GO ID GO Description p-value 
30198 extracellular matrix organization 2.54E-06 
43062 extracellular structure organization 2.54E-06 
32501 multicellular organismal process 2.54E-05 
48731 system development 5.20E-05 
16043 cellular component organization 7.28E-05 
48856 anatomical structure development 1.93E-04 
7275 multicellular organismal development 1.93E-04 
48513 organ development 4.39E-04 
32502 developmental process 1.05E-03 
30199 collagen fibril organization 1.97E-03 
 
Table 3-3: Top 10 enriched biological processes in the secretome 
GO ID GO Description p-value 
5198 structural molecule activity 2.52E-11 
5201 extracellular matrix structural constituent 8.61E-9 
4859 phospholipase inhibitor activity 3.50E-5 
50840 extracellular matrix binding 5.01E-5 
5509 calcium ion binding 8.94E-5 
30674 protein binding, bridging 1.00E-4 
55102 lipase inhibitor activity 1.01E-4 
43236 laminin binding 1.34E-4 
5544 calcium-dependent phospholipid binding 2.72E-4 










Figure 3-6: BiNGO generated biological processes and molecular function networks for differentially 
expressed proteins in the secretome of Ac-SDKP treated fibroblasts. 
Colour of the nodes is indicative of the p-value for the statistical significance of the enrichment of a GO 
term while node size is indicative of the number of proteins associated with a GO term. 
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 Enriched Reactome pathways in the secretome 
To investigate which pathways are affected by Ac-SDKP in the secretome, the differentially 
expressed protein list was input into the online Reactome Pathway Database.  The top 10 results 
are shown in Table 3-4 below). 
Table 3-4: Ac-SDKP mediated Reactome pathway enrichment in the secretome 
Pathway name Entities Reactions 
found ratio pValue FDR found ratio 
ECM proteoglycans 10/79 0.006 3.18E-11 1.16E-08 14/23 0.00187 
Extracellular matrix 
organization 
15/329 0.024 4.55E-10 8.32E-08 120/318 0.02584 
Interleukin-4 and Interleukin-
13 signalling 
12/211 0.015 2.64E-09 3.22E-07 3/46 0.00374 
Integrin cell surface 
interactions 
8/86 0.007 3.47E-08 3.16E-06 10/54 0.00439 
Signalling by Interleukins 17/639 0.045 8.08E-08 4.89E-06 7/490 0.03981 
Platelet degranulation  9/137 0.010 8.81E-08 4.89E-06 5/11 8.94E-04 
Platelet activation, signalling 
and aggregation 
12/293 0.021 9.41E-08 4.89E-06 37/114 0.00926 
Response to elevated platelet 
cytosolic Ca2+ 
9/144 0.010 1.34E-07 6.01E-06 5/14 0.00114 
HSP90 chaperone cycle for 
steroid hormone receptors 
(SHR) 
7/70 0.005 1.60E-07 6.05E-06 12/12 9.75E-04 
Degradation of the 
extracellular matrix 
9/148 0.010 1.68E-07 6.05E-06 19/105 0.00853 
 
The most enriched pathways include ECM proteoglycans, Extracellular matrix organization, 
Interleukin-4 and Interleukin-13 signalling, and Signalling by Interleukins. These findings support 
a role for Ac-SDKP in the modulation of the extracellular matrix. 
 Fibrotic proteins identified in the secretome  
Some of the differentially regulated secretome proteins may be involved in conferring the 
antifibrotic effect of Ac-SDKP.  The Reactome pathway analysis data was manually scanned to 
identify pathways and their respective entity proteins likely to be involved in the fibrotic processes 
(Table 3-5).  
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Table 3-5: Reactome pathways entities putatively involved in the fibrotic process in the secretome 
Reactome Groups Protein Entities 




Collagen chain trimerisation 
Collagen formation 
Collagen degradation 
LAMC1 COL6A3 COL6A2 FBN2 EFEMP2 PLEC AGRN FN1 
LTBP4 LUM COL1A1 COL1A2 DCN HSPG2  
Interleukin-4 and Interleukin-13 
signalling 
FN1 FSCN1 VIM HSPA8 ANXA1 COL1A2 
Degradation of the 
extracellular matrix 
 
COL1A1 FBN2 COL1A2 COL6A2 FN1 COL6A3 LAMC1 HSPG2 
DCN 
Signalling by TGF-beta family 
members 
TGF-beta receptor signalling in 





The proteins identified are listed by name in Table 3-5 and grouped according to whether they 
were over-expressed or under-expressed in the Ac-SDKP treated secretome (Table 3-6).  Ac-SDKP 
is seen to lead to a decrease in the expression of various collagens and ECM proteins as well as 
TGF-β mediated proteins (Latent-transforming growth factor beta-binding protein 4 and Peptidyl-
prolyl cis-trans isomerase).   However, Ac-SDKP treatment led to a decrease in the expression of 
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Table 3-6: Ac-SDKP mediated differentially secreted proteins putatively involved in the fibrotic process 
Up regulated proteins Down regulated proteins   
Heat shock protein HSP 90-beta  
Plectin 
 
Collagen alpha-3(VI) chain 
Collagen alpha-2(VI) chain 
Collagen alpha-2(I) chain 






Laminin subunit gamma-1 
Filamin-C 
Tropomyosin alpha-4 chain 
Talin-1  
EGF-containing fibulin-like 
extracellular matrix protein 2 
Latent-transforming growth factor 
beta-binding protein 4 
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 Effect of Ac-SDKP on the proteome 
 STRING interactions of differentially expressed proteins in the proteome 
In the proteome, a total of 114 differentially expressed proteins were identified between the Ac-
SDKP and TGF-β-only treated proteomes following Student’s t-test comparisons (p< 0.05). Of 
these 52 proteins had higher expression levels and 62 proteins had decreased expression levels 
in the Ac-SDKP group. The fold change in protein expression levels ranged from 1.21- to 4.85- fold 
with an average of 3.15- fold change.  
String analysis of differentially regulated proteins in the proteome revealed multiple clusters in 
the interaction network including i) proteins of the cellular transcription and translation 
machinery, and ii) fibrotic and inflammatory proteins (Figure 3-7).   











Figure 3-7: String interaction network of Ac-SDKP differentially expressed protein groups in the 
proteome.  
The cluster with the most evidence contains proteins of the cellular transcription and translation 
machinery. 
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 GO enrichment of differentially expressed proteome proteins 
In the Ac-SDKP treated proteome, 34 molecular function terms and 201 biological pathway terms 
were significantly enriched (p <0.05) in BiNGO (Figure 3-8).  BiNGO terms for the biological 
pathways were further summarised using REVIGO. 
The most highly enriched molecular functions (Table 3-7) in the proteome were protein binding 
(GO:0005515) and structural constituent of ribosome (GO:0003735).   Extracellular matrix binding 
(GO:0005201), integrin binding (GO:0005178) and collagen binding (GO:0005518) were also 
among the top 10 most significantly enriched functions. 
Differentially expressed proteins were enriched in the biological process category (Table 3-8) for 
angiogenesis (GO:0009987), translation elongation (GO:0008152), and protein localization 
(GO:0051179).  Interestingly, significantly enriched processes also included fibroblast growth 
factor receptor signaling (GO:0008543), extracellular matrix organization (GO:0030198), 
regulation of collagen biosynthetic pathway (GO:0032965) and regulation of programmed cell 
death (GO:0043067) (Figure 3-8).  
 
Table 3-7: Top 10 BiNGO enriched molecular functions in the proteome 
GO ID GO Description p-value 
5515 protein binding 2.99E-07 
3735 structural constituent of ribosome 2.27E-06 
5198 structural molecule activity 1.91E-05 
3723 RNA binding 5.17E-05 
5488 binding 9.40E-05 
50840 extracellular matrix binding 3.53E-03 
5178 integrin binding 4.05E-03 
5093 Rab GDP-dissociation inhibitor activity 4.05E-03 
5518 collagen binding 5.81E-03 
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Table 3-8: Top 10 REVIGO sorted enriched biological processes in the proteome 
GO ID GO Description log10 p-value 
1525 angiogenesis -4.3958 
6414  translational elongation -7.7545 
8104  protein localization -4.3958 
8152 metabolic process -4.7033 
9987 cellular process -2.6364 
22610 biological adhesion -1.6402 
31589 cell-substrate adhesion -3.1421 
32501 multicellular organismal process -0.4318 
32502 developmental process -0.8356 
 





































Figure 3-8: BiNGO generated biological processes and molecular function networks for differentially 
expressed proteins in the proteome of Ac-SDKP treated fibroblasts. 
Colour of the nodes is indicative of the p-value for the statistical significance of the enrichment of a GO 
term while node size is indicative of the number of proteins associated with a GO term. 
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 Enriched Reactome pathways in the proteome 
The top 10 enriched Reactome pathways in the proteome are listed in Table 3-9. 
Table 3-9: Ac-SDKP mediated Reactome pathway enrichment in the proteome 
Pathway name Entities Reactions 
found entities pValue FDR found ratio 
Peptide chain elongation 15 97 0.007 2.2E-11 1.11E-8 0.00187 
L13a-mediated translational 
silencing of Ceruloplasmin 
expression 
16 120 0.008 4.04E-11 1.11E-8 
0.02584 
GTP hydrolysis and joining 
of the 60S ribosomal subunit 
16 120 0.008 4.04E-11 1.11E-8 0.00374 
Eukaryotic Translation 
Elongation 
15 102 0.007 4.39E-11 1.11E-8 0.00439 
Formation of a pool of free 
40S subunits 
15 106 0.007 7.43E-11 1.49E-8 0.03981 
Eukaryotic Translation 
Initiation 





16 130 0.009 1.28E-10 1.85E-8 0.00926 
Nonsense Mediated Decay 
(NMD) independent of the 
Exon Junction Complex (EJC) 














Enriched pathways in the proteome included peptide chain elongation, L13a-mediated 
translational silencing of Ceruloplasmin expression, GTP hydrolysis and joining of the 60S 
ribosomal subunit, and Eukaryotic Translation Elongation, and are indicative of active protein 




81 | Chapter 3: The molecular specificity of the antifibrotic action of Ac-SDKP 
 
 
 Reactome pathways in the proteome putatively associated with fibrosis 
Significantly enriched Reactome pathways putatively involved in the antifibrotic role mediated by 
Ac-SDKP are listed in Table 3-10.  These pathways were selected based on the literature by 
manually scanning Reactome pathway analysis results.  Various signalling pathways including 
PTK2 signalling, NOTCH4, Raf/MAP, MAPK, and SMAD are likely candidates for Ac-SDKP mediated 
antifibrotic actions.  Importantly, FGFR1 signalling which is the only known receptor for Ac-SDKP 
was significantly enriched in the proteome. 
 
Table 3-10: Proteome Reactome pathways putatively associated with the antifibrotic role of Ac-SDKP 
Reactome Groups p value Protein Entities 
MET activates PTK2 
signalling 
8.71E-06 ITGB1 COL1A1 ITGA2 FN1 LAMC1 PTK2 
Localisation of the 
PINCH-ILK-PARVIN 
complex to focal 
adhesions   
3.06E-05 ITGB1 ILK PARVA 
Signalling by NOTCH4 
  
6.92E-05 ACTA2 PSMA5 PSMC1 PSME1 PLAT RPS27A RTN4 
ECM proteoglycans 
  
1.76E-04 ITGB1 COL1A1 SPARC ITGA2 SERPINE1 FN1 
LAMC1 
RAF/MAP kinase cascade
   
3.60E-04 EEF1A1 PSMA5 EGF PSMC1 PSME1 FN1 TLN1 
RPS27A FGF2 PTK2 VCL FGFR1 
Signalling by NOTCH 
  
4.23E-04 ACTA2 PSMA5 HDAC1 STAT1 EGF PSMC1 PSME1 
PLAT RPS27A RTN4 
MAPK1/MAPK3 
signalling   
4.50E-04 EEF1A1 PSMA5 EGF PSMC1 PSME1 FN1 TLN1 
RPS27A FGF2 PTK2 VCL FGFR1 
Extracellular matrix 
organisation   
0.001 ITGB1 COL1A1 SPARC MMP1 ITGA2 SERPINE1 
FN1 MYH9 LAMC1 COLGALT1 FGF2 
Signalling by FGFR1 in 
disease   
0.002 STAT1 FGF2 FGFR1 
SMAD2/SMAD3:SMAD4 
heterotrimer regulates 
transcription   
0.003 HDAC1 SERPINE1 RPS27A 
 
 




The objective of this section was to employ MS-based discovery proteome and secretome analysis 
to identify a wider range of proteins regulated by Ac-SDKP in the fibrotic environment and hence 
further understand the spectrum of its antifibrotic action.  The main finding from this section was 
the identification of an array of proteins and potential pathways which are significantly regulated 
by Ac-SDKP.  Upregulated secretome proteins included collagens I and VI, fibrillin, laminin, 
decorin, and lumican while downregulated proteins comprised the glycoproteins fibrillin and 
laminin.  ECM proteins and proteoglycans were also enriched in the proteome as evidence by GO 
and Reactome analysis.  Proteins mapping to these pathways included collagens and other 
proteins of the matrisome, integrins, matrix metalloprotease 1 (MMP-1), secreted protein acidic 
and rich in cysteine (SPARC), serpine-1 and fibroblast growth factor-2.  Importantly, many of the 
ECM and intracellular proteins have not been previously associated with Ac-SDKP and thus 
represent novel mechanisms of action of Ac-SDKP.   
 In the secretome, only 58 differentially expressed proteins were identified, owing to the presence 
of fetal calf serum proteins in the culture medium of the fibroblasts which likely masked the 
detection of low abundance proteins (0.01%).  Challenges in secretome analysis have been 
described and the balance between minimising cell stress/death and elimination of serum 
proteins can be tricky (Stastna and Van Eyk, 2012).  Nevertheless, the small number of 
differentially regulated proteins identified can be thought to represent a snapshot of the most 
abundant extracellular proteins regulated by Ac-SDKP.  Ac-SDKP increased the expression of 23 
proteins and decreased the expression of 35 proteins in the secretome.  Given the inhibitory 
function Ac-SDKP both in cell proliferation and fibrosis, it is not surprising that more proteins are 
downregulated than upregulated (Wdzieczak-Bakala et al., 1990)(Volkov et al., 1996)(Kanasaki et 
al., 2003). 
These proteins grouped mainly to extracellular matrix organization and extracellular structure 
organization in their molecular function GO term categorisation and enriched biological GO 
processes mapped most significantly to structural molecule activity and extracellular matrix 
structural constituent.  Similarly, the two most enriched Reactome pathways include ECM 
proteoglycans and extracellular matrix organization.  Considering the role of Ac-SDKP in inhibiting 
ECM protein deposition, these results are in concordance with known functions of Ac-SDKP  
(Zhang et al., 2011)(Shibuya et al., 2005).   
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The ‘core matrisome’ which regroups ECM and ECM-associated proteins comprises approximately 
300 proteins (Yue, 2014)(Hynes and Naba, 2012)(Herrera et al., 2018a).  Various key components 
of the matrisome were identified to be differentially regulated in the secretome including 
collagens I and VI, fibrillin, laminin, decorin, and lumican.  Ac-SDKP inhibited the expression of 
two collagen I proteins and two collagen VI proteins in the secretome.  Collagen I is a fibrillar type 
of collagen and is known to promote EMT transition in response to TGF-β stimulation through the 
expression of microRNA-29 (Zeisberg et al., 2001)(Wang et al., 2012).   Type VI collagen is part of 
microfibrillar meshworks which does not form part of major fibrillar systems but is surmised to 
anchor elements between collagen I and III fibrils in the basement membrane.  Ac-SDKP has 
previously been shown to inhibit collagen I, III and IV but not collagen VI (Xu et al., 2012)(Peng et 
al., 2012)(Hajem et al., 2013).  This is possibly due to the fact that antibodies to collagen VI have 
not been used in previous studies to investigate collagen modulation by Ac-SKP.  However, 
increased collagen VI expression has been previously described in lung fibrosis (Specks et al., 
1995).  
Among the matrisome components are a large number of non-collagenous ECM proteins which 
serve to regulate collagen fibrillogenesis (Yue, 2014).  These include small leucine-rich repeat 
proteoglycans like decorin and lumican and the heparan sulphate proteoglycan agrin which were 
significantly downregulated by Ac-SDKP treatment in our study.  Decorin binds a wide range of 
matrix structural components, such as collagens, and growth factors (Reed and Iozzo, 2002).  
Lumican interacts with fibrillar collagens and has been previously linked to  pulmonary fibrosis 
(Chakravarti et al., 1998) (Pilling et al., 2015).  Agrin plays a key role in the organisation of the 
cytoskeleton and interacts with other ECM proteins including laminin (Cotman et al., 1999) 
(Bezakova and Ruegg, 2003).  It is intuitive that an alteration in collagen biosynthesis is likely to 
be accompanied by a concomitant alteration in the expression of its interacting counterparts. 
In our study, Ac-SDKP also lead to a decrease in the expression of other components of the 
matrisome including the glycoproteins fibrillin and laminin.  Fibrillin is an important component 
of extracellular matrix fibrils which accumulates in fibrosis (Sakai et al., 1986) (Kissin et al., 2002).   
Fibrillin also bears binding sites for integrin receptors which influence the extracellular 
microenvironment through the cytoskeleton and by inducing the release and activation of matrix-
bound latent TGF-β complexes (Olivieri et al., 2010).  Laminin is a major structural component of 
the basement membrane and plays important roles in fibroblast proliferation and is upregulated 
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in various forms of fibrosis, including lung fibrosis (Timpl, 1989)(Couchman et al., 1983)(Moriya 
et al., 2001).  
In the proteome, the expression of 114 proteins was found to be affected by Ac-SDKP.  Previous 
MS based techniques to detect Ac-SDKP regulated proteins in the intracellular lung fibroblast 
environment employed two-dimensional electrophoresis followed by MALDI-TOF/TOF MS and 
identified 29 differentially regulated proteins (Xiaojun et al., 2016).  The GO distribution of the 
Ac-SDKP differentially expressed proteins in our study was assessed with BiNGO.  In the molecular 
function category, proteins which functioned in protein binding and as structural constituents of 
ribosomes were most significantly enriched.  Similarly, Xiaojun et al.  found binding proteins to 
rank the highest in Ac-SDKP treated rat fibroblast cells (Xiaojun et al., 2016).  In the biological 
process category, proteins involved in angiogenesis and translation initiation were most enriched.  
Processes more relevant to fibrosis prevention including fibroblast growth factor receptor 
signaling and extracellular matrix organization proteins were also identified.   
ECM proteins and proteoglycans were enriched in GO biological processes and Reactome and also 
formed a network in STRING.  These proteins comprised collagens and other proteins of the 
matrisome, integrins, matrix metalloprotease 1 (MMP-1), secreted protein acidic and rich in 
cysteine (SPARC), serpine-1 and fibroblast growth factor-2.  MMP-1 is a secreted collagenase, 
involved in the turnover of collagen fibrils in the extracellular environment (Vincenti and 
Brinckerhoff, 2001).   SPARC is a secreted collagen-binding glycoprotein which plays a key role in 
ECM assembly and molding, and is commonly upregulated in fibrosis, including lung fibrosis 
(Demopoulos et al., 2002)(Trombetta-eSilva and Bradshaw, 2012)(Sangaletti et al., 2011).  Despite 
seeing a reduction in the levels of MMP-1 and SPARC in the Ac-SDKP proteome, these proteins 
were not detected in the secretome.   This is likely due to the low number of proteins detected in 
the secretome which resulted in a loss of detection of low abundance proteins.  Serpine-1, also 
known as plasminogen activator inhibitor 1 (PAI‐1), is a serine proteinase involved primarily in 
fibrinolysis but also in the modulation of ECM turnover and cell adhesion (Lijnen, 2005).  Various 
studies have highlighted a critical role for serpine-1 in the development of fibrosis, particularly in 
lung fibrosis (Eitzman et al., 1996)(Jiang et al., 2017).  Interestingly, ACEi have demonstrated an 
antifibrotic action through an increase in fibrinolysis and ECM degradation mediated by the 
inhibition of serpine-1 expression (Oikawa et al., 1997).  A mechanism for the suppression of 
serpine-1 by ACEi could thus be through the upregulation of Ac-SDKP.  
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The integrin-linked kinase (ILK) is an important component of cell to ECM adhesions through 
interactions with the β1 integrin cytoplasmic domain (Wu, 2004).  The focal adhesion protein 
PINKCH consists of primarily five LIM domains (double-zinc finger motif) and forms a stable 
complex with ILK and CH-ILKBP/actopaxin/α-parvin (abbreviated parvin)(Wu, 2005).  This complex 
localises to focal adhesions and is regulated by TGF-β1, hence contributing to TGF-β1 mediated 
effects on cell proliferation (Stanchi et al., 2009)(Jung et al., 2007)(S. M. Kim et al., 2007).  It is 
involved in fibronectin matrix deposition and has hence been implicated in fibrosis including in 
lung fibrosis (Guo and Wu, 2002)(Kavvadas et al., 2010).  Ac-SDKP negatively regulated the 
localisation of PINCH-ILK-PARVIN pathway in our TGF-β treated fibroblasts.  It is interesting to 
note that Tβ4 has been shown to inhibits the effects of PINCH-1 and ILK and Ac-SDKP is known to 
share many roles with its precursor (Qiu et al., 2011).  
Various signalling pathways were also modulated by Ac-SDKP in the proteome.  FGFR signalling 
was identified among the enriched GO biological processes as well as Reactome analysis.  
Importantly, FGFR-1 has been implicated in Ac-SDKP mediated endothelial-to-mesenchymal 
transition (EndMT) and endothelial mitochondrial biogenesis (Li et al., 2017)(Hu et al., 2018).  It is 
believed that Ac-SDKP may bind the FGFR receptor to induce downstream MAP kinase signalling 
(Li et al., 2017).  It is thus possible that Ac-SDKP also binds the FGFR-1 receptor in the WI-38 lung 
fibroblasts to induce antifibrotic effects.  While Ac-SDKP mediated FGFR signalling stimulates 
MAP4K4 (Li et al., 2017), MAP4K4 expression levels were not found to be different in the 
proteome.  However, this does not indicate a lack of activation of MAP4K4 which could also 
manifest as an increase in its phosphorylation.  Proteins grouping to the Raf/MAP kinase cascade 
and MAPK1/MAPK3 signalling were nevertheless modulated by Ac-SDKP.  Ac-SDKP has been 
previously shown to inhibit MAPK p44/42 activation in rat mesangial cells (Rhaleb et al., 
2001a)(Peng et al., 2012).  Proteins of the Notch signalling family were also differentially regulated 
by Ac-SDKP.  Notch signalling has been associated with fibrogenesis across a range of pathologies 
including pulmonary fibrosis (Nemir et al., 2014)(Dees et al., 2011).  An upregulation of Notch 
signalling is crucial for the myofibroblast differentiation of lung fibroblast (Kavian et al., 2012).  
Interestingly, some of the beneficial effects of Tβ4 in fibrotic pathological processes have been 
attributed to Notch signalling suppression (Hong et al., 2017). 
We have assessed the effect of Ac-SDKP on the proteome and secretome of TGF-β stimulated 
fibroblasts.  This has not only confirmed previous observations of ECM constituent reduction by 
Ac-SDKP but also identified various matrisome components which had not been previously 
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described to be affected by Ac-SDKP.  Additional novel mechanisms for antifibrotic actions of the 
peptide and signalling pathways potentially regulated by Ac-SDKP have been uncovered.  
Together, these data provide further insight into the molecular actions of Ac-SDKP as well as 
provide a better understanding of the potential beneficial effects of ACEi and Ac-SDKP 
therapeutics in fibrotic pathologies. 
 
 




Treatment options for fibrotic conditions are scarce and largely non-specific.  Although various 
compounds have been shown to demonstrate in vitro and in vivo (animal models) efficacy, few 
many compounds have met success in undergoing clinical trials and being approved for the 
therapy of fibrosis (Trautwein et al., 2015).  The success of the synthetic molecules, pirfenidone 
and nintedanib in the treatment of idiopathic pulmonary fibrosis is not common and while the 
precise mechanisms of action of the small molecules is yet to be elucidate, their antifibrotic 
effects are attributed to the inhibition of pro-fibrotic mediators such as TGF-β, PDGF and 
interleukins (Distler et al., 2019)(Aimo et al., 2020)(Sgalla et al., 2020).  Furthermore, the complex 
and insidious mechanism of tissue fibrosis makes its treatment particularly challenging and is 
likely to require combination therapy targeting more than one pathological arm of the fibrotic 
process.  Thus, the rational selection and testing of new compounds for the treatment of fibrosis 
is warranted. 
The role of Ac-SDKP in the prevention and reversal of fibrosis has piqued interest into its 
therapeutic potential in the management of fibrotic conditions.  Ac-SDKP has a short half-life of 
80minutes, suggesting that it is constantly being synthesised and degraded in tissues (Rieger et 
al., 1993).  ACEi provide a way of up-regulating Ac-SDKP levels.  However, sACE comprises two 
individual domains, namely, the N and C domains which are both inhibited by currently available 
ACEi.  This may pose a problem in the administration of ACE inhibitors in healthy normotensive 
patients due to the impairment of the C domain to hydrolyse Ang I and thereby to maintain blood 
pressure homeostasis.  Ac-SDKP is predominantly hydrolysed by the N domain of sACE: studies 
whereby one of the ACE domains was functionally knocked out via a mutation of the zinc 
coordinating residue found the N domain to be 40 times more effective at cleaving Ac-SDKP as 
compared to the C domain (Rousseau-Plasse et al., 1996).  The phosphinic peptide inhibitor 
RXP407 displays three orders of magnitude selectivity for the N domain (Dive et al., 1999).  It has 
been shown to completely inhibit N domain activity without interrupting Angiotensin II (Ang II) 
formation by the C domain in mice (Junot et al., 2001).  Although RXP407 has low bioavailability 
and cannot be used in therapy, it can be used in vitro to predict the effects of N domain-selective 
ACE inhibition. 
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Ac-SDKP analogues resistant to ACE hydrolysis provide another way of potentially increasing basal 
Ac-SDKP levels in fibrosis therapy.  In mice with diabetic renal fibrosis, co-treatment with both Ac-
SDKP and the ACE inhibitor ramipril further reduced renal fibrosis, as compared to Ac-SDKP or 
ramipril alone (Castoldi et al., 2013).  This additive effect of Ac-SDKP with respect to ACE inhibition 
suggests that Ac-SDKP administration might not only provide an alternative form of therapy but 
also additional protective effect against fibrosis as compared to ACE inhibition alone.  This is not 
surprising as chronic ACE inhibition by ACE inhibitors do not result in a massive accumulation of 
Ac-SDKP.  An intermittent reactivation of ACE in between doses of ACE inhibitors as well as an 
increase in the glomerular filtration of Ac-SDKP by the kidney is thought to be responsible for 
these observed Ac-SDKP levels (Azizi et al., 1997)(Azizi et al., 1999)(Comte et al., 1997).  There is 
thus merit to combination therapy with ACEi and Ac-SDKP analogues in the management of 
fibrotic conditions. 
Various Ac-SDKP analogues have been previously synthesised; analogues in which tetrapeptide 
bonds have been replaced by reduced bonds, analogues whereby the L-amino acids were 
swapped for the corresponding D-amino acid residue and analogues lacking the C-terminal 
carboxylate moiety.  HPLC analysis revealed greater than 97% residual peptide activity for all the 
analogues with reduced peptide bonds after 24hours incubation with ACE, as compared to no 
residual activity of the parent compound Ac-SDKP (S. Gaudron et al., 1997)(Thierry et al., 
1990)(Ma et al., 2014).  Replacing the carboxylate moiety with a carboxamide C-terminus also 
resulted in protection from hydrolysis but the absence of C-terminal carboxylate group confers 
no protection (S Gaudron et al., 1997).  Finally analogues whereby the D-amino acids were 
introduced were also resistant to ACE degradation in vitro and displayed significantly increased 
half-lives in vivo (Ma et al., 2014)(Zhang et al., 2019). 
The in vitro effects of the pseudo peptides on haematological cell proliferation have also been 
investigated.  Ac-Serψ(CH2-NH)Asp-Lys-Pro, Ac-Ser-Aspψ(CH2-NH)Lys-Pro, Ac-Ser-Asp-Lysψ(CH2-
NH)Pro, and the C-terminus modified peptide (Ac-SDKP-NH2) significantly reduced the numbers 
of Colony Forming Unit, CFU-granulocyte/macrophage in the S phase and prevented the mitotic 
cycling of highly proliferating stem cells (Gaudron et al., 1999).   
Further, the Ac-SDDKDP analogue in which Asp and Lys were replaced with their D-isomers was 
tested in cardiac and hepatic fibrosis mice models (Ma et al., 2014)(Zhang et al., 2019).  The Ac-
SDDKDP analogue displayed a prolonged in vivo half-life and significantly improved pathological 
tissue fibrosis in both models through TGF-β/Smad pathway modulation.  Analogues were also 
used to probe the molecular specificity of the inhibitory action of Ac-SDKP on primitive murine 
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haematopoietic cell cycling.  The tri-peptide Ala-Asp-Lys also failed to inhibit the cellular 
proliferation, but interestingly the tri-peptide Ser-Asp-Lys retained the anti-proliferative ability.  
Thus the SDK sequence appears to be vital for the prevention of S phase entry into the mitotic 
cycle (Robinson et al., 1993).  However, the molecular specificity of the antifibrotic of Ac-SDKP 
has not been investigated.  This chapter addresses the important question of whether specific 
fragments of Ac-SDKP can confer antifibrotic activity; this could in turn lead to the design of 






























In order to investigate the antifibrotic potential of Ac-SDKP analogues in a cell line model of 
fibrosis, the following objectives were identified: 
1. investigation of the effects of Ac-SDKP on the TGF-β pathway in a lung fibroblast cell line 
2. cleavage site determination of Ac-SDKP analogues by ACE 
3. investigation of the contribution of the amino acid residues in the Ac-SDKP sequence 
towards its antifibrotic effects 
4. investigation of the effects of Ac-SDKP in combination with ACE inhibitors in preventing 
collagen deposition in cells 
 
  




  Ac-SDKP analogue design 
Ac-SDKP sequences were designed to investigate the functional portion of Ac-SDKP in its 
antifibrotic role.  Sequence tripeptides SDK and DKP in both the acetylated and unacetylated 
forms were ordered from Biopep Peptide group (Stellenbosch, South Africa) (Table 4-1, peptides 
2-5).  An analogue, previously shown to be resistant to ACE enzymatic cleavage was also used to 
compare its antifibrotic effect to physiological Ac-SDKP (Gaudron et al., 1999).  In the AcSDψKP 
analogue, the peptide bonds between the Asp-Lys has been converted to the non-hydrolysable 
CH2-NH bonds.  The Ac-SDKP analogue (Table 4-1, peptide 6) was synthesised by Sigma (USA). 
 
Table 4-1: Ac-SDKP sequences and analogues used to investigate the specificity of the antifibrotic effect  
  
1 Acetyl Ser (CO-NH) Asp (CO-NH) Lys (CO-NH) Pro Ac-SDKP 
2 Acetyl Ser  Asp  Lys   Ac-SDK 
3  Ser  Asp  Lys   SDK 
4    Asp  Lys  Pro DKP 
5 Acetyl   Asp  Lys  Pro Ac-DKP 
6 Acetyl Ser  Asp (CH2-NH) Lys  Pro Ac-SDψKP 
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  Cell culture 
WI-38 lung fibroblasts or CT-1 fibroblasts (ultraviolet-irradiated WI-38 cells) were cultured 
according to 3.3.1.   The fibroblasts were used to assess the effects of Ac-SDKP, ACE inhibitors and 
Ac-SDKP analogues on the prevention of fibrosis.  
Briefly, the cells were reconstituted into 75cm2 flasks and grown in 10ml of growth medium, lifted 
using Trypsin-EDTA (Gibco®, USA) and seeded into 6-well plates.   
  Cell treatment and lysis 
Cells were treated with TGF-β (5 ng/ml) or ET-1 (100 ng/ml) for 48 hours in the presence of 
ascorbic acid (50 μg/ml) for 6 to 48 hours to induce fibrosis.  To assess the protective effect of Ac-
SDKP, cells in a 25cm2 flask were lysed in 300μl of Triton lysis buffer (0.05 M HEPES, 0.5 M NaCl, 
1% triton X-100, 1 mM PMSF supplemented with 1:1000 Protease Inhibitor Cocktail (Set III, 
Calbiochem, USA) and Phosphatase Inhibitor Cocktail (PhosSTOP, Roche, Switzerland)).  The lysate 
was centrifuged at 10 000 g at 4oC and the supernatant used for western blot analysis. 
  Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
Cell lysates were boiled with Laemmli buffer (60 mM Tris-Cl, 2% SDS, 10% glycerol, 5% 2-
mercaptoethanol, 0.01% bromophenol blue, pH 6.8) for 10 minutes.  The reduced samples were 
separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli, 
1970) with the Mini PROTEANTM III system (BIO-RAD, USA).   An 8% resolving gel (0.3% SDS, 125 
mM Tris-HCl, pH 8.8) was used for the detection of sACE.   A 3% stacking gel (0.3% SDS, 37.5 mM 
Tris buffer, pH 6.8) was used in and gels were run in Tris-glycine-SDS buffer (pH 8.3) at 25mA per 
gel. 
  Western blotting  
Following gel electrophoresis, a transfer sandwich was set up using the Mini PROTEAN™ III system 
(Biorad, USA).  Proteins were electrophoretically transferred from gel to Hybond ECL 
nitrocellulose membrane (GE Healthcare LifeSciences, UK) in cold transfer buffer (20mM Tris-
base, 150mM glycine, 20% methanol) at a current of 100V for 1hour.  Membranes were incubated 
for 1hour in blocking buffer (Tris-buffered saline, 0.1% tween-20, 5% skim-milk).  Following 
blocking, membranes were incubated overnight in primary antibody (4G6 rat) dilution (1:100).  
Primary antibody binding was detected with the corresponding secondary HRP-conjugated 
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antibody (goat anti-rat) using the Immun-star WesternC™ detection system (BIO-RAD, USA). The 
chemiluminescence detector (G:BOXChemi, Syngene, USA) was used to detect the light emission 
produced in the peroxidase catalysis of the oxidation of luminol.  
  HPLC analysis and progress curves 
HPLC of the Ac-SDKP peptides was performed using a Poroshell 120 EC-C18 column (Agilent, USA). 
To plot progress curves for the hydrolysis of the various Ac-SDKP peptides, 1nM sACE was 
incubated with 1mM Ac-SDKP at different time points in HEPES assay buffer (50 mM HEPES buffer, 
300 mM NaCl, 10 μM ZnSO4, pH6.8) at 37°C. Reactions were stopped by the addition of 
trifluoroacetic acid (TFA) to a final concentration of 0.1%.  Reaction mixtures were analysed by 
HPLC over a gradient of 2% to 95% ACN (in 0.1 % TFA) on the Agilent 1260 Infinity HPLC (Agilent, 
USA) at multiple wavelengths simultaneously.  The area under the peak for the peptides and their 
cleavage products was measured using the Agilent 1260 software at λ =214nm.  
 Hydroxyproline assay 
Collagen deposition was assessed as a marker of fibrosis using an assay for hydroxyproline, the 
major constituent of collagen (Sigma, USA).  The hydroxyproline assay kit adapted from a method 
by Kivirikko et al., was used according to manufacturer’s protocol to produce a colorimetric 
product from the reaction of oxidized hydroxyproline with 4-(Dimethylamino) benzaldehyde 
(DMAB), which was measured at 560nm (Kivirikko et al., 1967). 
 Statistical analysis 
Data analysis was performed using the statistical software GraphPad PRISM 6.0 (GraphPad 
software Inc, USA).  To compare ratios of treated vs. untreated samples, un-paired, 
nonparametric, student t-tests were employed with a cut off for statistical significance of p<0.05.   
 
  




 Ac-SDKP inhibits TGF-β/Smad signalling and collagen deposition in lung 
fibroblasts 
 Ac-SDKP inhibits AngII and ET-1 mediated TGF-β expression 
To investigate the effect of that Ac-SDKP on TGF-β activation in our cell line  
(WI-38 cells), western blots for TGF-β levels were performed.  Additionally, the effect of Ac-SDKP 
on AngII and ET-1 mediated TGF-β signalling was studied.  
Treatment of WI-38 cells with AngII and ET-1 induced 1.26 and 1.48-fold increases in TGF-β levels, 
respectively (Figure 4-1).  In both AngII and ET-1 stimulated cells, Ac-SDKP significantly inhibited 
the increase in TGF-β levels in the cell culture supernatant.  This confirmed that WI-38 cells could 
be used for investigating the antifibrotic actions of Ac-SDKP.  Since ET-1 induced a slightly higher 
























Figure 4-1: Effect of Ac-SDKP on Ang II and ET-1 mediated TGF-β expression 
Representative western blot for TGF-β (5 ng/ml) in WI-38 cells treated with A. Ang II  
(100mM) or B. ET-1 (100ng/ml) for 48hours in the presence or absence of 100nM Ac-
SDKP. Densitometry of western blots performed in triplicate for cells treated with C. Ang 
II and D. ET-1 for 48hours. Controls represent cells treated with vehicle accordingly. Data 
is representative of ± standard of the mean (SEM) of triplicates.  Significance (p < 0.05) is 
indicated as # for a difference from control or denoted graphically by * with corresponding 




 Ac-SDKP inhibits TGF-β/Smad3 signalling in WI-38 cells 
The binding of TGF-β to its receptor induces Smad2/3 phosphorylation.  We investigated whether 
the inhibition of TGF-β expression by Ac-SDKP causes a reduction in pSmad3 levels.  WI-38 cells 
pre-treated with Ac-SDKP were stimulated with ET-1 for 6hr prior to lysis.  Cell lysates were 
investigated for pSmad3 and Smad3 levels as well as the housekeeping protein GAPDH.  Ratios of 
pSmad3/Smad3, adjusted for GAPDH levels, were determined (Fig 4-2). 
 




Figure 4-2: The prevention of TGF-β mediated pSmad-3 signalling by Ac-SDKP.  
Lysates from WI-38 cells pre-treated with 100nM Ac-SDKP for 30mins and 
incubated with TGF-β (5 ng/ml) for 6hours. A. Representative western blots for 
pSmad-3, Smad-3 and GAPDH on cell lysate. B. Densitometry of pSmad-3/Smad-3 
ratios adjusted for GAPDH expression. Data is representative of ±SEM of three 
experimental repeats and each sample blotted n=2 (technical repeat). Significance 
(p < 0.05) is indicated as # for different from control or denoted graphically by * 
with corresponding bars on the graphs. 
 
The addition of TGF-β to the WI-38 cells induced a 1.8-fold increase in Smad3 phosphorylation (p 
< 0.05).  This suggests that TGF-β induces downstream cell signalling in WI-38 cells.  Ac-SDKP alone 
had no effect on pSmad3 phosphorylation in WI-38 cells.  However, Ac-SDKP significantly inhibited 
TGF-β mediated phosphorylation of Smad3.  Thus, Ac-SDKP inhibits TGF-β/Smad signalling in WI-
38 through the inhibition of TGF-β expression as well as Smad3 phosphorylation. 
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 Ac-SDKP prevents TGF-β mediated collagen accumulation 
TGF-β/ Smad signalling is known to induce the transcription of extracellular matrix components 
involved in the fibrotic process.  Collagen expression by the lung fibroblasts was investigated as a 
marker of fibrosis.  The hydroxyproline (major constituent of collagen) content of the WI-38 cells 
was measured using a specific assay.  The hydroxyproline levels in CT-1 cells (γ- irradiated WI-38 
cells) was also measured as the cells grow at a much faster rate and have been shown to have an 
increased basal expression level of collagen (Namba et al., 1980). 
Confluent WI-38 or CT-1 cells were pre-treated with Ac-SDKP or vehicle for 30 mins prior to 48hr 
incubation with TGF-β.  The fold change in the hydroxyproline content of the cells (adjusted using 
protein content quantification by a Bradford assay) was assessed (Figure 4-3).  TGF-β significantly 
induced collagen expression in WI-38 and CT-1 cells (1.63- and 1.87-fold respectively).  In both 
cell lines, pre-treatment with Ac-SDKP prevented the collagen upregulation measured upon 
stimulation with TGF-β.  Thus, Ac-SDKP leads to a decrease in extracellular matrix components 











Figure 4-3: Effect of Ac-SDKP on TGF-β mediated cellular collagen levels in WI-38 and CT-1 
fibroblasts.   
Hydroxyproline content of pre-treated WI-38 or CT-1 cells (100nM Ac-SDKP) prior to the 
addition of TGF-β (5 ng/ml). The fold increase in hydroxyproline following subtraction of spiked 
hydroxyproline content is shown. Data is representative of ±SEM of duplicates of two 
experimental repeats. Significance (p < 0.05) is indicated as # for different from control or 
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 Investigating the specificity of the antifibrotic effects of Ac-SDKP 
 The cleavage of Ac-SDKP sequence peptides by ACE 
Ac-SDKP is a well-known substrate of ACE and the ability of sACE to cleave the peptides Ac-SDK, 
SDK, AC-DKP and DKP was probed.  The HPLC chromatograms of the hydrolysis of the parent Ac-
SDKP by sACE indicated two product peaks labelled (P1 and P2) eluting at 1.9 and 2.8 mins, 
respectively (Fig 4-4).  Both products eluted before the full-length Ac-SDKP which reflects the 
decrease in hydrophobicity of the shorter fragment peptides. 
The Ac-SDKP-derived peptides were incubated with 10nM sACE in a time course experiment and 
the relative AUC for the uncleaved peptides (S1) were recorded in Fig 4-5.  Only Ac-SDKP and Ac-
DKP were cleaved by sACE as seen in the progress curves and as evident from P1 and P2 peak 








Figure 4-4: Representative chromatograms of Ac-SDKP peptide cleavage by sACE. 
 HPLC chromatograms of A. The substrate, 1mM Ac-SDKP in the absence of sACE B. Ac-SDKP 
incubated with 1nM sACE for 30minutes. C. Ac-SDKP incubated with 1nM sACE for 60minutes. 
The substrate peak is indicated as S1 whilst product peaks is denoted as P1 and P2 respectively. 
 





Figure 4-5: Progress curve of the cleavage of Ac-SDKP peptide sequences by sACE.  
The % AUC of the substrate peak S1 as indicated in section 5.4 for the parent peptide Ac-SDKP and 
the sequence peptides Ac-SDK, SDK, Ac-DKP and DKP are plotted.   
 
 
 Ac-SDKP and Ac-DKP inhibit TGF-β expression in WI-38 cells 
To determine whether the Ac-SDKP peptides have antifibrotic activity, their effects on ET-1 
mediated TGF-β expression was measured in WI-38 cells.  Confluent WI-38 cells were pre-treated 
with 100nM of the different Ac-SDKP peptides for 30mins and subsequently incubated with ET-1 
for 48hr.  TGF-β levels in concentrated cell culture supernatants were determined by western 
blotting.  Equal amounts of protein were loaded (verified by Ponceau staining) and TGF-β levels 
were normalised to the untreated control (Figure 4-6).  Upon ET-1 stimulation a 1.4-fold increase 
in TGF-β levels was observed.  Only Ac-SDKP and Ac-DKP significantly inhibited the upregulation 
of TGF-β induced by ET-1.  This inhibitory effect appears more marked for Ac-SDKP (although no 
statistical difference in the Ac-SDKP and Ac-DKP group was observed).  It thus appears that the 
minimal requirement for TGF-β inhibition is the Ac-DKP fragment of Ac-SDKP. 
 




Figure 4-6: Prevention of AngII mediated fibrosis in WI-38 by Ac-SDKP sequence peptides.  
A. Representative western blot for TGF-β in CT-1 cells treated with ET-1 (100 ng/ml)  for 
48hours in the presence or absence of 100nM of respective Ac-SDKP peptides B. 
Densitometry of western blots performed in duplicate for cells treated with ET-1 for 
48hours. Controls represent cells treated with vehicle accordingly. Data is representative of 
±SEM of duplicates.  Significance (p < 0.05) is indicated as # for different from control or 
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 Ac-SDKP sequence peptides do not inhibit TGF-β-mediated collagen 
upregulation 
The ability of the sequence peptides to inhibit TGF-β mediated collagen accumulation was 
investigated in CT-1 cells.  Confluent CT-1 cells were pre-treated with the respective Ac-SDKP 
peptide for 30mins and incubated with TGF-β for 48hr.  The fold change in the hydroxyproline 
content measured by the assay (adjusted by protein content measured by a Bradford assay) is 
plotted (Figure 4-7).  As seen previously, TGF-β significantly induced collagen expression in CT-1 
cells.  Despite the ability of Ac-DKP to inhibit TGF-β expression, a small but not significant 
inhibition of collagen/hydroxyproline levels was observed indicating a tendency towards an 
antifibrotic profile for the peptide.   
 
 
Figure 4-7: Effect of Ac-SDKP sequence peptides on ET-1 mediated collagen levels. 
Hydroxyproline content of pre-treated CT-1 cells (100nM Ac-SDKP peptides: Ac-
SDKP, Ac-SDK, SDK, Ac-DKP, DKP) prior to the addition of ET-1 (100 ng/ml).  The fold 
increase in hydroxyproline following subtraction of spiked hydroxyproline content is 
shown.  Data is representative of ±SEM of duplicates of two experimental repeats. 
Significance (p < 0.05) is indicated as # for different from control or denoted 
graphically by * on the graphs. 
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 The antifibrotic potential of the Ac-SDψKP analogue 
 Ac- SDψKP resists cleavage by ACE 
Ac- SDψKP was previously shown to be uncleaved by ACE.  To confirm this finding, Ac-SDψKP was 
incubated with sACE as seen in 4.4.2.1.  Similarly, the relative AUC for the uncleaved substrate 
(S1) is plotted in Fig 4-8.  No cleavage of Ac-SDψKP was seen at any of the time points, validating 
its resistance to ACE degradation.   
 
 
Figure 4-8: Progress curve of the cleavage of Ac-SDψKP peptide bond analogue by sACE.  
The integrated peak areas of the substrate as indicated by S1 in section 4.4 for the parent peptide Ac-
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 Ac- SDψKP inhibits the TGF-β/Smad signalling pathway 
The ability for Ac-SDψKP to inhibit the TGF-β/Smad pathway was assessed in a similar fashion to 
4.4.1 and 4.4.2.  The comparative effect of Ac-SDψKP pre-treatment on TGF-β levels and 
downstream pSmad3 activation was measured in WI-38 cells.   In ET-1 treated cells, Ac-SDψKP 
has a comparable effect to Ac-SDKP in preventing TGF-β accumulation in the cell culture 
supernatant (Fig 4-9 A&B).  Similarly, in TGF-β treated cells, Ac-SDψKP also inhibited an increase 
in Smad3 phosphorylation (Fig 4-9 C&D).   
Ac-SDψKP has demonstrated here an antifibrotic potential similar to the physiological Ac-SDKP 
peptide.  Ac-SDψKP showed a tendency towards a better inhibition of the TGF-β signalling than 























Figure 4-9: Effect of Ac-SDψKP on TGF-β/Smad signalling in WI-38 cells  
A. Representative western blot for TGF-β in WI-38 cells treated with Ang II (100mM) for 48hours in the 
presence or absence of 100nM Ac-SDKP or 100nM Ac-SDψKP B. Densitometry of western blots performed 
in triplicate.  C. Representative western blots for pSmad-3, Smad-3 and GAPDH on equal protein 
concentrations of WI-38 lysates treated with TGF-β for 6hours in the presence or absence of 100nM Ac-SDKP 
or 100nM Ac-SDψKP.  D. Densitometry of pSmad-3/Smad-3 ratios adjusted for GAPDH expression.  Controls 
represent cells treated with vehicle accordingly. Data is representative of ±SEM of triplicates for TGF-β 
densitometry and ±SEM of duplicates of two experimental repeats for pSmad-3 and Smad-3.  Significance (p 
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 Investigating the effect of ACEi in combination with Ac-SDKP on collagen levels 
An additive effect for ACEi and exogenous Ac-SDKP has previously been demonstrated in mice 
models of fibrotic disease (Castoldi et al., 2013).  To investigate whether the addition of ACEi could 
confer increased protection, lisinopril or the N domain-selective ACEi RXP407 were supplemented 
to Ac-SDKP and Ac-SDψKP treated CT-1 cells.   
Ac-SDψKP, lisinopril and RXP407 alone had no effect on the hydroxyproline content of the cells 
(Figure 4-10).  As previously observed, TGF-β induced an increase in the hydroxyproline content 
of the cells.  Ac-SDKP and Ac-SDψKP alone prevented TGF-β mediated increases in hydroxyproline 
levels.  The combination of Ac-SDKP and lisinopril had no additive effect on inhibiting 
hydroxyproline levels of CT-1 cells.  However, the combination of Ac-SDKP and RXP407 
demonstrated a greater inhibition of hydroxyproline (p<0.01).  On the other hand, hydroxyproline 
inhibition by Ac-SDψKP was not improved by ACEi supplementation, either with lisinopril or 
RXP407.  However, the antifibrotic effect of Ac-SDψKP was comparable to the combination of Ac-





















Figure 4-10: Effect of Ac-SDψKP and ACEi on TGF-β mediated cellular collagen levels.   
Hydroxyproline content of A. unstimulated and B. TGF-β (5 ng/ml) pre-treated CT-1 cells (100nM Ac-
SDKP, 100nM Ac-SDψKP, 100nM Lis, 100nM, RXP407) prior to the addition of ET-1 for 48hours.  The fold 
increase in hydroxyproline following subtraction of spiked standard is shown.  Data is representative of 
±SEM of duplicates of two experimental repeats.  Significance (p < 0.05) is indicated as # for different from 
control or denoted * for different from TGF-β treatment alone.  ** denotes a significance of p<0.01. 
 
  




There were four key findings from this section of our study.  First, the antifibrotic effects of Ac-
SDKP were confirmed in a lung fibroblast cell line (WI-38 and its irradiated CT-1 counterpart), 
demonstrating, for the first time, that this cell line could be used as a model for fibrosis to test 
the effects of Ac-SDKP, particularly in the prevention of TGF-β mediated Smad phosphorylation 
and collagen deposition.  Second, a large stride was made in identifying the minimal requirement 
of the Ac-SDKP peptide for its antifibrotic action of Ac-SDKP.   The Ac-DKP fragment significantly 
inhibited TGF-β expression, although this inhibition was less than that of the parent peptide.  
Importantly, this identified a different minimal requirement to its anti-proliferative ability (SDK 
fragment identified to be important)(Gaudron et al., 1999).  Third, the Ac-SDψKP analogue, shown 
to be resistant to ACE cleavage, demonstrated an antifibrotic potential.  This is the first study to 
test the effect of this particular Ac-SDKP analogue on fibrosis prevention.  Ac-SDψKP significantly 
inhibited the TGF-β/Smad signalling pathway and collagen expression.  The fourth finding was 
that the combination of ACEi with Ac-SDKP treatment resulted in an increased prevention of 
collagen expression as compared to Ac-SDKP treatment alone.  Importantly, the N domain-
selective inhibitor RXP407 demonstrated the most pronounced enhancement of the antifibrotic 
action of Ac-SDKP.  
Fibrosis is driven by an interplay between inflammatory immune cells and fibroblasts, which 
synthesise ECM components (Kendall and Feghali-Bostwick, 2014).  Ac-SDKP largely exerts its 
beneficial effects through the inhibition of TGF-β/Smad signalling to prevent ECM protein 
deposition (Peng et al., 2010)(Yang et al., 2004).  Ac-SDKP significantly inhibited both AngII and 
ET-1-mediated TGF-β release in the cell culture supernatant of the lung fibroblasts.  Both AngII 
and ET-1 induce fibrosis through the activation of the TGF-β/Smad cascade (Leask, 2010)(Border 
and Noble, 1998)(Ruiz-Ortega et al., 2005). Ac-SDKP has previously been shown to inhibit both 
AngII and ET-1-mediated fibrotic gene expression (González et al., 2014)(Peng et al., 2012). Having 
established that TGF-β upregulation is induced by AngII and ET-1 in fibroblasts, we next conducted 
experiments to determine whether Ac-SDKP would inhibit TGF-β-mediated Smad3 signalling.  Ac-
SDKP significantly inhibited TGF-β-mediated phosphorylation of Smad3, suggesting that Ac-SDKP 
modulates TGF-β/smad3 signalling in WI-38 cells.  This inhibition by Ac-SDKP resulted in a 
significant reduction in collagen levels in both WI-38 and CT-1 culture supernatants. This result is 
not unsurprising and confirms the findings of a myriad of studies which has demonstrated the 
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ability for Ac-SDKP to inhibit both TGF-β and collagen levels in (Xiaojun et al., 2016)(Rhaleb et al., 
2013). 
The ability of ACE to degrade Ac-SDKP peptides was investigated using HPLC analysis of the 
peptides incubated with ACE for different time periods.  Only the Ac-DKP fragment was cleaved 
by ACE; however, its hydrolysis was less efficient than that of Ac-SDKP. It is unclear why only the 
Ac-DKP fragment can be cleaved by ACE. A crystal structure of the KP fragment of Ac-SDKP in the 
N domain of ACE has provided insight into the binding of the small tetrapeptide to the relatively 
large ACE catalytic site. This has facilitated  the molecular docking of the full-length Ac-SDKP into 
both the N and C domains of ACE (Masuyer et al., 2015).  The docking revealed that the specificity 
of the interaction of Ac-SDKP with the N domain occurs primarily as a result of bonds formed in 
the S2 subsite of the enzyme, where the Ac-Ser forms interactions with a conserved histidine of 
the N domain. However, while we observed that the Ac-DKP fragment was cleaved by ACE, the 
Ac-SDK peptide was not.  It is likely that while interactions in the S2 subsite of the enzyme are 
important for specificity, interactions with other subsites drive the correct orientation and binding 
of the full length and tripeptides in the ACE active site.  
The effects of Ac-SDKP on haematological stem cell proliferation have also been documented 
previously (Gaudron et al., 1999). It is plausible that upregulation of Ac-SDKP levels, through the 
administration of an Ac-SDKP analogue to reduce inflammation and fibrosis, could result in 
reduced haematological stem cell division.  Acute and chronic ACEi therapy increase plasma Ac-
SDKP levels approximately 5-fold and higher levels of Ac-SDKP levels are unlikely to arise due to 
the intermittent reactivation of ACE (Azizi et al., 1996)(Inoue et al., 2011)(Azizi et al., 1997).  Thus, 
the administration of an Ac-SDKP analogue which might increase Ac-SDKP levels beyond a 5-fold 
increase could potentially lead to adverse effects of haematopoietic stem cell inhibition.  Since it 
had been determined that the minimum requirement of the Ac-SDKP sequence for mitotic cycle 
progression is the SDK sequence (Gaudron et al., 1999), we sought to investigate the minimum 
sequence requirement for fibrosis prevention using peptides SDK, DKP, Ac-SDK, and Ac-DKP. The 
Ac-DKP fragment significantly inhibited the upregulation of TGF-β induced by ET-1 but not to the 
same extent as the physiological Ac-SDKP peptide.  However, this only translated into a small, 
non-significant inhibition of collagen/ hydroxyproline levels.  It is likely that further inhibition of 
the TGF-β levels are required to further prevent the downstream accumulation of collagen levels.  
This finding suggests that the minimum requirement for the antifibrotic effect could be the Ac-
DKP fragment but that its binding to its receptor is impaired.   
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Various Ac-SDKP analogues have previously been described, including the Ac-SDDKDP analogue in 
which Asp and Lys were replaced with their D-isomers, which demonstrated antifibrotic effects in 
cardiac and hepatic fibrosis mice models (Ma et al., 2014)(Zhang et al., 2019).  The Ac-SDψKP 
peptide with a reduced peptide bond was synthesised and as expected, the peptide was resistant 
to ACE cleavage with 96% of the peptide remaining after 24 h incubation with ACE.  We tested 
the effect of the Ac-SDψKP analogue on the WI-38 fibroblasts and demonstrated that Ac-SDψKP 
could inhibit TGF-β/ Smad 3 signalling and collagen deposition.   Our findings provide a rationale 
for the testing of this peptide in in vivo models of fibrosis. 
Fibrosis typically arises as a result of chronic low-grade inflammation (Wynn, 2008), which 
disrupts the ECM balance, leading to collagen and ECM protein deposition (Herrera et al., 2018b).  
The complex aetiology of fibrosing conditions, and their insidious nature, has made their 
prevention and management particularly challenging (Wilson and Wynn, 2009). Effective 
therapeutics for the treatment of fibrosis have largely remained elusive. The recognition of Ac-
SDKP as an effective and necessary physiological player in the prevention of disseminated fibrosis 
has uncovered new opportunities for understanding and targeting pathophysiological processes 
arising during fibrosis (Peng et al., 2007)(Carretero, 2005).   
ACEi and Ac-SDKP analogues provide separate but non-redundant ways of preventing fibrosis.  
ACEi inhibit both the formation of AngII and the cleavage of Ac-SDKP, whereas Ac-SDKP analogues 
can result in much higher concentrations of the antifibrotic peptide than is achieved by ACEi.  We 
thus investigated whether the addition of ACEi lisinopril or the N domain-selective ACEi RXP407 
could result in increased prevention of TGF-β/ Smad 3 signalling.   Only, the combination of Ac-
SDKP and RXP407 demonstrated a greater inhibition of hydroxyproline as compared to Ac-SDKP 
alone.  This may be due solely to the inhibitory action of the ACEi on the breakdown of Ac-SDKP 
thus leading a maintenance in its concentrations.  This would explain why the exhanced effect 
was not more effective than the Ac-SDψKP analogue.  However, a different situation might be 
observed in an in vivo model where the different mechanisms of action of ACEi, particularly on 
AngII metabolism come into play.  





Different signalling pathways contribute to the pathological processes that lead to inflammation, 
and ultimately to fibrosis (Wynn, 2008)(Grynberg et al., 2017)(Ponticos et al., 2009)(Matsuoka et 
al., 2002).  The ACE signalling pathway initially described by the laboratory of Ingrid Flemming 
revealed the activation of MAPK and JNK signalling, which overlap with pro-inflammatory 
pathways (Kohlstedt et al., 2002)(Kohlstedt et al., 2004)(Reis et al., 2018). 
The ACE cytoplasmic tail bears five serine residues, three of which are located within known 
kinase sequence motifs.  An ACE signal transduction pathway has been described whereby the 
ACEi and substrate binding to ACE on the cell surface membrane trigger ACE dimerization and CK-
2-mediated cytoplasmic tail phosphorylation (Kohlstedt et al., 2004)(Kohlstedt et al., 2006). 
Through the sequential mutation of the three potential CK-2 phosphorylation targets, Ser1270 
has been shown to be the site of phosphorylation that triggers the signalling cascade (Kohlstedt 
et al., 2002)(Kohlstedt et al., 2004).  This cascade leads to the activation of downstream pathways 
including the c-Jun NH2-terminal kinase (JNK) and MAPK pathway, as evidenced by JNK and ERK 
phosphorylation (Kohlstedt et al., 2004)(Reis et al., 2018).  Activation of the JNK and MAPK 
pathways leads to AP-1 induced activation or repression of target genes, including ACE (ACE99 
gene), COX-2, β-arrestin 2, and interleukin-1 (Tournier et al., 1997)(Kohlstedt et al., 2005)(Reis et 
al., 2018). 
Ac-SDKP induces the ACE signalling pathway in CHO cells in N or C domain catalytic knockouts of 
murine ACE (X. Sun et al., 2010).  Interestingly, no signalling induction was observed in the fully 
active conformation of murine ACE. However, it has been shown that the ACE pathway is species- 
specific, and while there was no signalling response in response to AngI in porcine cells expressing 
human sACE, a significant activation of JNK was observed upon AngI binding to murine sACE in 
CHO cells (Kohlstedt et al., 2005).  The effect of Ac-SDKP on human sACE signalling remains 
unknown.  Activation of the ACE signalling pathway leads to JNK activation; however, Ac-SDKP 
inhibits both the JNK and ERK pathways, eventually inhibiting TGF-β-induced collagen expression 
(Zhang et al., 2011) (Kanasaki et al., 2006).  
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Different ACE inhibitors can induce different activation profiles in the same cell type (Reis et al., 
2018). Captopril, which bears a sulfhydryl group that is associated with additional 
cardioprotective effects through free radical-scavenging, caused a significantly higher amount of 
JNK and ERK phosphorylation than ramipril in CHO cells expressing murine ACE (Pasini et al., 2007) 
(Reis et al., 2018).  Next-generation N domain-selective ACE inhibitors have been proposed for 
the treatment of fibrosis (Douglas et al., 2013).  Comparisons between the activation of ACE 
signalling by an N-selective inhibitor and a non-selective inhibitor would further clarify the 
suitability of these inhibitors for treating fibrosis.  
It is unclear whether the ACE signalling cascade leads to a pro- or an anti-inflammatory response. 
While COX-2 often leads to inflammatory effects and contributes to pathological processes 
through the induction of local prostaglandin production, COX-2 inhibitors present a risk factor for 
atherosclerosis by increasing platelet aggregation, despite the inflammatory nature of the 
atherosclerotic process (Crofford, 1997)(Mukherjee and Nissen, 2001).  It is also plausible that the 
protective or detrimental effects of the ACE signalling pathway might be tissue- and site-specific. 
A recent study by Reis et al. supports a beneficial, anti-inflammatory effect for the activation of 
the ACE signalling cascade (Reis et al., 2018).  Cellular signalling through ACE upon Ac-SDKP 
binding could be yet another mechanism by which ACE can exert protective effects.  
A direct indication of the degree of activation of the ACE signalling cascade can be obtained by 
quantifying the levels of phosphorylation at the signalling-specific S1270 site. ACE 
phosphorylation at this specific site is implicated in the shedding levels of ACE (Kohlstedt et al., 
2004). Phosphorylation of ACE by CK2 may modulate enzyme shedding in vivo by increasing the 
stability of the membrane-anchored sACE (Kohlstedt et al., 2004). An assay to quantify ACE 
Ser1270 phosphorylation would thus provide an indicator of ACE signalling induction.  
Phosphorylation and dephosphorylation events are central to most intracellular pathways that 
distribute signals across the cell (Graves and Krebs, 1999). Approaches such as mass spectrometry 
provide a unique opportunity to investigate serine/threonine- and tyrosine-phosphorylation sites, 
especially in the absence of a readily available antibody to a specific phosphorylation site (Pawson 
and Scott, 2005). Mass spectrometry is a highly sensitive method for the detection and 
characterisation of protein phosphorylation (Mann et al., 2002)(McLachlin and Chait, 2001). It is 
increasingly used in the semi-quantitative measurement of protein/peptide phosphorylation, 
with reproducible results obtained even in label-free quantitative approaches (Piersma et al., 
2015)(Y.-T. Wang et al., 2010)(Soderblom et al., 2011).  
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The objective of this chapter is to investigate whether Ac-SDKP and the N domain-selective ACEi, 
RXP407, induce ACE phosphorylation and the downstream cellular signal transduction through 
the: 
1. determination of substrate/inhibitor induced phosphorylation of Ser1270 using a mass 
spectrometry approach. 
2. investigation of the association between ACE and pJNK following treatment with lisinopril, Ac-
SDKP, or RXP407 using immunoprecipitation and immunoblotting. 
3. analysis of JNK phosphorylation or ACE expression as a result of ACE signalling induction. 
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 Cell culture and treatment 
 Cell culture conditions 
CHO-K1 cells (American Type Culture Collection-ATCC®CCL-61) transfected with various human 
sACE constructs (WT-sACE and the C domain knock out, CKO) were reconstituted into 75 cm2 
flasks and grown in 10 ml of growth medium (50% Dulbecco’s Modified Eagle Medium (DMEM) 
(Sigma, USA), 50% HAMS-F12 (Sigma, USA), 20 mM HEPES buffer, pH 7.5, supplemented with 10% 
foetal calf serum (FCS) [heat-inactivated for 30 min at 56°C]). Cells were grown to 75% confluency, 
lifted using Trypsin-EDTA (Gibco®, USA) and seeded into 6-well plates. Prior to treatment (see 
3.3.2), cellular growth and division was synchronised through serum starvation for 18 hours in 2% 
FCS medium and 1 hour in Opti-MEM (Gibco®, USA)(Cooper, 2003). All flasks and plates were 
incubated at 37°C, 5% CO2 and 80% humidity.   
 Cell treatment with Ac-SDKP or ACEi 
Ac-SDKP or inhibitors were added to 85% confluent cells in 6-well plates. One ml of 100 nM 
inhibitor (lisinopril, RXP407) or 100 nM Ac-SDKP in Opti-MEM was added to the cells and 
incubated for 5 mins to 24 h. Plain Opti-MEM was used as a control in all experiments. The 
reaction was stopped by removing the inhibitor or substrate and adding 1 ml of ice-cold 1x 
phosphate buffered saline (PBS). Extensive washing with 1x PBS was performed to remove all 
traces of BSA. Cells were then lysed overnight at 4°C in 200 µl of RIPA lysis buffer for subsequent 
MS analysis, or in 100 μl of Triton buffer (0.05 M HEPES, 0.5 M NaCl, 1% triton X-100, 1 mM PMSF 
supplemented protease inhibitor cocktail (Set III, Calbiochem, USA)) and phosphatase inhibitor 
cocktail (PhosSTOP, Roche, Switzerland)) for immunoprecipitations and western blotting. Triton 
lysates were centrifuged at 10000 g at 4°C and the supernatants were retained. Supernatants 
were either used immediately or stored at -80°C for western blot analysis. For in-gel tryptic digest 
of proteins, samples were lysed overnight in 250 µl of Laemmli buffer and boiled for 15 minutes. 
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 Western blotting and immunoprecipitation 
 SDS-PAGE gel electrophoresis  
SDS-PAGE gels were carried out as per section 4.3.4.  
 Immunoprecipitation (IP) 
IP of ACE, JNK, and p-JNK was performed using specific monoclonal antibodies (Bonifacino et al., 
1999). The ACE 9B9 antibody was obtained from our collaborator, while the JNK and p-JNK 
antibodies were ordered from Cell Signalling Technology (USA) (Gordon et al., 2010). Briefly, 200 
µl of cell lysates were pre-cleared with 20 μl of 50% magnetic protein-G Dynabead slurry 
(Thermofischer, USA). Lysates were thereafter incubated at 4°C with gentle rotation overnight 
with a 1/100 antibody: sample ratio. Following antibody binding, 25 µl of Protein-G Dynabeads 
was added to the mixture and incubated at 4°C for 3 hours with gentle rotation. After binding, the 
supernatants were removed by precipitating the magnetic beads with a strong magnet and 
washing 3 times with 250 μl of lysis buffer. The elution of the antigen and antibody was performed 
by boiling the beads with 30 μl of Laemmli buffer for 5 minutes. The detection of 
immunoprecipitated p-JNK and co-immunoprecipitated ACE and pJNK was carried out by western 
blotting using ACE and JNK antibodies, respectively. 
 Western blotting  
Western blots were performed according to section 4.3.5. The 4G6 monoclonal antibody (a gift 
from our collaborator) was used for the detection of ACE (Balyasnikova et al., 2005). Antibodies 
for GAPDH, pJNK, and JNK were obtained from Cell Signalling Technology. Densitometry analysis 
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 Mass spectrometric detection of phosphorylated ACE at S1270 
 FASP 
FASP of cell lysates for discovery and targeted MS analysis was performed as per section 3.3.3.3 
using 200 μg of sACE-CHO cell lysate.  
 In-gel protein digestion and mass spectrometry analysis 
An in-gel digestion method was adapted from Shevchenko et al. for the tryptic digest of sACE-
CHO cell lysate (Shevchenko et al., 1996). Following 1-D reducing SDS-PAGE, proteins were 
visualised and fixed by staining with Coomassie staining solution (0.25% Coomassie brilliant blue, 
50% methanol, 10% acetic acid) and destained overnight (25% ethanol, 10% acetic acid). Bands of 
interest (size range of ≈ 150-250 kD) were excised and diced into 1 mm2 pieces, then destained 
with 200 mM ammonium bicarbonate (NH4CO3)/acetonitrile (ACN) (50:50) and vortexed until 
transparent. Samples were dehydrated with 100% ACN and dried in a Savant SpeedyVac 
(ThermoScientific, USA). Reduction and alkylation of cysteine residues was performed by 
incubating with 200 µl of 10 mM dithiothreitol (DTT) in 25 mM NH4HCO3 at 56°C for 1 hour, 
followed by incubating with 200 µl of 55 mM iodoacetamide (Sigma, USA) in 25 mM NH4HCO3 in 
the dark for 45 minutes at room temperature. Tryptic digest was performed by rehydrating the 
gel pieces in trypsin solution at a trypsin to protein ratio of 1:50 (New England Biolabs, USA). The 
gel pieces were covered in 25 mM NH4HCO3 and samples were incubated overnight in a wet 
chamber to allow diffusion of the trypsin into the gel pieces. 
 Sample desalting 
Desalting of tryptic peptides was performed according to 3.3.5. 
 Phosphopeptide enrichment by Fe-IMAC 
To perform phospho-enrichment, desalted tryptic peptides were reconstituted in 0.5 ml of Fe-
IMAC solvent A (30% ACN, 0.07% (v/v) TFA) and injected on a 4 mM iron (Fe)-IMAC column 
(Thermo Fisher Scientific, USA) coupled with an Agilent 1260 Infinity HPLC system (Agilent, USA). 
The column was charged with iron according to the manufacturer's instructions and prepared as 
described by Ruprecht et al (Ruprecht et al., 2017).  Briefly, the column was rinsed with 20 mM 
FA, charged with 25 mM FeCl3 in 100 mM acetic acid and washed extensively with 20 mM FA to 
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remove unbound iron ions. The sample was loaded onto the column at a rate of 0.1 ml/min for 5 
minutes and eluted with a non-linear 0% to 50% Fe-IMAC in solvent B (0.5% (v/v) NH4OH). The 
flow-through and phospho-enriched fractions were collected with the guidance of the UV signal 
(280 nm) and dried in a vacuum centrifuge prior to a second round of desalting as described in 
3.3.5.  
 Mass spectrometry 
Both discovery and targeted MS analysis was carried out on the Q-Exactive™ Hybrid Quadrupole-
Orbitrap Mass Spectrometer coupled to a Dionex UltiMate 3500 RSLC nano-LC system according 
to 3.3.4. For targeted MS, elution was carried out using a 140-minute linear gradient of 
acetonitrile/0.1% formic acid at a constant flow rate of 300 nl/min. The Q-Exactive was operated 
using the PRM method, with an isolation window of 4.0 m/z and an isolation list that was 
developed using Skyline (MacLean et al., 2010) to specifically target the cytoplasmic tail of ACE, 
detecting the doubly phosphorylated serine peptide (HSHGPQFGSEVELR (870.35 m/z) and singly 
phosphorylated peptides (HSHGPQFGSEVELR, HSHGPQFGSEVELR (830.36 m/z)), as well as the 
non-phosphorylated cytoplasmic tail peptide (HSHGPQFGSEVELR, (790.38 m/z)). Fragmentation 
of these selected peptides was performed by via high-energy collision dissociation with a 
normalized collision energy (NCE) of 27. The abundance threshold for targeted ion selection was 
1.7 x 104 and a charge exclusion of z=1 and z>4 ions was selected. Chromatograms of both parent 
and fragment ion transitions were subsequently analysed in Skyline. For discovery MS analysis, 
raw data was analysed in MaxQuant as described in section 3.3.5.  
 Statistical analysis 
Data analysis was performed using the statistical software GraphPad PRISM 6.0 (GraphPad 
software Inc, USA). Un-paired, nonparametric Student’s t-tests were employed for the 
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 ACE S1270 phosphorylation by lisinopril 
 Mass spectrometric detection of S1270 phosphorylation 
A direct quantification of the induction of the ACE signal cascade requires the quantification of 
phosphorylation levels at the implicated serine residue. We attempted to optimise the 
quantification of various modified variants of the cytoplasmic tail peptide during several MS 
experiments. CHO cells expressing s-ACE and incubated for 7minutes with lisinopril were used for the 
MS detection of phospho-Ser1270. Two sample preparation methods were used: FASP and in-gel 
tryptic digest. A targeted method was developed for targeting the phosphorylated cytoplasmic tail of 
ACE for detection of the doubly phosphorylated serine peptide (HSHGPQFGSEVELR (870.35 m/z) and 
singly phosphorylated peptides (HSHGPQFGSEVELR, HSHGPQFGSEVELR (830.36 m/z)), as well as the 
non-phosphorylated cytoplasmic tail peptide (HSHGPQFGSEVELR, (790.38 m/z)).  
Neither the unphosphorylated nor the phosphorylated versions of the cytoplasmic tail peptide of 
interest could be detected in discovery MS (data not shown). However, targeted MS is capable of 
extremely sensitive detection of target peptides and it does not rely on the chance inclusion of the 
target peptide in a top N method. Targeted MS is an effective tool for measuring low-abundance or 
otherwise elusive peptides in a complex mixture.  
 In targeted MS analysis of samples prepared by FASP and in-gel tryptic digests, a very low signal for 
the phosphorylated peptides was detected. A representative chromatogram is depicted in Figure 5-1.  
The unphosphorylated peptide of interest was identified across all the samples with both sample 
preparation methods.  However, due to the low intensity and lack of multiple co-eluting fragment ions 
for the modified peptide, no confident quantification of the phospho Ser1270 peptide could be 














Figure 5-1: Mass spectra chromatograms from 7-minute lisinopril treatment of sACE-expressing cells 
A. Skyline-generated representative extracted ion chromatograms of the unmodified and modified 
HSHGPQFGSEVELR peptide. B. Skyline chromatograms of the +2, +3 and +4 charged phosphorylated 
HSHGPQFGSEVELR peptide at Ser1270. Only the +4 peptide was detected above background levels. 
 
  
 Phosphopeptide enrichment for phospho S1270 detection 
Due to the substoichiometric nature of phosphorylation events (Steen et al., 2006), enrichment 
of phosphorylated peptides was performed on an Fe-IMAC column to improve the detection of 
the phosphopeptides of interest. A definite peak at 8.3 minutes was observed corresponding to 
phosphorylated peptides that had bound to the positively charged Fe+ ions of the column (Figure 
5-2). Unphosphorylated peptides eluted after 1 minute with the solvent. Both the 









Figure 5-2: Representative chromatogram of Fe-IMAC phospho peptide enrichment.  
HPLC chromatograms of the large unphosphorylated peptide peak co-eluting with the buffer at 1 
minute, and the small phosphorylated peptide peak eluting at 8.3 minutes. 
 
 Targeted MS of phospho-peptide pool 
Following peptide enrichment, both the phosphorylated and unphosphorylated fractions were 
analysed in a targeted PRM-MS experiment. The chromatograms of the different ion transitions 
were analysed in skyline and the corresponding peak area data was analysed (Figure 5-3). 
The doubly phosphorylated peptide was not detected but both the singly phosphorylated 
peptides at both serine sites were detected. The detection of the b9 ions for the 
HSHGPQFGSEVELR peptide of interest allowed for the distinction between the singly 
phosphorylated peptides. However, while a number of co-eluting fragment ions were identified 
for the unmodified peptide, this was not the case for the phosphorylated peptide. The 
predominant ion was the b2 ion for the Ser1270 phospho site, and so while the Ser1270 
phosphopeptide could be identified, accurate quantification could not be performed.  
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Figure 5-3: Extracted ion chromatograms and peak area proportions following 7-minute treatment of sACE- 
expressing cells with control (U) and lisinopril (L). 
A) Representative extracted ion chromatogram of the unmodified HSHGPQFGSEVELR peptide with the 
observed fragment ions in each of the replicates of the treated and untreated cell lysates. B) Representative 
chromatogram depicting fragment ion profile of the Ser1270 phosphorylated HSHGPQFGSEVELR peptide, 
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 Association between ACE and pJNK upon ACEi and Ac-SDKP treatment 
An association between ACE and pJNK occurs upon the activation of the ACE signalling cascade. 
To assess whether ACEi or Ac-SDKP induce sACE and pJNK association, co-immunoprecipitations 
were performed using specific antibodies, and signal-induced associations were detected by 
western blotting against sACE and pJNK. The cell lysates were normalised to the samples with the 
lowest total protein concentration prior to immunoprecipitation. Associations between pJNK and 
ACE were visualised by the detection of ACE in the JNK antibody immuno-precipitate, and the 
corresponding detection of pJNK in the ACE antibody (9B9) precipitate (Figure 5-4). Importantly, 
9B9 resulted in the immunoprecipitation of pJNK in the CHO-sACE lysate treated with ACEi and 
Ac-SDKP, but not in the control, indicating a lack of association in the absence of 
inhibitor/substrate binding to ACE. 
 
 
Figure 5-4: Co-immunoprecipitation of sACE and pJNK after treatment with lisinopril, 
RXP407 and Ac-SDKP. 
Western blot of the immunoprecipitation of sACE and pJNK in CHO-sACE cell lysis after a 7-
minute treatment with lisinopril. Bands corresponding to the correct size of sACE (≈170 kDa) 
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 Immuno-quantitation of pJNK induction by ACEi and Ac-SDKP 
 Dose response of pJNK to Ac-SDKP 
A range of Ac-SDKP concentrations were used to determine the optimal concentration of Ac-SDKP 
that induces pJNK phosphorylation in sACE-CHO cells. Samples were immunoprecipitated using 
an antibody specific to JNK and western blotting was used to probe for total JNK and induced pJNK 
levels. A 100 nM concentration of Ac-SDKP resulted in the maximum pJNK/tJNK induction and was 
therefore used in subsequent experiments (Figure 5-5). 
 
 
Figure 5-5: The dose-response of pJNK induction upon Ac-SDKP treatment. 
Densitometry of immunoprecipitation after treatment with various concentrations of Ac-SDKP 
for 7 min, probed with a JNK-specific antibody. Western blotting was performed using both pJNK 
and JNK antibodies and the ratios of the pJNK densitometry to tJNK was calculated as a 
percentage of the control. Data is the average ±SEM of two experiments in duplicate and 
significance is indicated by an asterisk (*) (p < 0.05). 
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 Immuno-quantitation of pJNK association with ACE 
IPs were performed with the specific monoclonal antibody 9B9 on CHO-sACE cells to determine 
whether lisinopril and Ac-SDKP induce an increase in the association between sACE and pJNK on 
the intracellular side of the membrane. Treatment with lisinopril as well as Ac-SDKP resulted in 
significant pJNK association with ACE, suggesting that activation of the JNK pathway is initiated 
upon binding of both the substrate and inhibitor (Figure 5-6). Notably, RXP407 treatment resulted 
in a significantly lower increase in pJNK association with ACE than lisinopril or Ac-SDKP.  
 
 
Figure 5-6: Increased co-immunoprecipitation of pJNK with sACE on treatment with 
ACEi and Ac-SDKP.  
sACE and associated pJNK was co-immunoprecipitated from CHO-sACE lysates with the 
ACE 9B9 antibody following treatment with 200 nM lisinopril, RXP407, or 100 nM Ac-
SDKP for 7 minutes. A) Representative western blot for sACE and pJNK B) Densitometry 
analysis of pJNK/ACE ratios over untreated samples. Data represents average ±SEM of 
two experiments, each in duplicate. Significance is indicated by * p < 0.05; ** p < 0.01. 
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 Immuno-quantitation of cytosolic pJNK levels  
To confirm that the observed pJNK levels associated with ACE translated into increased JNK 
pathway activation, the cytosolic ratio of pJNK/JNK was investigated. A JNK antibody was used for 
the IP and the levels of pJNK and JNK were measured by western blotting and densitometry 
(Figure 5-7).  
Both ACEi and Ac-SDKP induced an increase in the p-JNK/JNK ratio, indicative of activation of the 
JNK signalling cascade upon binding of substrate and inhibitor. The pattern of increased activation 
by lisinopril as compared to RXP407 was observed as in 5.4.3.2. 
 
Figure 5-7: Increased co-immunoprecipitation of pJNK with JNK on treatment with 
ACEi and Ac-SDKP. 
Densitometry of JNK and pJNK levels from CHO-sACE lysates following treatment with 
200 nM lisinopril/RXP407 or 100 nM Ac-SDKP for 7 minutes and measured by western 
blotting. Data is representative of mean ±SEM of two experimental experiments 
blotted n=2 each. Significance is indicated by * (p < 0.05). 
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 Effect of Ac-SDKP and inhibitors on ACE expression levels in sACE-CHO cells 
The downstream effect of ACE signaling pathway activation is an increase in ACE expression after 
12-24 hours of treatment (Kohlstedt et al., 2005)(X. Sun et al., 2010). The effects of ACEi and Ac-
SDKP were investigated in sACE-expressing cells at various time points (8 hours, 12 hours, and 24 
hours) following treatment. In the present study, the levels of ACE expression induced by 
inhibitors and Ac-SDKP were not significantly different than those of the untreated controls at the 
different incubation times, except for lisinopril treatment at 8 hours that showed increased ACE 
expression (Figure 5-8).  
 
Figure 5-8: sACE expression post lisinopril, Ac-SDKP, or RXP407 treatment.  
sACE-CHO cells were treated with 100 nM lisinopril, RXP407 or Ac-SDKP for 8-24 hours prior to lysis. 
Representative western blots of sACE and GAPDH after A) 8H B) 12H and C)24H treatments are depicted. 
Densitometry of sACE/GAPDH ratio bands as a percentage of vehicle treated samples for D) 8H, E) 12H, and 
F) 24H lysates are shown. Data represents the mean ±SEM of 3 experiments and significance is denoted by 
an asterisk (*) for p < 0.05. 
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 Effect of Ac-SDKP and inhibitors on ACE expression in CHO cells expressing sACE 
with inactivated C domain 
Ac-SDKP (at a 10 μM concentration) increased the expression of ACE after 24 h in N or C domain 
knock-out mutants of murine ACE (X. Sun et al., 2010). To investigate whether Ac-SDKP can induce 
ACE expression in a knock-out mutant of sACE, a CKO-CHO (transfected by Dr Kate Larmuth) cell 
line was used, where the zinc coordinating amino acid residues were mutated in the C domain to 
obtain a C domain catalytical knock-out. We investigated and quantified the effect of a range of 
concentrations of Ac-SDKP on ACE expression in CKO-CHO cells by western blotting and 
densitometry (Figure 5-9). GAPDH was used to control for differences in protein loading levels.  A 
slight but not significant increase in ACE expression was observed at 24 h when 1 and 10 μM Ac-
SDKP were added.  
 
Figure 5-9: sACE levels induced by Ac-SDKP treatment in CKO-CHO cells.  
CKO-CHO cells were treated with 100 nM-10 μM Ac-SDKP for 24 hours prior to lysis. A) 
Representative western blot of sACE and GAPDH after 24 h treatment. B) Densitometry of sACE 
bands as a percentage of vehicle treated samples. Data represents the mean ±SEM of 3 experiments. 
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The ACE signalling pathway, activated by the phosphorylation of Ser1270 on the cytoplasmic 
portion of the membrane-bound protein, can be triggered both by inhibitor and substrate 
binding to ACE (Sun et al., 2010).  We investigated for the first time whether Ac-SDKP and the 
N domain-selective ACEi RXP407 trigger the ACE signalling pathway via human sACE.  The first 
major finding from this chapter was that Ac-SDKP as well as RXP407 could induce signalling via 
binding to ACE, thus identifying a potential novel mechanism of action for the antifibrotic Ac-
SDKP.  A limitation of this study was that a quantification of the phosphorylation level could 
not be obtained.  The second important finding was that Ac-SDKP and ACEi did not result in an 
increase in ACE expression.  This is in line with their well-documented anti-inflammatory and 
antifibrotic effects as ACE expression leads to the formation of the pro-inflammatory AngII. 
The first step of the ACE signalling pathway involves the dimerization and CK-2-mediated 
phosphorylation of Ser1270 (Kohlstedt et al., 2006). This phosphorylation event has been 
linked to the shedding of ACE, with an accumulation of soluble ACE observed in the 
supernatant of human umbilical vein endothelial cells (HUVECs) transfected with non-
phosphorylated forms of ACE (Ser1270 mutated to Ala1270) (Kohlstedt et al., 2002). This was 
indirectly confirmed by Barauna et al., who demonstrated that ACE can act as a mechano-
sensor, able to sense shear stress, and is capable of regulating its own levels through a 
reduction in Ser1270 phosphorylation, JNK activation, and ACE expression levels (Moskowitz, 
2002)(Barauna et al., 2011). In an attempt to quantify the degree of phosphorylation of 
Ser1270, and thus the ACE signalling response upon treatment with Ac-SDKP and RXP407, we 
performed MS analysis of cell lysates of untreated and treated sACE-CHO cells. The initial 
discovery MS analysis failed to detect both the modified and unmodified variants of the 
peptide of interest. This was not surprising as discovery MS analysis does not necessarily 
provide full coverage of the protein sequence. Instead, the abundance of the protein in 
question as well as the ability of each specific peptide to ‘fly’ in the MS, as well as the 
complexities of the background matrix all affect the visibility of a particular peptide in discovery 
MS. As a result, regions/peptides of interest are routinely missing in discovery MS experiments 
(McLachlin and Chait, 2001). A targeted approach was thus adopted to localize and quantify 
the Ser1270 phosphorylation in an unenriched sample. Whilst this approach allowed the 
detection of the unmodified peptide, its phosphorylated counterpart could not be detected. 
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This is likely due to the sub-stoichiometric nature of phosphorylation modifications - since the 
phosphopeptide is present at far lower concentrations than the unphosphorylated one, its 
detection presents a challenge (Wu et al., 2011). The phospho-proteome represents 
approximately 1% of the total proteome.  Further, negatively charged modifications including 
phosphorylation can interfere with proteolytic digestion by trypsin, further affecting the 
visibility of phosphopeptides (Benore-Parsons et al., 1989).   
To circumvent these challenges in phosphopeptide detection, two fractionation strategies 
were used to reduce the complexity of the sample. Optimisation of the phosphopeptide 
detection was performed on the Q-Exactive using lisinopril as a positive control. An in-gel 
digestion strategy, whereby a gel piece in the molecular weight region corresponding to the 
size of sACE, was excised and digested. The unmodified peptide was detected with several co-
eluting fragment ions and a good signal: noise ratio, but the pSer1270 HSHGPQFGSEVELR 
variant had poor signal. Gel-based tryptic digests may result in incomplete digestion of proteins 
embedded in the polyacrylamide gel matrix, as well as during the extraction of digested 
peptides from the matrix (Gundry et al., 2009). An Fe-IMAC HPLC column was subsequently 
used for the enrichment of phosphopeptides. The strength of this technique lies in the linear 
efficiency of the enriched product with the quantity of starting material, and the negligible 
levels of incomplete phosphopeptide binding or elution from the column (Ruprecht et al., 
2017). This strategy allowed for the detection of the phosphorylated Ser1270 peptide. While 
the detection of the b9 ion for the HSHGPQFGSEVELR peptide confirmed the presence of the 
phosphorylated site of interest, the majority fragment ion observed was the b2 ion, which does 
not discriminate between the two potential serine phosphorylated sites on the peptide. The 
fragment ions co-eluting with b2 for the phosphopeptide had low intensity, so that accurate 
quantification of the phospho-Ser1270 levels in comparison to the unmodified peptide could 
not be performed. The detection of predominantly triply and quadruply charged precursors 
may point to the cause of the low abundance of this peptide despite enrichment strategies. 
Tryptic peptides often acquire higher charged states following ESI, and this is emphasised with 
phosphopeptides. If the precursor was multiply charged (>4+), the resulting fragment ions may 
have been multiply charged (>2+) and these may have been excluded during discovery MS. 
Another limitation of the approach used is the cell construct used for the inhibitor treatment. 
The sACE-CHO cells over-expresses sACE, so the ratio of phosphorylated to unphosphorylated 
sACE is unknown, as is the maximal phosphorylation level of this peptide.  
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We also investigated the effect of the N domain-selective RXP407 compared to that of lisinopril 
on ACE signalling. While the effects of ramipril, captopril, and enalapril on the ACE signalling 
pathway have been investigated, our group has been the first to test the effects of lisinopril 
and a domain-selective inhibitor on ACE signalling (Tournier et al., 1997)(Kohlstedt et al., 
2005)(Reis et al., 2018)(Sun et al., 2010). Both lisinopril and RXP407 lead to the activation of 
the ACE signalling cascade. Interestingly, lisinopril induced a small but significant increase in 
ACE expression at a single 8 h time point, while RXP407 did not cause any upregulation of ACE 
expression. Although ramipril induces ACE signalling, captopril failed to induce ACE expression. 
It is thus entirely plausible that lisinopril and RXP407 have minimal effects on ACE expression 
through their binding to ACE on the cell surface membrane.  This could also be due to the 
absence of the native promoter for ACE; therefore in vivo confirmation of these results are 
warranted. 
Ac-SDKP is well established in its role as an antifibrotic agent, and as an inhibitor of TGF-β/Smad 
signalling (Peng et al., 2001)(Cavasin et al., 2007). This effect was confirmed in our experiments 
on a fibroblast cell line (Chapter 4). Non-canonical TGF-β signalling can activate non-Smad 
pathways, including the JNK and MAPK pathways, leading to stress fibre formation as well as 
epithelial-to-mesenchymal differentiation (Derynck et al., 1998). Ac-SDKP inhibits both MAPK 
and JNK phosphorylation, decreasing collagen and extracellular matrix deposition (Rhaleb et 
al., 2001)(Peng et al., 2012)(Zhang et al., 2011). Conversely, Ac-SDKP induced JNK 
phosphorylation in the ACE signalling pathway in murine sACE (Sun et al., 2010). We therefore 
conducted experiments to determine whether Ac-SDKP activated JNK when bound to human 
sACE. In the present study, Ac-SDKP also activated ACE outside-in signalling, as evidenced by 
an increased association of pJNK with ACE compared to that of the control, suggesting that the 
ACE signalling pathway is activated upon Ac-SDKP binding to ACE. This resulted in an increase 
in circulating pJNK levels in sACE-CHO cells. However, no concomitant increase in ACE 
expression was detected in either the sACE-CHO or the CKO-CHO cell line. This contrasts with 
Sun., et al who observed increased mACE expression in C domain knock out mutants of murine 
ACE, despite the absence of the native ACE promoter. This again highlights the species-specific 
nature of the ACE signalling pathway, which has broader implications for models based on 
murine cells. 
While initial experiments of the ACE signalling pathway suggested a pro-inflammatory 
response profile, captopril treatment lead to a reduction in cyclooxygenase 2, IL-1β, and 
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arrestin-2 expression levels, which supports a protective role for the ACE pathway in 
inflammation and fibrosis (Reis et al., 2018). Ac-SDKP inhibits IL-1β-mediated increases in MMP 
activity and expression in cardiac fibroblasts, leading to an increase in TIMP-1 and TIMP-2 
expression (Rhaleb et al., 2013).  
The RAAS is inextricably linked to inflammation, and Ac-SDKP may therefore exert beneficial 
effects through the inhibition of IL-1β levels. The observed activation of ACE signalling by Ac-
SDKP could lead to a decrease in the expression of inflammatory mediators.  While the 
potential anti-inflammatory effects mediated by the ACE signalling pathway through Ac-SDKP 
and ACEi are likely to be environment- and cell- specific, the proposed mechanism of this 




Figure 5-10: Potential targets of Ac-SDKP-mediated ACE signalling cascade. 
Ac-SDKP has been shown in our study through binding to sACE to induce JNK signalling 
and in previous studies to cause ERK phosphorylation through binding to ACE.  This is 
proposed to lead to a decrease in inflammatory and fibrotic mediators such as COX-2 
and IL-1. MKK7: Map kinase kinase 7, CK2: Casein Kinase 2, AP1: Apoprotein 1, COX-2: 
Cyclooxygenase 2, IL-1: Interleukin 1.




The incidence of constrictive pericarditis, a fibrotic complication of tuberculous pericarditis, 
has highlighted the need for studies into the pathological mechanisms of fibrosis in the 
pericardial environment (Naicker and Ntsekhe, 2020).  The overarching aim of this thesis is to 
study and gain further insight into the molecular mechanisms and mediators involved in the 
development of fibrosis, particularly in TB pericarditis. In Chapter 2, the roles played by Ac-
SDKP, ACE, POP and Gal-3 in the pathophysiology of constrictive TB pericarditis were 
investigated.  The levels of Ac-SDKP and Gal-3 in TB+ and TB- pericardial fluid were quantified. 
Notably, Ac-SDKP levels were decreased in TB+ pericardial fluid; however, there was no 
significant change in the levels of profibrotic Gal-3.  The physiological importance of Ac-SDKP 
has been highlighted in the disseminated organ fibrosis occurring as a result of POP inhibitor 
administration (Carretero, 2005).  This points to a potent effect of the tetrapeptide in its 
immediate environment and hence, its absence constitutes a highly plausible factor for 
pericardial fibrosis progression. Importantly, we investigated the Ac-SDKP metabolism through 
the quantification of the enzymatic activities of i) its rate limiting synthesising enzyme POP, 
and ii) its predominant degrading enzyme ACE.  This uncovered a potential mechanism for 
reduced Ac-SDKP levels in TB pericardial fluid.  An increase in ACE activity, arising from an 
immune/inflammatory response to the presence of M.tb in the pericardium, results in 
increased cleavage of Ac-SDKP.  The rate limiting enzyme involved in Ac-SDKP formation, 
notably POP, was also present in pericardial fluid suggesting the local production of Ac-SDKP. 
The precise molecular effects of Ac-SDKP is unknown and in Chapter 3 MS-based discovery 
proteomics was used to interrogate intracellular and extracellular proteins that are regulated 
by the tetrapeptide.  We observed that Ac-SDKP was capable of inducing a range of cellular 
and extracellular dysregulations.  In the secretome, Ac-SDKP inhibited the expression of various 
ECM constituents including both collagens and non-collagenous proteins.  This study is the first 
to demonstrate the inhibitory action of Ac-SDKP on collagen VI, lumican and decorin.  
Additionally, fibrogenic players, modulated by Ac-SDKP in the intracellular space including 
SPARC, serpine-1 and fibroblast growth factor-2, were identified.  Ac-SDKP is likely to induce 
its effects by binding to the FGFR-1 receptor as suggested in previous studies (Li et al., 2017)(Hu 
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et al., 2018).  Further novel mechanisms of action for Ac-SDKP, including the PINCH-ILK-PARVIN 
complex mediated focal adhesion and Notch signalling, were identified.   
Fibrosis is increasingly recognised as a significant contributor to morbidity and mortality across 
a myriad of disease aetiologies.  However, treatment strategies which specifically target 
the pathological processes occurring in fibrosis, are scarce.  In Chapter 4, the antifibrotic 
potential of Ac-SDKP analogues and ACEi was assessed.  In WI-38 human fibroblasts, Ac-SDKP 
significantly inhibited TGF-β expression, Smad phosphorylation and a downstream reduction 
in collagen levels.  Previous studies revealed that SDK is the minimum requirement for the anti-
proliferative effects of Ac-SDKP (Robinson et al., 1993). Thus the effect of peptides SDK, DKP, 
Ac-SDK, and Ac-DKP on fibrosis prevention were tested.  Only the Ac-DKP fragment moderately 
inhibited TGF-β expression and could be slowly cleaved by ACE.   We also demonstrated that 
the Ac-SDψKP peptide could inhibit TGF-β/ Smad 3 signalling and collagen deposition.  In 
addition, the Ac-SDKP physiological peptide, but not Ac-SDψKP in combination with ACEi, 
demonstrated a greater inhibition of hydroxyproline as compared to Ac-SDKP alone.   
In Chapter 5, we investigated the effects of Ac-SDKP, lisinopril and RXP407 on the ACE-
signalling cascade.  Ac-SDKP and ACE inhibitors are known to induce anti-inflammatory and 
antifibrotic effects.  However, earlier reports of ACE-signalling pointed to a pro-inflammatory 
profile of ACE-cascade signalling with a downstream increase in AP1 mediated COX-2 and ACE 
expression (Kohlstedt et al., 2005).  Interestingly, Ac-SDKP is known to inhibit the JNK pathway 
leading to a reduction in differentiation, proliferation, inflammation and apoptosis (Zhang et 
al., 2011).  It was thus of interest to determine whether Ac-SDKP and the ACE inhibitors could 
potentiate JNK activation in a different pathway to induce the expression of ACE.  Ac-SDKP and 
RXP407 induced JNK phosphorylation but not ACE expression, a finding in support of their anti-
inflammatory and antifibrotic profiles. 
The treatment of fibrotic conditions, including fibrosing pericarditis, remains a major challenge.  
This study has added to the understanding of the antifibrotic action of Ac-SDKP and has 
confirmed its altered metabolism in the TB pericardium.  These findings provide rationale for 
the investigation of ACEi therapeutics, specifically N domain ACEi as well as Ac-SDKP analogues, 
in fibrosing conditions.  This study also paves the way for in vivo studies investigating the 
efficacy of ACEi in TB pericarditis. 
 
  
135 | Chapter 6: Conclusions, limitations and future directions 
 
 
Considering the evidence that Ac-SDKP may play a central role in prevention or reduction in 
pericardial fibrosis we hypothesized that low levels of Ac-SDKP in patients with TB pericarditis 
would contribute to the pathophysiology of pericardial fibrosis. Although a disrupted Ac-SDKP 
metabolism was demonstrated in our study, a major limitation was that these levels have not 
been directly correlated with phenotypic evidence of pericardial fibrosis.  Cardiac magnetic 
resonance (CMR) imaging, the gold standard for the non-invasive diagnosis of constriction, 
could be employed for the visualisation of pericardial thickening as it allows for high-resolution 
imaging though its multiple modalities (Srichai, 2011)(Ariyarajah et al., 2009).  This was piloted 
in our study on a small subset of patients (12 patients) by performing CMR analysis at 6- or 12-
months post pericardiocentesis (see Appendix 1).  High mortality rates associated with HIV and 
TB pericarditis co-infection prevented CMR analysis 12 months post pericardiocentesis in many 
patients which lead to a much smaller than intended sample size of patients who were followed 
up. Thus, the study was amended to allow for follow up at 6 months.  This inherently induces 
a bias as it is possible that patients who passed away prior to a 12 month follow up may have 
had the most advanced form of the disease and presented with the more pronounced fibrosis.  
This potentially explains why only one patient in our study population had a pericardium of 
greater than 4 mm thickness on CMR (4.5mm).  Thus, future studies should allow for multiple 
and long term CMR imaging events to visualise the onset and progression of pericardial 
abnormalities and correlate these findings to Ac-SDKP and ACE levels. 
In order to further map out the effects of Ac-SDKP on fibroblasts, a discovery mass 
spectrometric approach was used.  A major limitation in our secretomic analysis is the presence 
serum proteins in the sample used.  Hence, the 355 differentially expressed proteins observed 
are likely to represent only a portion of the proteins regulated by Ac-SDKP.  Thus, low 
abundance proteins or proteins displaying a very small fold change are likely to have been 
missed on our study.  In the future, the depletion of serum proteins or the study of exosomal 
vesicle proteins may provide further insight into the secretome modulation by Ac-SDKP.   
Finally, the quantification of the initial signalling response induced through the binding of Ac-
SDKP and the ACEi to ACE could be improved in future studies.  Targeted MS was used to 
identify the unphosphorylated and phosphorylated peptide bearing the Ser1270 residue 
whereby the cascade is initiated.  Although the phosphorylated peptide of interest was 
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detected, it was not in sufficiently high abundance to distinguish between a different Ser 
phosphorylation site on the peptide.  Thus, the degree to which the ACE signalling cascade is 
induced could not be quantified.  The synthesis of a labelled unmodified and modified 
HSHGPQFGSEVELR peptide could aid in the detection of its physiological counterpart.  This 
would overcome the low abundance issue of the pSer1270 peptide as well as aid in the 
distinction between the two phosphorylation sites.  This would also be the first step in mapping 
the entire ACE signalling pathway activated by Ac-SDKP and ACEi in order to fully understand 
its physiological importance. 
 
The need for novel and better biomarkers to improve diagnosis and therapy as well as to 
monitor responses to therapy across a large spectrum of pathologies has been increasingly 
recognised (Rifai et al., 2006)(Williams et al., 2012)(Butler, 2008).  The identification of a 
predictive biomarker for high risk TB pericarditis patients for constriction would aid in the pre-
emptive management of the complication, thus potentially reducing the need for 
pericardiectomies.  This study has identified Ac-SDP and ACE dysregulation in the TB pericardial 
environment. Future work to correlate the decreased Ac-SDKP levels with the occurrence of 
pathophysiological fibrotic changes in the pericardium is warranted.  Interestingly, our 
observation of heightened ACE activity has raised questions as to whether ACEi can be 
implemented in the management of TB pericarditis to prevent the development of fibrosing 
pericarditis.  Whilst a mouse model of TB pericarditis is currently not available, future studies 
can investigate whether ACEi can penetrate the pericardium and whether they affect local 
AngII and Ac-SDKP levels in patients undergoing open heart surgery who are on ACEi therapy. 
The antifibrotic effects of Ac-SDKP have been demonstrated in a wide range of studies.  
However, the precise molecular machinery triggered by Ac-SDKP binding to fibroblast cells is 
unknown.  We identified of a myriad of proteins and signalling pathways modulated by Ac-
SDKP including matrisomal proteins and inflammatory and fibrotic glycoproteins. Future 
studies to validate these mechanisms are warranted.  Moreover, phospho-proteomic studies 
can shed further light on signalling pathways activated or repressed in the antifibrotic action 
of Ac-SDKP.   
Lastly, ACEi and Ac-SDKP analogues have been identified as non-redundant options in the 
therapeutic management of fibrotic conditions.  A mild antifibrotic action of Ac-SDKP for the 
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Ac-DKP peptide has been identified in this study.  In the future, the antifibrotic effect and anti-
proliferative effects of a synthesised Ac-ADKP peptide for instance could be investigated to 
determine whether the stability of the Ac-DKP fragment can be improved whilst maintaining 
its specificity of action.  Further, the Ac-SDψKP analogue displayed a similar in vitro antifibrotic 
effect as Ac-SDKP.  Future in vivo work needs to be performed as a different picture may 
emerge in more complex environments where the half-life of the Ac-SDψKP analogue is likely 
to be much longer than that of the physiological peptide, hence potentiating its protective 
effects.  Finally, future studies are warranted on the combination of the Ac-SDψKP analogue 
with the N domain-selective RXP407 in an in vivo model of fibrosis. 
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Appendix 1: CMR analysis 
Our study design involving TB pericarditis patients thus included a clinical follow up of patients 
with the aim of correlating molecular findings with imaging findings consistent with pericardial 
inflammation or fibrosis.  Follow up of enrolled patients with known/suspected TB pericarditis 
was done between January 2014 and December 2018 at Groote Schuur Hospital, Observatory, 
Cape Town.  A CMR was performed at 6 to 12 months post pericardiocentesis.  A standard CMR 
protocol used at the Groote Schuur Hospital was employed for imaging the pericardium.  
Written, informed and voluntary consent was provided by all patients participating in the 
study.  CMR analysis, to extract relevant cardiac and pericardial measurement and to describe 
pericardial features, was performed by Stephen Jermy from Prof Ntobeko Ntusi’s group.  
Documented CMR parameters were thereafter analysed and features of pericardial 
inflammation and fibrosis were probed according to Table 3-1 (Petersen et al., 2017).   
Table 8-1: CMR features of constrictive pericarditis 
Feature Evidenced by 
Thickened Pericardium T1 and T2 weighted images and LGE 
images  
Atrial enlargement Right atrial (RA) and left atrial (LA) 
area 
Dilated Superior Vena Cava (SVC) SVC measurement 
Dilated Inferior Vena Cava (IVC) IVC measurement 
Presence of Effusion Absent or present 
Abnormal Pericardial presentation Late Gadolinium Enhancement 
images 
 
Features of fibrosis were investigated in 6-12 month follow ups CMRs, on a subset of TB+ 
patients.  It is unfortunate that a proportion of TB+ patients enrolled in the study were lost to 
follow up; either as a result of death or from loss to follow up.  These circumstances lead to 
the need for earlier (6 month) follow ups in a subset of patients. 
From 16 patients who were followed up with CMR, only one demonstrated pericardial 
thickening (beyond 4mm)(see Table 8-3).  Whilst a thickened pericardium is typically the 
hallmark of pericardial fibrosis, it is not always present in constriction (Napolitano et al., 2009).   
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Four patients had a pericardial effusion 6-12 months post pericardiocentesis.  Patient CMR6 
had a pronounced effusion ranging from 13-19 cm likely manifesting as ECP whereby the 
presence of the effusion results in constrictive disease in the absence of pericardial thickening.  
Finally, atrial enlargement was commonly observed in the patients.  It is possible that these 
represent early features of fibrosing pericarditis which would later be accompanied by more 
pronounced pericardial thickening.   
 
Table 8-3: CMR features of fibrosing pericarditis in follow up TB+ patients. 
Cells highlighted in red represent abnormal findings whereas cells highlighted in orange represent values 
























3.2 18 19 17 15 No 
CMR3 
3.5 27 26 18 14 No 
CMR4 
3.5 20 22 20 15 No 
CMR5 
4.5 25 17 19 18 No 
CMR6 
3 21 18 14 13 Yes 
CMR7 
2.9 16 28 16 16 No 
CMR8 
3 13 14 13 11 No 
CMR9 
2.8 21 20 18 12 No 
CMR10 
2.8 25 24 15 15 No 
CMR11 
2.8 27 32 19 19 Yes 
CMR12 
NA 13 13 17 12 No 
CMR13 
2.7 24 19 14 14 No 
CMR14 
3 22 24 15 13 No 
CMR15 
3.5 37 29 18 23 Yes 
CMR16 3.4 39 19 21 17 Yes 
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Appendix 2: Standard Curves 
Ac-SDKP Standard Curve 
An Ac-SDKP standard curve was generated to determine Ac-SDKP concentrations using the Ac-SDKP 




Galectin-3 Standard Curve 
A Gal-3 standard curve was generated to determine Gal-3 concentrations using the Gal-3 standards 
provided in the ELISA kit.  A linear regression was plotted according to manufacturer’s instructions. 
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HL Standard Curve  




AMC Standard Curve 
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Hydroxyproline Standard Curve 
A hydroxyproline standard curve was used to determine cellular hydroxyproline levels using 
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Appendix 3: Western Blotting 
SDS-PAGE resolving gels  
0.3 % SDS, 1.125 M Tris, pH 8.8 
 SDS-PAGE 3% stacking gels  
0.3 % SDS, 0.375 M Tris, pH 6.8 
Transfer Buffer 
20 mM Tris, 150 mM glycine, 20 % methanol 
Blocking buffer 
5% (w/v) skim milk, 0.1% (v/v) Tween-20, 0.2 M NaCl, 0.05 M Tris (pH7.4) 
TBS-T 
0.1% (v/v) Tween-20, 0.2 M NaCl, 0.05 M Tris (pH7.4) 
Laemmli Buffer 
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Appendix 4: MS Results 
Table 8-4: BiNGO Enriched molecular functions in the secretome 





















LMNA ANXA1 TPI1 
TPM4 ANXA2 HSPA5 
LUM ANXA5 FN1 
HSPG2 YWHAZ DCN 




PTX3 TLN1 PFN1 

























ANXA2 LUM COL6A2 














LMNA ANXA1 TPI1 
ANXA2 HSPA5 FN1 



















LMNA ANXA1 TPI1 
ANXA2 HSPA5 FN1 
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C1S LAMC1 LGALS1 
PRDX1 LMNA 
ANXA1 ANXA2 
HSPA5 FN1 HSPG2 




















HSPA5 FN1 HSPG2 
















HSPA5 FN1 LAMC1 















VCP LAMC1 CST3 
TUBA1B LMNA PTRF 
HSPA8 ANXA2 LUM 
ANXA5 FN1 ACTN4 




ANGPTL2 PTX3 TLN1 








2.06E-03 5/54 9.2% 36/5957 
0.6% 
CST3 FKBP1A ECM1 
HSPA5 ANGPTL2 










TPM4 C1S HSPA5 
ANXA5 FN1 PARK7 
ACTN4 YWHAZ DCN 

























C1S HSPA5 ANXA5 
PARK7 ACTN4 
YWHAZ DCN NME1 
COL1A1 LGALS1 
COL6A2 PRDX1 


















2.45E-02 2/54 3.7% 3/5957 
0.0% 
ANXA1 ANXA2 















2.83E-02 4/54 7.4% 40/5957 
0.6% 























2.83E-02 3/54 5.5% 18/5957 
0.3% 





2.83E-02 3/54 5.5% 18/5957 
0.3% 
ANXA1 FN1 DCN 
































3.06E-02 3/54 5.5% 19/5957 
0.3% 










FBN2 ANXA2 HSPA5 
FN1 LAMC1 HSPG2 
DCN DKK3 FKBP1A 
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COL1A1 COL1A2 
PTX3 PFN1 VCL 













4.71E-02 3/54 5.5% 23/5957 
0.3% 
COL1A1 C1S NME1 




4.71E-02 4/54 7.4% 52/5957 
0.8% 
LAMC1 TLN1 VCL 
PLEC 








VCP HSP90AB1 C1S 
PARK7 ENO1 CST3 
EFEMP2 LGALS1 
PRDX1 HSPA8 
ANXA1 TPM4 HSPA5 
ANXA5 FN1 ACTN4 
YWHAZ DCN NME1 
COL1A1 COL6A2 
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Table 8-5: BiNGO Enriched biological processes in the secretome 




















FBN2 ANXA1 TPM4 LUM RPL12 
FN1 LAMC1 COL1A1 TUBA1B 
EFEMP2 TUBB2A COL1A2 
COL6A2 LMNA VIM TLN1 AGRN 











FBN2 COL1A1 EFEMP2 COL1A2 






2.56E-03 3/55 5.4% 8/6246 
0.1% 





2.75E-03 4/55 7.2% 24/6246 
0.3% 
ECM1 LGALS1 AGRN DCN 








FBN2 EFEMP2 ANXA1 TPM4 
ANXA2 C1S HSPA5 ANXA5 






3.17E-03 5/55 9.0% 54/6246 
0.8% 







3.17E-03 3/55 5.4% 11/6246 
0.1% 





3.68E-03 3/55 5.4% 12/6246 
0.1% 







6.64E-03 3/55 5.4% 15/6246 
0.2% 










CST3 ANXA1 ANXA2 HSPA5 









ECM1 VCP HSP90AB1 LTBP4 
PARK7 LAMC1 ENO1 CST3 
TUBA1B UCHL1 EFEMP2 
LGALS1 PRDX1 LMNA FLNC 
PTRF HSPA8 ANXA1 TPI1 TPM4 
ANXA2 HSPA5 LUM ANXA5 FN1 
ACTN4 PDIA6 HSPG2 YWHAZ 
DCN NME1 FKBP1A COL1A1 
TUBB2A PKM COL1A2 COL6A2 
HNRNPA2B1 FSCN1 ANGPTL2 






3.22E-02 3/55 5.4% 28/6246 
0.4% 






3.22E-02 4/55 7.2% 62/6246 
0.9% 
TUBA1B VIM TLN1 AGRN 






3.22E-02 2/55 3.6% 8/6246 
0.1% 
PRDX1 PARK7 

















TPM4 ANXA2 FSCN1 ACTN4 






















EEF1A1 RPS15A RPL18A RPL10 
RPL23 RPL13A RPL15 RPS2 RPL8 












PYGB ILK PLAT PPP2R2A RPL8 
RPL9 FGF2 MYLK RPL18A SCP2 
SCRN1 ANPEP CCN2 CCN1 EIF5A 
PRMT5 MMP1 RPL23 RPL13A 
MOGS OXSR1 EEF1A1 PSMA5 
UGDH PSME1 MYH9 PTMA DDX5 
RPL10 HDAC1 SRSF1 GNS 
HSP90B1 DPP4 RPS15A PCBP1 
RPL15 RPS2 RPS27A RPL19 CTSA 
ST13 STAT1 EGF FN1 PTK2 
COL1A1 HNRNPL HNRNPK PSMC1 
DNAJA2 HNRNPD BAX TPP1 












RPL10 HDAC1 ILK PLAT PPP2R2A 
RPL8 RPL9 FGF2 MYLK HSP90B1 
DPP4 RPS15A RPL18A SCP2 
SCRN1 ANPEP RPL15 RPS2 CCN1 
RPS27A RPL19 CTSA EIF5A PRMT5 
ST13 MMP1 STAT1 EGF RPL23 
FN1 RPL13A MOGS OXSR1 PTK2 
EEF1A1 PSMA5 PSMC1 DNAJA2 
PSME1 MYH9 BAX TPP1 FGFR2 
HSPA1B FGFR1 











RPL10 HDAC1 ILK PLAT PPP2R2A 
RPL8 RPL9 FGF2 MYLK HSP90B1 
RPS15A RPL18A SCP2 RPL15 RPS2 
CCN1 RPS27A RPL19 EIF5A 
PRMT5 ST13 STAT1 EGF RPL23 
FN1 RPL13A MOGS OXSR1 PTK2 
EEF1A1 PSMA5 PSMC1 DNAJA2 













PYGB HEXA ILK PLAT PPP2R2A 
ENO1 RPL8 RPL9 FGF2 MYLK 
RPL18A SCP2 SCRN1 ANPEP CCN2 
CCN1 PGM1 EIF5A PRMT5 MMP1 
RPL23 RPL13A MOGS OXSR1 
APRT EEF1A1 PSMA5 UGDH PKM 
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DDAH2 PSME1 MYH9 PTMA 
DDX5 RPL10 HDAC1 SRSF1 GNS 
HSP90B1 DPP4 RPS15A PCBP1 
RPL15 RPS2 RPS27A RPL19 CTSA 
GOT1 ST13 STAT1 EGF FN1 PTK2 
HNRNPL HNRNPK PSMC1 DNAJA2 
HNRNPD BAX TPP1 GALM PFKM 











PYGB HEXA ILK PLAT PPP2R2A 
ENO1 RPL8 RPL9 FGF2 MYLK 
RPL18A LAMP1 SCP2 NAGLU 
SCRN1 ANPEP CCN2 CCN1 PGM1 
EIF5A PRMT5 MMP1 RPL23 
RPL13A MOGS OXSR1 APRT 
EEF1A1 PSMA5 UGDH PKM PPA2 
DDAH2 PSME1 MYH9 PTMA 
DDX5 RPL10 HDAC1 SRSF1 GNS 
HSP90B1 DPP4 RPS15A PCBP1 
RPL15 RPS2 RPS27A RPL19 CTSA 
CYB5B GOT1 ST13 STAT1 EGF FN1 
PTK2 COL1A1 HNRNPL HNRNPK 
PSMC1 DNAJA2 HNRNPD BAX 
TPP1 GALM PFKM RBMX FGFR2 












PYGB ILK PLAT PPP2R2A ENO1 
RPL8 RPL9 FGF2 MYLK RPL18A 
LAMP1 SCP2 ANPEP CCN2 CCN1 
PGM1 EIF5A PRMT5 RPL23 
RPL13A MOGS OXSR1 APRT 
EEF1A1 PSMA5 UGDH PKM PPA2 
DDAH2 PSME1 MYH9 PTMA 
DDX5 RPL10 HDAC1 SRSF1 
HSP90B1 RPS15A PCBP1 RPL15 
RPS2 RPS27A RPL19 CYB5B GOT1 
ST13 STAT1 EGF FN1 PTK2 
HNRNPL HNRNPK PSMC1 DNAJA2 
HNRNPD BAX TPP1 GALM PFKM 













PYGB ILK PLAT PPP2R2A RPL8 
RPL9 FGF2 MYLK RPL18A SCP2 
CCN2 CCN1 EIF5A PRMT5 RPL23 
RPL13A MOGS OXSR1 EEF1A1 
PSMA5 PSME1 MYH9 PTMA 
DDX5 RPL10 HDAC1 SRSF1 
HSP90B1 RPS15A PCBP1 RPL15 
RPS2 RPS27A RPL19 ST13 STAT1 
EGF FN1 PTK2 HNRNPL HNRNPK 
PSMC1 DNAJA2 HNRNPD BAX 










EGF ANPEP FN1 MYH9 CCN2 









EIF5A RPL10 RPL23 RPL13A RPL8 
RPL9 EEF1A1 RPS15A RPL18A 
RPL15 RPS2 RPS27A RPL19 












CTSA EIF5A GOT1 GDI1 EGF 
RPL23 ITGA2 GDI2 AP1B1 AP3B1 
ACTN4 FGF2 HSP90B1 COL1A1 
SNX18 LMAN2 MYH9 TPP1 CCN1 
TLN1 SEC22B VCL RAN 










COL1A1 EGF ANPEP FN1 MYH9 
PLAT CCN2 CCN1 FGF2 RTN4 
PTK2 FGFR1 










EGF ANPEP FN1 MYH9 PLAT CCN2 












CTSA EIF5A GOT1 GDI1 RPL23 
ITGA2 GDI2 AP1B1 AP3B1 ACTN4 
FGF2 HSP90B1 COL1A1 SNX18 












COL1A1 EGF ANPEP FN1 MYH9 














EIF5A HDAC1 STAT1 EGF ITGA2 
ILK LAMC1 FGF2 DPP4 RPS15A 











CTSA EIF5A GOT1 GDI1 EGF 
RPL23 ITGA2 GDI2 AP1B1 AP3B1 
ACTN4 FGF2 HSP90B1 COL1A1 
SNX18 SCP2 LMAN2 MYH9 TPP1 
CCN1 TLN1 SEC22B VCL RAN 












EIF5A PRMT5 EGF ITGA2 
SERPINE1 FN1 ILK ACTN4 ARPC5 












CTSA EIF5A GOT1 GDI1 RPL23 
GDI2 AP1B1 AP3B1 ACTN4 FGF2 
HSP90B1 COL1A1 SNX18 LMAN2 




























EGF FN1 ILK FGF2 RTN4 PTK2 
COL1A1 ACTC1 ANPEP MYH9 












EIF4A1 EGF ITGA2 SERPINE1 FN1 
ILK PLAT LAMC1 FGF2 RTN4 PTK2 
COL1A1 ACTA2 UGDH ACTC1 
SCP2 ANPEP MYH9 BAX TPP1 











ITGB1 ITGA2 FN1 ILK CCN2 
LAMC1 VCL 










DPP4 COL1A1 ITGA2 SERPINE1 
ILK CCN1 EDIL3 GAL1 










DPP4 MYH9 FGF2 PTK2 
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ITGB1 LGALS3BP PYGB SERPINE1 
ILK PLAT PPP2R2A ENO1 LAMC1 
RPL8 RPL9 FGF2 MYLK ACTR1A 
RPL18A LAMP1 SCP2 SCRN1 
ANPEP FLOT2 CCN2 CCN1 EDIL3 
PGM1 GAL1 EIF5A PRMT5 RPL23 
ITGA2 AP1B1 RPL13A MOGS 
AP3B1 ACTN4 OXSR1 APRT 
EEF1A1 PSMA5 UGDH PKM PPA2 
DDAH2 PSME1 MYH9 TLN1 
SEC22B PTMA VCL DYNC1I2 DDX5 
RPL10 HDAC1 SRSF1 RTN4 
HSP90B1 DPP4 RPS15A PCBP1 
RPL15 RPS2 RPS27A RPL19 CTSA 
CYB5B GOT1 ST13 STAT1 EGF FN1 
PARVA ARPC5 PTK2 COL1A1 
HNRNPL SNX18 HNRNPK ACTC1 
PSMC1 DNAJA2 HNRNPD BAX 
TPP1 GALM PFKM RBMX FGFR2 
HSPA1B RAN FGFR1 








EIF5A PRMT5 DDX5 RPL10 STAT1 
RPL23 SRSF1 RPL13A RPL8 RPL9 
EEF1A1 HNRNPL HNRNPK RPS15A 
RPL18A PCBP1 HNRNPD RPL15 













FN1 ILK LAMC1 























ITGB1 ITGA2 FN1 PLAT ARPC5 
LAMC1 FGF2 PTK2 DPP4 MYH9 
CCN2 TLN1 VCL 











EIF5A SPARC HDAC1 STAT1 EGF 
ITGA2 SERPINE1 ILK LAMC1 FGF2 
DPP4 RPS15A DNAJA2 CCN2 












EIF5A RPL10 STAT1 EGF RPL23 
RPL13A MOGS RPL8 RPL9 EEF1A1 
COL1A1 UGDH RPS15A RPL18A 



























COL1A1 ILK CCN2 LAMC1 CCN1 
PTK2 











ACTA2 DDX5 ILK ENO1 ARPC5 
FGF2 RTN4 FGFR2 HSPA1B FGFR1 
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DDX5 HDAC1 SERPINE1 ILK PLAT 
ENO1 FGF2 RTN4 HSP90B1 CCN1 
GOT1 ITGA2 FN1 AP3B1 ARPC5 
PTK2 ACTA2 MYH9 BAX TPP1 


























SERPINE1 ILK ACTN4 FGF2 VCL 










DDX5 ILK ENO1 FGF2 RTN4 FGFR2 
HSPA1B FGFR1 








DPP4 ITGB1 FN1 MYH9 PLAT 












DDX5 HDAC1 SERPINE1 ILK 
LAMC1 FGF2 RTN4 DPP4 RPS15A 
CCN2 CCN1 EDIL3 GAL1 EIF5A 
GOT1 STAT1 EGF ITGA2 AP3B1 
ACTN4 PSMA5 PSMC1 DNAJA2 
PSME1 BAX PFKM FGFR2 RAN 
FGFR1 











DDX5 ILK ENO1 ARPC5 FGF2 RTN4 









ITGB1 DYNC1I2 GDI1 GDI2 PLAT 
LAMC1 FGF2 HSP90B1 DPP4 
ACTR1A SCP2 SCRN1 LMAN2 
CCN2 CCN1 CTSA EIF5A CYB5B 
TMED9 GOT1 EGF RPL23 ITGA2 
AP1B1 FN1 AP3B1 ACTN4 PTK2 
COL1A1 SNX18 ACTC1 MYH9 BAX 











CTSA EIF5A EGF RPL23 AP1B1 
AP3B1 FGF2 PTK2 ACTC1 SCRN1 
MYH9 TPP1 CCN2 CCN1 TLN1 
SEC22B VCL RAN 










CTSA EIF5A EGF RPL23 AP1B1 












CTSA EIF5A EGF RPL23 AP1B1 
TPP1 AP3B1 CCN1 FGF2 VCL RAN 











ITGA2 SERPINE1 ILK 












SERPINE1 FN1 ILK MYH9 BAX 























PYGB UGDH PKM GALM ENO1 
PFKM PGM1 
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DPP4 ITGB1 FN1 MYH9 PLAT 
CCN2 LAMC1 FGF2 PTK2 








DPP4 ITGB1 FN1 MYH9 PLAT 













EIF5A RPL10 STAT1 EGF RPL23 
RPL13A MOGS RPL8 RPL9 EEF1A1 
RPS15A RPL18A CCN2 RPL15 












EIF5A DDAH2 HDAC1 SERPINE1 













PYGB UGDH PKM ENO1 PFKM 
PGM1 








ITGB1 LGALS3BP ITGA2 FN1 ILK 
PARVA LAMC1 DPP4 FLOT2 MYH9 











ITGB1 LGALS3BP ITGA2 FN1 ILK 
PARVA LAMC1 DPP4 FLOT2 MYH9 











ACTA2 ACTC1 TPM2 TLN1 VCL 
MYLK 










ILK ENO1 CCN2 CCN1 FGF2 RTN4 
HSPA1B 











COL1A1 GOT1 SERPINE1 PLAT 
CCN2 










GDI1 STAT1 EGF TPM2 ITGA2 
SERPINE1 GDI2 ILK FGF2 HSP90B1 







































PYGB UGDH PKM GALM ENO1 
PFKM PGM1 


































PYGB GOT1 ENO1 GNS HSP90B1 
PSMA5 PKM LAMP1 DDAH2 
PSMC1 PSME1 HNRNPD MYH9 
BAX TPP1 PFKM HSPA1B 










































DDX5 HDAC1 SERPINE1 ILK 
LAMC1 FGF2 RTN4 DPP4 RPS15A 
CCN2 CCN1 EDIL3 GAL1 EIF5A 
GOT1 STAT1 EGF ITGA2 AP3B1 
ACTN4 PSMA5 PSMC1 DNAJA2 













PSMA5 PYGB PSMC1 PSME1 












RPL10 RPL8 RPL9 FGF2 RPS15A 
RPL18A SCP2 CCN2 RPL15 RPS2 
RPS27A RPL19 EIF5A GOT1 STAT1 
EGF RPL23 RPL13A MOGS APRT 
EEF1A1 COL1A1 UGDH DDAH2 
PTMA 








HNRNPL PRMT5 DDX5 HNRNPK 
PCBP1 SRSF1 HNRNPD RBMX 










ILK ENO1 CCN2 CCN1 FGF2 RTN4 

















































CTSA EIF5A RPL23 AP1B1 TPP1 
AP3B1 CCN1 FGF2 RAN 




















DPP4 ITGB1 FN1 MYH9 PLAT 

























HNRNPL PRMT5 DDX5 HNRNPK 













PYGB UGDH PKM GOT1 HEXA 
MOGS GALM ENO1 GNS PFKM 
PGM1 
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EIF5A HDAC1 STAT1 SERPINE1 ILK 
ACTN4 FGF2 RTN4 HSP90B1 













ACTC1 MYH9 PARVA ACTN4 












CTSA EIF5A RPL23 AP1B1 AP3B1 
FGF2 PTK2 ACTC1 SCRN1 MYH9 











ACTC1 MYH9 BAX PARVA ACTN4 
ARPC5 TLN1 PTK2 RAN HSP90B1 





































EIF5A HDAC1 STAT1 SERPINE1 ILK 
ACTN4 FGF2 RTN4 HSP90B1 
DDAH2 BAX CCN2 GAL1 HSPA1B 
FGFR1 











GDI1 STAT1 TPM2 ITGA2 













EIF5A DDAH2 HDAC1 SERPINE1 












SERPINE1 ILK FGF2 VCL 









































PYGB UGDH PKM GOT1 MOGS 













EIF5A DDAH2 HDAC1 SERPINE1 
ILK BAX HSPA1B HSP90B1 FGFR1 











GDI1 STAT1 EGF TPM2 ITGA2 
SERPINE1 GDI2 ILK ACTN4 FGF2 
HSP90B1 PSMA5 PSMC1 PSME1 
BAX TPP1 CCN2 
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ACTC1 MYH9 PARVA ACTN4 
ARPC5 TLN1 HSP90B1 











ITGA2 ILK RTN4 PTK2 GAL1 

























PSMA5 STAT1 EGF ITGA2 PSMC1 

























PSMA5 STAT1 EGF ITGA2 PSMC1 
PSME1 ILK BAX TPP1 CCN2 ACTN4 
FGF2 
























EIF5A GOT1 RPL10 STAT1 EGF 
RPL23 RPL13A MOGS RPL8 RPL9 
FGF2 APRT EEF1A1 UGDH RPS15A 
RPL18A DDAH2 CCN2 RPL15 RPS2 






















CTSA MMP1 PLAT HSP90B1 DPP4 
PSMA5 SCRN1 ANPEP PSMC1 













ITGB1 HNRNPK MMP1 HDAC1 













PYGB PKM ENO1 PFKM 













PRMT5 SRSF1 ILK PARVA ACTN4 
LAMC1 PTK2 HSP90B1 ACTC1 






















































































CTSA EIF5A ACTC1 RPL23 AP1B1 
MYH9 TPP1 AP3B1 CCN1 SEC22B 
FGF2 RAN 
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Table 8- 7: BiNGO Enriched molecular functions in the proteome 








ITGB1 LGALS3BP EIF4A1 
PYGB SPARC GDI1 SERPINE1 
HEXA GDI2 ILK PLAT 
PPP2R2A ENO1 LAMC1 FGF2 
MYLK TXNDC17 ACTR1A 
RPL18A SCP2 FLOT2 CCN2 
CCN1 EDIL3 GAL1 EIF5A 
GSTK1 PRMT5 RPL23 TPM2 
ITGA2 AP1B1 AP3B1 ACTN4 
OXSR1 RANGAP1 APRT 
EEF1A1 PSMA5 ACTA2 PKM 
DDAH2 MYH9 TLN1 SEC22B 
VCL DYNC1I2 DDX5 TAGLN 
HDAC1 SRSF1 TWF2 KLC1 
GNS RTN4 HSP90B1 DPP4 
RPS15A PCBP1 RPS2 CTSA 
FARP1 ST13 STAT1 EGF FN1 
PARVA ARPC5 DEK PTK2 
COL1A1 HNRNPL NSFL1C 
SNX18 HNRNPK ACTC1 
PSMC1 DNAJA2 HNRNPD 
BAX TPP1 PFKM RBMX 












RPS15A RPL18A RPL10 RPL23 
RPL13A RPL15 RPS2 RPL8 











RPL10 RPL23 TPM2 FN1 
RPL13A ARPC5 LAMC1 RPL8 
RPL9 COL1A1 RPS15A 
RPL18A RPL15 RPS2 TLN1 
RPS27A VCL RPL19 








EIF5A EIF4A1 DDX5 RPL10 
RPL23 SRSF1 RPL8 RPL9 
HSP90B1 HNRNPL HNRNPK 
RPS15A RPL18A PCBP1 










EIF4A1 SPARC SERPINE1 
PLAT PPP2R2A ENO1 RPL8 
RPL9 FGF2 MYLK TXNDC17 
RPL18A SCP2 ANPEP CCN2 
CCN1 GSTK1 RPL23 TPM2 
AP1B1 ACTN4 EEF1A1 PPA2 
TLN1 VCL DDX5 TWF2 KLC1 
GNS RTN4 HSP90B1 DPP4 
PCBP1 CTSA APA1 GOT1 
ST13 FN1 PARVA ARPC5 
PTK2 COL1A1 HNRNPL 
NSFL1C HNRNPK HNRNPD 
TPP1 FGFR2 FGFR1 ITGB1 
LGALS3BP PYGB GDI1 HEXA 
GDI2 ILK LAMC1 ACTR1A 
FLOT2 EDIL3 PGM1 GAL1 
EIF5A PRMT5 MMP1 ITGA2 
AP3B1 OXSR1 RANGAP1 
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APRT PSMA5 ACTA2 UGDH 
PKM DDAH2 MYH9 SEC22B 
DYNC1I2 TAGLN RPL10 
HDAC1 SRSF1 RPS15A 
LMAN2 RPL15 RPS2 RPS27A 
RPL19 CYB5B FARP1 STAT1 
EGF DEK SNX18 ACTC1 
PSMC1 DNAJA2 BAX GALM 











PYGB LMAN2 FN1 GALM 
CCN2 CCN1 FGF2 PFKM 























SPARC ITGA2 CCN1 GAL1 








ITGA2 ILK CCN2 ACTN4 EDIL3 










COL1A1 CCN2 RPS2 CCN1 
FGFR2 FGFR1 








FN1 CCN2 CCN1 FGF2 FGFR2 
FGFR1 








DPP4 SPARC ITGA2 FN1 





















DPP4 CTSA SCRN1 ANPEP 
TPP1 








TAGLN TPM2 TWF2 MYH9 
PARVA ACTN4 ARPC5 TLN1 
MYLK 













































FARP1 TAGLN ACTC1 TPM2 
TWF2 MYH9 PARVA ACTN4 
ARPC5 TLN1 MYLK 










ITGB1 GSTK1 PYGB HDAC1 
ITGA2 ACTN4 OXSR1 DPP4 












FN1 CCN2 CCN1 FGF2 FGFR2 
FGFR1 








FN1 CCN2 CCN1 FGF2 FGFR2 
FGFR1 








EIF4A1 DYNC1I2 DDX5 
HDAC1 HEXA PLAT PPP2R2A 
ENO1 KLC1 GNS DPP4 SCP2 
NAGLU SCRN1 ANPEP CCN1 
CTSA MMP1 MOGS EEF1A1 
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PSMA5 ACTC1 PPA2 DDAH2 
PSMC1 MYH9 TPP1 RAN 








EIF4A1 DDX5 SRSF1 TWF2 
ILK MYLK HSP90B1 ACTR1A 
RPL23 OXSR1 PTK2 APRT 
EEF1A1 HNRNPL ACTA2 
UGDH PKM ACTC1 PSMC1 
DNAJA2 HNRNPD MYH9 
PFKM RBMX FGFR2 HSPA1B 
RAN FGFR1 























DPP4 ITGB1 PYGB SCP2 
ITGA2 HEXA MYH9 BAX 












EIF4A1 DDX5 TWF2 ILK 
OXSR1 PTK2 MYLK HSP90B1 
APRT ACTA2 ACTR1A PKM 
ACTC1 PSMC1 DNAJA2 














SCP2 PPP2R2A CCN1 








EIF4A1 DDX5 TWF2 ILK 
ACTN4 OXSR1 PTK2 MYLK 
HSP90B1 APRT ACTA2 
ACTR1A PKM ACTC1 PSMC1 
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